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ABSTRACT 
 
This is the third phase of a project to identify, confirm, and operationalise biomarkers 
for crystalline silica dust exposure that could be used for surveillance of dust exposure 
levels in South African mines. The first phase of the project involved a comprehensive 
review of the relevant literature [Gulumian et al., 2006] from which ten potential 
biomarkers of  effect were identified as being worthy of further investigation. The 
second phase of the project examined the ten identified biomarkers in silica dust-
exposed and unexposed black male subjects [Murray et al., 2006]. Two of the ten short 
listed biomarkers, namely erythrocyte glutathione peroxidase (GPx) and serum Clara 
cell protein 16 (CC16), were found to have significantly reduced levels in the silica 
dust-exposed versus unexposed subjects. In addition, the biomarkers were found to be 
unaffected by HIV sero-status, smoking, age and the presence of silicosis. As a result, 
this third phase of the project aimed to confirm the levels of and further analyze GPx 
and CC16 in miners exposed to crystalline silica dust.  
 
This third phase involved the measurement of the levels of erythrocyte GPx and serum 
CC16 in 80 adult male gold miners upon their return from leave and then again two to 
six months after they had returned to work (involving exposure to crystalline silica). 
Before the field work was conducted, however, the optimal operational parameters for 
the biomarkers (namely storage temperature, delay in time between blood collection and 
separation, laboratory temperature and storage duration) were established. The results of 
these optimization experiments were used to develop Standard Operating Procedures 
(SOPs) for biomarker specimen handling and storage under field conditions, and for 
laboratory assays.  
  
 
 vii 
In this phase, the findings of the second phase were confirmed in that the levels of GPx 
and CC16 were lowered in miners exposed to crystalline silica dust and were unaffected 
by age, race and cigarette smoking. In addition, while CC16 was unaffected by the 
presence of radiological silicosis, GPx may have been affected. Finally, the decrease in 
the levels of GPx activity and CC16 concentration observed in the study were 
unaffected by the level of silica dust exposure (high or low) as determined by job 
category or by the duration of crystalline silica exposure.  
 
Regarding the levels of GPx activity, the results suggested that GPx levels decrease 
after two to six months of chronic exposure to crystalline silica dust and remain 
decreased (throughout the working week and over a weekend) and then increase or even 
recover to normal levels during a period of leave. It was therefore concluded that GPx 
activity levels rise and fall, in response to silica dust exposure, gradually and over 
periods of some time, possibly months.  
 
The CC16 results were, however, less promising. After two to six months of chronic 
exposure to crystalline silica dust there was a significant change in CC16 on a 
Wednesday afternoon following an 8-hour shift and during the duration of a shift. In 
addition, there is the possibility that the observed changes were due to a time-dependent 
diurnal variation in the CC16 levels.   
 
It was concluded that the results of the current phase warrant further research into the 
use of erythrocyte GPx and serum CC16 as biomarkers of early effect from crystalline 
silica exposure. 
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 1 
Chapter 1: 
INTRODUCTION 
 
Exposure to respirable crystalline silica can result in a variety of diseases the most 
common of which is silicosis [NIOSH, 2002], a potentially fatal, irreversible, progressive 
and untreatable fibrotic lung disease [Greenberg et al., 2007].  
 
In South Africa, gold miners constitute the largest group of workers exposed to crystalline 
silica containing-dust [Murray et al., 2006] and despite control measures in place to limit 
the inhalation of this dust by gold miners, the prevalence of silicosis is still high [Girdler-
Brown et al., 2008]. Although there are currently no methods available to assess the early 
health outcomes of dust control measures, the field of biomarkers may provide the 
solution. 
 
If scientifically acceptable biomarkers were found that allowed the changes that occur 
between silica exposure and silicosis to be measured, they could be used to detect early 
adverse effects of silica exposure and to evaluate dust-control methods thereby allowing 
intervention schemes to be implemented quickly [Gulumian et al., 2006].  
 
The dissertation starts with a background to the project and a review of the relevant 
literature. Following a description of the methodology used (including statistical methods), 
the relevant results are presented. Finally, the results are discussed and conclusions are 
drawn.  
 
  
 
 2 
1.1 Background to the project 
 
This is the third phase of a project to identify, confirm, and operationalise biomarkers for 
crystalline silica dust exposure that could be used for surveillance of dust exposure levels 
in South African mines.  
 
The project was solicited by the South African Mines Health and Safety Council (MHSC) 
in an attempt to identify biomarkers that could help to assess the success of respirable 
crystalline silica dust exposure control measures in South African gold mines. The project 
was not intended to identify a diagnostic test(s) for the diagnosis of silicosis disease in 
individuals as biomarkers would probably be too non-specific for such a definitive 
diagnostic purpose. In addition, due in part to high variability in some biomarker levels, 
individual test results cannot be used to indicate (in an absolute sense) an individual 
volunteer’s dust exposure levels. As a result, phases two and three of the project were both 
epidemiological studies focusing on population-based average readings. 
 
The first phase of the project was a comprehensive review of the relevant literature on 
prospective silicosis biomarkers [Gulumian et al., 2006]. From the literature, ten potential 
biomarkers were identified that were considered worthy of further investigation in the 
project. The ten biomarkers identified were: reactive oxygen species (ROS) measurement 
by chemiluminescence (neutrophil release), erythrocyte glutathione (GSH), erythrocyte 
glutathione-S-transferase (GST), erythrocyte glutathione peroxidase (GPx), n-8 
isoprostane, tumour necrosis factor alpha (TNF-α), platelet-derived growth factor (PDGF), 
interleukin-8 (IL-8), Clara cell protein 16 (CC16), and total antioxidant status as a trolox 
equivalent (TAS). None of these biomarkers were biomarkers of susceptibility since such 
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biomarkers would not indicate excess exposure to silica dust but rather an individual’s 
predisposition to silicosis. 
 
 The second phase of the project evaluated the ten biomarkers, identified in phase one, to 
determine the influence (if any) of Human Immunodeficiency Virus (HIV) infection, anti 
retroviral (ARV) treatment, smoking, age and the ability to discriminate between silica 
exposed and unexposed individuals. The ten biomarker levels were measured in 60 African 
male underground gold miners (20 HIV sero-positive and 40 HIV sero-negative) and 60 
African males who had never been exposed to silica dust (28 HIV sero-positive and 32 
HIV sero-negative). Two of the ten biomarkers investigated, namely erythrocyte GPx and 
serum CC16, were found to be significantly decreased in the silica dust-exposed subjects. 
In addition, the two biomarkers were unaffected by HIV infection, ARV treatment, 
smoking, age and the presence of radiological silicosis. [Murray et al., 2006].   
 
This third phase of the project aimed to confirm the levels of and further analyze serum 
CC16 and erythrocyte GPx in miners exposed to low and high levels of crystalline silica 
dust.  
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1.2 Literature review 
 
1.2.1. Crystalline silica exposure 
 
Exposure to respirable crystalline silica occurs in a number of industries and, because of its 
toxicity, can result in a variety of diseases.  
 
1.2.1.1 Definition of crystalline silica  
 
Silicon is the second most common element in the earth’s crust, making up approximately 
28% [Mandel and Mandel, 1996]. Due to their abundance, silicon and oxygen atoms 
commonly combine to form a fundamental tetrahedral unit (SiO4) which consists of a 
central silicon ion with oxygen attached at the four ‘corners’ of the tetrahedron. These 
tetrahedral units are joined by common oxygen atoms to form a molecule, with an average 
stoichiometric formula of SiO2, known as silicon dioxide or silica. [Parkes, 1974].  
 
Silica can exist in two forms, namely non-crystalline (amorphous) silica and crystalline 
silica (figure 1.2.1.1). In crystalline silica, the atoms and molecules are arranged in a three-
dimensional repeating pattern. In amorphous silica, the atoms and molecules are randomly 
arranged with no pattern [USBM, 1992].  
 
 
 
 
  
 
 5 
 
 
 
 
 
Figure 1.2.1.1: The different structural forms of silica: A) the silicon-oxygen tetrahedron, B) the 
repeating pattern of crystalline silica, and C) the random pattern of amorphous silica.  
Silicon (ο) and oxygen (•). Adapted from [USBM, 1992]. 
 
Crystalline silica exists as at least eight different polymorphs (same chemical composition 
but different structure), the most common of which are quartz, cristobalite and tridymite 
[Guthrie and Heaney, 1995]. Quartz can exist as one of two forms, alpha (α) and beta (β), 
depending on the conditions. Under ambient conditions, quartz exists as α-quartz but at 
high temperatures (above 573oC) and pressures it transforms into β-quartz. [USBM, 1992].  
 
Alpha quartz (the most abundant form of crystalline silica) is the second most common 
mineral in the world. It is the major component of sand and of dust in the air and is also 
abundant in igneous, sedimentary and metamorphic rock. [USBM, 1992].  
 
1.2.1.2 Industries involving crystalline silica exposure 
 
Exposure to crystalline silica occurs in a wide variety of industries, with the most common 
exposures occurring in mining and mining-related occupations [Rees and Murray, 2007]. 
 
In gold mining, in particular, a significant release of crystalline silica is expected since 
quartz forms veins in sedimentary rock and it is these veins that form the matrix for 
B C A 
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precious metals such as gold [DOL, 2005]. During the mining process, a number of 
activities (such as drilling, hewing, shovelling, crushing, tunnelling and the use of 
explosives) can generate a large of amount of crystalline silica containing-dust [Parkes, 
1974].  
 
In South African gold mines, the mined rock usually contains 60-90% of quartz while the 
respirable dust generated contains approximately 30% free quartz  [Hnizdo and Sluis-
Cremer, 1991].  
 
In addition to the mining industry, exposure to crystalline silica has been shown to occur in 
the following industries: glass, ceramic and fine china manufacturing; the construction 
industry; heavy industry such as the oil and gas industry; agriculture; and in high-
technology applications such as the field of laser optics [USBM, 1992].  
 
1.2.1.3 Factors affecting crystalline silica toxicity  
 
In order to identify potential biomarkers of crystalline silica exposure, the factors 
responsible for its toxicity need to be understood. A number of factors affect the biological 
toxicity of silica polymorphs including: origin, structure, composition, crystallinity, 
solubility, particle size, interactions with other chemicals/minerals, and most importantly 
the surface properties. [Gulumian, 2007] 
 
Origin: 
The matrix in which the silica particle is found (for example in coal mine dust) can affect 
the toxicity of the particle [Donaldson et al., 2001]. This is because silica commonly bonds 
  
 
 7 
with elements such as sodium, potassium, calcium, magnesium, iron and aluminium 
(forming compounds called silicates) [USBM, 1992] and it is these other contaminating 
elements that may play an important role in the toxicity of crystalline silica [Donaldson 
and Borm, 1998]. 
 
Size: 
The size of a particle is an important factor in determining its ability to penetrate deep into 
the lung. When air is inhaled through the nose, the majority of particles greater than 10 µm 
in diameter are trapped in the nose and pharynx [Parkes, 1974]. Respirable free crystalline 
silica particles (defined as particles less than 10µm in diameter) are most likely to have a 
toxic effect, with particles 1 to 3 µm in diameter having greatest capability to deposit in the 
alveoli [Ziskind et al., 1976]. 
 
Crystallinity:  
Only crystalline silica has been found to be toxic [Fubini and Fenoglio, 2007]. 
 
Solubility in biological fluids:  
The amount of time a particle stays in the body depends on the effectiveness of the 
clearance mechanisms and solubility. The longer the particle remains unaltered in the 
biological compartment (where it can cause stress to cells and tissue), the greater the extent 
of any damage caused. [Fubini and Fenoglio, 2007]. 
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Surface reactivity: 
Because it is the surface of the silica particle that interacts with biological fluids and 
molecules, the properties of the particle surface ultimately determine the particles’ toxicity 
[Guthrie and Heaney, 1995].   
 
The surface properties of a particle are determined by their history (such as the method by 
which the dust was generated), weathering, processing conditions and the presence of 
contaminants [Fubini and Fenoglio, 2007].  
 
For example, when crystalline silica is cut, ground, or milled (as occurs during occupations 
such as sandblasting, rock drilling, tunnelling, and silica milling) the crystal is fractured. 
This results in cleavage planes which have surface properties (such as the presence of 
reactive oxygen species) that make them more reactive for lung tissue and therefore more 
likely to cause rapid development of pulmonary disease [Castranova et al., 1996a].  When 
silica crystals are freshly fractured, the silicon-oxygen bond is cleaved via either a 
homolytic pathway (which results in the reactive surface radicals Si• and SiO•) or a 
heterolytic pathway (which results in the surface charges Si+ and SiO-) as illustrated in 
figure 1.2.1.3. These reactive species tend to either recombine or to react with atmospheric 
components, yielding reactive oxygen species (ROS) at the surface and in the subsurface 
layers of the particle [Fubini et al., 1995].  In aqueous conditions (such as the lung lining 
fluid or tissue fluid) the Si• and SiO• radicals can give rise to highly reactive hydroxyl 
radicals (OH•) [Castranova et al., 1996a] and the Si+ and SiO- charges can interact with 
membranes [Fubini et al., 1995]. It has been shown that aqueous suspensions of freshly 
fractured quartz particles can produce hydroxyl radical (OH•), hydrogen peroxide (H2O2), 
superoxide anion radical (O2•-), and singlet oxygen(O2) [Shi et al., 1995].  
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Figure 1.2.1.3: The pathways by which reactive surface radicals (Si• and SiO•) and surface 
charges (Si+ and SiO-) are produced by the cleavage of the silicon-oxygen bond. Adapted from 
[Fubini et al., 1995]. 
 
 
In addition to its ability to produce free radicals, the surface properties of a particle that are 
most likely to influence its toxicity are its ability to adsorb endogenous molecules, and its 
degree of hydrophilicity and hydrophobicity [Fubini and Fenoglio, 2007]. 
 
Age:  
A number of studies have shown that freshly fractured silica is more cytotoxic and 
inflammatory than aged silica of similar size and composition [Castranova et al., 1996b, 
Vallyathan et al., 1995, Shoemaker et al., 1995, Vallyathan et al., 1988, Vallyathan et al., 
1991]. The higher toxicity of freshly fractured silica has been attributed to the ability of the 
newly created surfaces to generate surface radicals, which has been shown to decrease with 
age [Castranova et al., 1996a]. 
 
 
Homolytic pathway: 
 
                                                                                                            • 
                      O                                                                                O 
              •                       •                                                                                                        • 
                                                                                                                  •                                         • 
                         •                •                                                                Si           +          Si 
        Si                       Si 
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            •                                                                                                        • 
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1.2.1.4 The pathway of inhaled crystalline silica  
 
 
Figure 1.2.1.4: The human respiratory system  [WAHSA/NIOH, 2006]. 
 
Airborne crystalline silica particles enter the body through the mouth or nose during 
inhalation of air (in which they are suspended). Once inhaled, the silica particles first travel 
through the upper airways from the trachea through the bronchi to the bronchioles (the 
small airways). At this stage, the majority of the inhaled silica particles are either exhaled 
or deposited in the upper airways where they are then removed by the mucociliary 
‘escalator’ (which involves the movement of ciliated epithelium [Beckett, 2000]). If the 
particles are not removed they can travel through the lower airways from the terminal 
bronchioles into the respiratory bronchioles which end in alveolar sacs consisting of 
clusters of alveoli.  It is in these respiratory bronchioles and alveoli areas that small silica 
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particles (less than 10 µm in aerodynamic diameter) can be deposited. [WAHSA/NIOH, 
2006].  
 
The depth to which the particles travel in the lung is determined by their physical 
characteristics (size, density, shape and aerodynamic properties) and by the volume of each 
inhalation. Because the majority of particles are removed from the lung, their concentration 
in the inhaled air needs to be high in order to allow some particles to be deposited in the 
lungs. [Parkes, 1974]. 
 
1.2.1.5 Diseases associated with crystalline silica exposure 
 
The most common disease caused by crystalline silica exposure is silicosis [NIOSH, 2002]. 
However, exposure to crystalline silica can lead to a number of other diseases such as 
emphysema, immunologic reactions, interstitial fibrosis, industrial bronchitis, small airway 
disease, vascular diseases [Ding et al., 2002] and lung cancer [IARC, 1997]. Exposure to 
crystalline silica has also been implicated in the development of a number of autoimmune 
diseases, including systemic sclerosis, rheumatoid arthritis, systemic lupus erythematosis, 
and chronic renal disease [Rimal et al., 2005]. In addition, respirable crystalline silica 
exposure (even in the absence of radiological silicosis) has been found to increase the risk 
of pulmonary tuberculosis [te Water Naude et al., 2006, Hnizdo and Murray, 1998].    
 
Lung cancer: 
The relationship between silica exposure, silicosis and lung cancer has been hypothesized, 
investigated and debated for many years. In 1997, after a review of research published until 
then, the International Agency for Research on Cancer (IARC) concluded that there was 
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sufficient evidence in humans for the carcinogenicity of inhaled crystalline silica (in the 
form of quartz) from occupational sources. As a result, crystalline silica (quartz) was 
classified as a Group 1 carcinogen. However their final evaluation noted that 
carcinogenicity was not found in all the industries studied and they therefore speculated 
that “Carcinogenicity may be dependent on inherent characteristics of the crystalline silica 
or on external factors affecting its biological activity or distribution of its polymorphs”. 
[IARC, 1997]. It is generally thought that if crystalline silica is a human lung carcinogen, it 
is a relatively weak one [Wong, 2002]. 
 
Silicosis:  
Silicosis is a potentially fatal, irreversible, progressive and untreatable fibrotic lung disease 
caused by the inhalation and deposition of respirable crystalline silica [Greenberg et al., 
2007].  
 
Pulmonary tuberculosis (PTB) is a common complication of silicosis. Although PTB may 
occur at any stage in the development of silicosis, it is more likely to occur in older 
workers with severe grades of silicosis [Cowie, 1994]. 
 
Pulmonary tuberculosis is epidemic on South African gold mines with the incidence of 
PTB among South African gold miners much higher than that of the general population. A 
study carried out by  te Water Naude and colleagues [2006] examined 520 gold miners 
over 37 years of age and found a PTB prevalence of 35% even though the average 
concentration of respirable quartz was 0.053 mg/m3 (below the current occupational 
exposure limit, OEL, of 0.1 mg/m3). Even more worrying is that this study and one by 
Hnizdo and Murray [1998] showed that even in the absence of silicosis, exposure to silica 
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dust increases the risk of  developing tuberculosis and that this risk persists long after 
exposure ends. Hnizdo and Murray also found that the risk of developing PTB increased 
with the presence of radiologically diagnosed silicosis, with increasing cumulative 
exposure to crystalline silica, and with tobacco pack years. 
 
Silicosis [Hnizdo and Murray, 1998, Cowie, 1994] and HIV [Corbett et al., 1999, Corbett 
et al., 2000] are strong risk factors for tuberculosis. The study by Corbett [2000] showed 
that, in South African gold miners, the effects of silicosis and HIV infection on the risk for 
PTB are multiplicative rather than additive. It found that silicosis increased the PTB risk 
threefold while HIV increased the PTB risk fivefold and the combined effects of silicosis 
and HIV infection increased the PTB risk 15 times. 
 
1.2.1.6 A history of silicosis 
 
It is thought that silicosis has afflicted miners for centuries, probably since mining 
activities started between 4000 and 3000 B.C. in China, India and Egypt. Around 400 B.C., 
Hippocrates described lung disease in miners when he described the metal digger as a man 
who breathes with difficulty. Pliny (A.D. 23-79) suggested that miners wear protective 
masks to prevent the inhalation of “fatal dust” in the mines and Galen (A.D. 131-201) was 
the first to describe the symptoms of silicosis [Harley and Vallyathan, 1996]. In 1866, the 
German pathologist Fredrich von Zenker used the term pneumokoniosis (“dust lung”) to 
describe dust-related lung diseases such as silicosis and in 1870 the term “silicosis” was 
first used by Visconti [Greaves, 2000]. Since then, pneumoconiosis has been defined as 
“The presence of inhaled dust in the lungs and their non-neoplastic tissue reaction to it” 
  
 
 14 
[Parkes, 1974] and it has become widely accepted that silicosis is caused by the inhalation 
and deposition of crystalline silica. 
  
In South Africa, gold mining started in the Witwatersrand in 1886 [Gold rush, 2009]. Since 
then, there have been four main periods in the history of silicosis on the Witwatersrand 
mines: 1) the initial period of gold mining on the rand, from 1886 to 1899, was a period of 
ignorance as to the dangers of silicosis, 2) the dangers of silicosis and the nuisance of 
prevention measures were first realised in the period from 1902 to 1910, 3) a legal system 
of compensation for silicosis and preventative measures were introduced in the period from 
1911 to 1916, and 4) full systematised measures of prevention, detection and compensation 
were implemented from 1916 to the current day [Donsky, 1993].  
 
1.2.1.7 Current prevalence of silicosis in South African mine workers 
 
Despite silicosis prevention measures currently employed in South African mines, the 
prevalence of silicosis is high among currently employed, retired and deceased miners. 
This has been demonstrated by a number of studies, both radiography-based and autopsy-
based.  
 
 A cross-sectional study conducted with living black ex-miners from Botswana showed an 
overall prevalence of pneumoconiosis of  between 26.6% and 31.0% [Steen et al., 1997], 
while a similar study in the Eastern Cape showed an overall prevalence of between 22% 
and 36% [Trapido et al., 1998].  In both studies, the relatively insensitive method of chest 
radiographs were used to diagnose the pneumoconiosis and therefore the disease rates may 
have been underestimated. A study of active black South African gold miners (over 37 
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years of age) found a silicosis prevalence of between 18.3% and 19.9% [Churchyard et al., 
2004]. However, due to the healthy worker effect the disease rates may also have been 
underestimated. Since silicosis prevalence rates can also be estimated by autopsy based 
studies, a number of studies have been carried out using the data from the pathology 
automation system (PATHAUT) database. The PATHAUT database contains the clinical 
files of and the pathological findings of autopsies carried out on deceased South African 
miners since 1975. It is the only comprehensive surveillance database on occupational 
respiratory diseases available to the South African mining industry. The 2007 annual 
PATHAUT surveillance report showed that the overall prevalence of silicosis in deceased 
gold miners increased from 19.1% in 2000 to 31.6% in 2006. [Ndlovu et al., 2007]. 
 
These high silicosis prevalence rates indicate that: 1) the dust control measures in place are 
not adequate, 2) the levels of respirable crystalline silica are too high, and 3) the 
surveillance of workers’ health is not effectively organised [Fedotov, 2006]. 
 
It is therefore important that more effective control measures for crystalline silica dust 
exposure, are implemented to prevent the significant silicosis problem facing South 
African gold miners.  
 
1.2.1.8 The development of silicosis 
 
A number of factors influence the development of silicosis. The main determinants of 
whether an individual develops silicosis are the silica dose in the ambient air (including the 
percentage of free crystalline silica in the dust particles), the duration of exposure, and the 
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characteristics of the silica particle [Banks, 1996]. Host factors, such as genetic variation, 
also influence an individual’s susceptibility [Rees and Murray, 2007].  
 
1.2.1.9 Mechanisms in the pathogenesis of silicosis  
 
Once a silica particle has been deposited in the alveolar spaces of the lungs, it may 
contribute to the pathogenesis of silicosis in a number of ways, including direct 
cytotoxicity and stimulation of alveolar macrophages.  
 
Direct cytotoxicity: 
As described in section 1.2.1.3, ROS can be generated on the surface of silica particles. 
These ROS are strongly implicated in the mechanisms of silica toxicity in that they can 
cause lipid peroxidation (leading to cell membrane damage) and cell damage [Fubini, 
1998]. In addition, if ROS are produced in excess, they can overwhelm the lungs’ 
antioxidant defences and lead to oxidative stress and inflammation, which would then 
result in scarring, fibrosis and diminished gas exchange [Castranova, 1996].  
 
Stimulation of alveolar macrophages: 
The alveolar walls contain various cell types (including type I pneumocytes, type II 
pneumocytes, alveolar macrophages (AM), endothelial cells, epithelial cells, fibroblasts, 
leucocytes and lymphocytes). These cells are responsible for a variety of functions in the 
lung, such as gas exchange, disposal of inhaled foreign bodies, and immunological 
activities. [Parkes, 1974].  
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Alveolar macrophages are the lungs’ most important means of defence against inhaled 
pollutants and they function to engulf and eliminate foreign bodies (such as silica particles) 
[Balduzzi et al., 2004]. They do so by invagination of their boundary membrane to form a 
vesicle called the phagosome (the process is referred to as phagocytosis) [Parkes, 1974].  
 
Once a silica particle has been deposited in the alveolar spaces of the lungs, the immune 
system is activated and AMs are recruited to eliminate the particles [Fubini and Fenoglio, 
2007]. Activation of AMs leads to the production and release of ROS [Rahman and 
MacNee, 2000], and inflammatory cytokines; such as tumor necrosis factor (TNF-α), 
interleukin-1 (IL-1), interleukin-6 (IL-6), and platelet-derived growth factor (PDGF) 
[Green and Vallyathan, 1996]. The increased production of ROS is referred to as the 
“respiratory burst” as it results in an increase in oxygen consumption [Ding et al., 2002]. 
 
Because the crystalline silica particles are cytotoxic they eventually cause AMs to die and 
release the particle as well as additional ROS and cytokines into the surroundings [Fubini 
and Fenoglio, 2007]. This leads to the activation of redox-sensitive transcription factors, 
such as nuclear factor-kappa Β (NF-κΒ) and activator protein-1 (AP-1), which regulate the 
antioxidant genes and the genes for pro-inflammatory cytokines [Rahman et al., 2006]. 
This results in inflammation.  
 
Although inflammation is usually a protective response to cellular or tissue injury (which 
aims to promote repair), if uncontrolled it results in excessive cell or tissue damage and 
eventually chronic inflammation and the destruction of normal tissue [Rahman and 
MacNee, 2000] .  
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Additionally, the inflammatory cytokines released by the AMs act as chemoattractants that 
help recruit new immune-defence cells (AMs and polymorphonucleated, PMN, cells). A 
continuous cycle of recruitment and cell death is therefore established and this results in 
sustained inflammation (which lasts as long as the particle remains in the lungs) and 
oxidative stress, which can eventually lead to fibrosis. [Fubini and Fenoglio, 2007].  The 
severe inflammation that follows silica exposure therefore appears to be the initiating step 
in the development of silicosis [Rimal et al., 2005]. 
 
1.2.1.10 Pathological features of silicosis 
 
There are four pathologically distinct forms of silicosis: chronic silicosis, progressive 
massive fibrosis, accelerated silicosis, and alveolar lipoproteinosis [Rees and Murray, 
2007]. 
 
1. Chronic (nodular) silicosis  
This is the most common form of silicosis. It can take 10 to 30 years (a working lifetime) 
of low intensity exposure to crystalline silica before abnormalities can be seen on a chest 
radiograph. Thereafter, the disease may progress slowly over a long period of time [Green 
and Vallyathan, 1996], even after exposure to silica has ceased [Hnizdo and Sluis-Cremer, 
1993, Hnizdo and Murray, 1998].   
 
Chronic silicosis is characterised by the presence of small rounded opacities (less than       
1 cm in diameter) known as silicotic nodules. Individuals with chronic silicosis don’t 
usually present with chest symptoms, however, some have reported a chronic productive 
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cough [Banks, 1996]. This type of silicosis is common in occupations such as quarrying, 
stone cutting and mining [Vallyathan and Shi, 1997]. 
 
2. Progressive massive fibrosis (PMF) 
PMF develops when neighbouring smaller silicotic nodules coalesce and collapse into one 
another to form an opacity (greater than 1 cm in diameter) [Green and Vallyathan, 1996]. 
 
Steen and colleagues [1997] found that the latency period between crystalline silica 
exposure and the manifestation of radiological abnormalities was at least 15 years for 
PMF. 
 
3. Accelerated silicosis 
Although this form of silicosis is radiologically identical to chronic silicosis, the time from 
initial exposure to crystalline silica to the development of silicotic nodules (latency period) 
is much shorter [Banks, 1996]. It usually develops after 1 to 14 years of high to moderate 
exposure to crystalline silica  [Green and Vallyathan, 1996].  
 
4.  Alveolar lipoproteinosis  
This is the most aggressive form of silicosis as it progresses rapidly (it may develop after 
only six months of exposure to crystalline silica) and has a high mortality rate [Green and 
Vallyathan, 1996]. It results from exposure to extremely high concentrations of respirable 
crystalline silica. The individual progresses to disabling chest symptoms and extreme 
respiratory impairment, which ultimately leads to respiratory failure and death [Banks, 
1996]. 
  
 
 20 
This type of silicosis is common in occupations such as silica flour mill operations, surface 
mine drilling, tunnelling, sandblasting, and pottery manufacturing [Vallyathan and Shi, 
1997]. 
 
The silicotic nodule  
Chronic silicosis is characterised by the silicotic nodule, which is morphologically distinct 
from lesions formed by exposure to other inorganic particles. Macroscopically, the nodules 
appear as rounded, firm to hard regions of fibrosis that are easily distinguishable from the 
surrounding lung parenchyma. [Green and Vallyathan, 1996].  
 
1.2.1.11 Detection of silicosis 
 
The detection of silicosis in dust exposed workers is based on the presence of silicotic 
nodules on a chest radiograph [Hnizdo et al., 1993]. 
 
       
Figure 1.2.1.11: Chest radiographs depicting A) normal lung tissue, B) small parenchymal 
opacities (found in nodular silicosis), and C) large parenchymal opacities (found in PMF). 
[CDC, http://www.cdc.gov/niosh/topics/chestradiography/ilo.html]. 
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In order for a diagnosis of silicosis to be made, three conditions need to be met. Firstly, the 
individual must provide a history of silica exposure which would be sufficient to cause 
silicosis. Secondly, the chest radiograph must show opacities which are consistent with 
silicosis. Thirdly, no underlying illnesses which could mimic silicosis should be present. 
The diagnosis of silicosis does not require respiratory symptoms or lung function 
impairment (even though they might be present). [Banks, 1996].  
 
1.2.1.12 Classification of silicosis 
 
The International Labour Organisation (ILO) has standardized the radiographic 
classification of pneumoconioses by providing a set of standardized radiographs and 
guidelines for their use. During the classification process a number of factors are 
described, such as the technical quality of the radiograph; the size, shape (round or 
irregular), affected zones of the lungs and profusion of parenchymal abnormalities; and the 
characteristics of pleural abnormalities.  
 
Parenchymal abnormalities include both small opacities (< 1 cm in diameter), such as the 
simple silicotic nodule, and large opacities (> 1 cm in diameter), such as the nodules 
characteristic of complicated silicosis. For small opacities, the term profusion is used to 
describe the concentration of small opacities in the affected zones of the lungs. There are 
four main categories and twelve subcategories of profusion, ranging from 0/0 (no small 
opacities present) to 3/+ (a high concentration of small opacities present), as illustrated in 
figure 1.2.1.12 below.  The size of opacities is also described. [ILO, 2000].  
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Figure 1.2.1.12: Guideline for the classification of the profusion of small opacities on chest 
radiographs. [ILO, 2000] 
 
Silicosis can also be classified by means of a macroscopic and microscopic examination of 
the lung parenchyma at autopsy. The degree of silicosis is based on the number of palpable 
silicotic nodules as follows: none (0), insignificant (< 5), slight (5-9), moderate (10-29), 
and marked (≥ 30). Microscopic analysis of the histological slides is used to confirm the 
presence of silicotic nodules. [Hnizdo et al., 1994]. 
 
1.2.1.13 Limitations of silicosis detection  
 
Although standard chest radiography is inexpensive, widely available and involves low 
amounts of radiation; it also has some significant limitations: 
1) It is widely known that routine standard chest radiographs are relatively insensitive 
for diagnosing interstitial lung disease when compared to direct microscopic 
analysis of the tissue [Checkoway and Franzblau, 2000, Hnizdo and Sluis-Cremer, 
1993, Hnizdo et al., 1993]. As a result, misclassification of silicosis may occur. 
2) Large inter-reader and intra-reader variability can arise in the assessment of 
abnormalities. A number of factors that can potentially contribute to this variability 
 
Increasing profusion of small opacities    
 
 
  Categories 
 
Subcategories 
          0             1              2                         3 
       0/0   0/1     1/0   1/1   1/2     2/1   2/2   2/3     3/2   3/3   3/+ 
  
 
 23 
are radiographic technique and quality, age, obesity, cigarette smoking, gender, and 
differences in readers’ tendencies [Meyer et al., 1997, Dick et al., 1992].  
3) Errors in the interpretation of chest radiographs can also occur due to rotation of the 
subject, exhalation while the radiograph is taken, and the presence of soft tissue 
shadows [Parkes, 1974]. 
 
A further limitation of the radiological diagnosis of silicosis is the fact that silicotic 
nodules are late and irreversible manifestations of the disease. As a result, the annual chest 
radiograph used to screen miners for silicosis is only a late indicator of harmful dust 
exposure and therefore does not provide an effective way to measure and control the dust 
exposure.   
 
1.2.1.14 Treatment of silicosis 
 
At present there is no effective treatment for silicosis [Greenberg et al., 2007]. As a result, 
one can only attempt to prevent the development of silicosis by limiting exposure to 
crystalline silica.  
 
1.2.1.15 Prevention of silicosis 
 
Numerous measures can be implemented to help prevent silicosis, such as: the enforcement 
of exposure limits and safety standards, the use of engineering controls (for example the 
use of personal protection, improved ventilation, wet techniques, and process enclosure) 
and safe work practices, evaluation of the working environments to assess the effectiveness 
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of preventative measures, epidemiological evaluations, medical surveillance of workers at 
risk (for early detection of the disease), and training and health education [Fedotov, 2006]. 
 
Industrialised countries (such as the United Kingdom and the United States) have shown 
that the incidence rate of silicosis can be significantly reduced with well-organised silicosis 
prevention programmes[Fedotov, 2006]. 
 
In 1995 the Joint International Labour Organization (ILO) and World Health Organization 
(WHO) Committee on Occupational Health established the ILO/WHO Global Programme 
for the Elimination of Silicosis (GPES) by 2030. At the South African Mine Health and 
Safety Summit in 2003, the Minister of Minerals and Energy emphasised the need for 
improvements in health and safety in the South African mining industry. It was at this 
summit that the following milestones for the elimination of silicosis, in South Africa, were 
set:  
1) By 2008, 95% of all dust exposure measurements should be below the respirable 
crystalline silica Occupational Exposure Limit (OEL) of 0.1mg/m3. 
2) By 2013, no new cases of silicosis in previously unexposed individuals should be 
diagnosed (using current diagnostic techniques). 
In June 2004, the National Programme for the Elimination of Silicosis (NPES) in South 
Africa was launched by the Department of Labour.[Stanton et al., 2005]. In addition, the 
Mine Health and Safety Council also launched a Silicosis Elimination Programme which is 
a research-based programme aimed particularly at the mining industry [Rees, 2006].  
 
In the United States of America, the Occupational Safety and Health Administration 
(OSHA) set a permissible exposure limit (PEL) of 0.1 mg/m3 for an 8-hour work shift 
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[Greaves, 2000] while the National Institute for Occupational Safety and Health (NIOSH) 
set a recommended exposure limit (REL) of 0.05 mg/m3 for up to 10 hours per day for a 
40-hour work week [NIOSH, 2002]. In South Africa, the OEL for crystalline silica is 0.1 
mg/m3 [DME, 2006]. 
 
Alarmingly, evidence suggests that this current respirable crystalline silica OEL of 0.1 
mg/m3 may be insufficient to protect workers from developing silicosis. This was 
highlighted by Greaves [2000] who reviewed three important epidemiological studies (one 
of which was conducted in South Africa). He illustrated (with the aid of figure 1.2.1.15 
below) that after 45 years of exposure to respirable crystalline silica at the current OEL of 
0.1 mg/m3, the risk of developing silicosis of grade 1/1 or greater would be over 40% and 
that if the OEL were lowered to 0.05 mg/m3, the risk of developing silicosis would be 
about 10-20%. As observed in figure 1.2.1.15, the estimated silicosis risks presented by 
Kreiss and Zhen [1996] were almost double those found by Hnizdo and Sluis-Cremer 
[1993] and Steenland and Brown [1995] which may be explained by the fact that the latter 
studies estimated silica exposures from the average silica content of ore or dust samples 
while the former study used job title-specific silica exposure measurements which are less 
likely to result in silica exposure misclassification [Kreiss and Zhen, 1996]. 
 
The conclusion that the OEL of 0.1 mg/m3 is not protective against silicosis was also made 
by Churchyard [2004], Finkelstein [2000] and Murray [1996]. The no-observed-adverse-
effect-level (NOAEL) for respirable crystalline silica is currently unknown but it is clear 
that the current OEL of 0.1 mg/m3 is too high and that even lowering the OEL to 0.05 
mg/m3 would offer no adequate protection against silicosis. 
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Figure 1.2.1.15:  Comparison of silicosis risks in three studies of hard rock miners. In this 
case, silicosis was defined by the presence of small round opacities with profusion 1/1 or greater. 
The average respirable silica levels were derived from cumulative exposure data assuming 45 years 
of continuous exposure. Purple and orange dotted arrows are used to indicate the risk of developing 
silicosis (of grade ≥ 1/1) at an average silica exposure level of 0.1mg/m3 and 0.05mg/m3, 
respectively. Graph constructed by Greaves [2000] using data from Hnizdo and Sluis-Cremer 
[1993], Steenland and Brown [1995], and Kreiss and Zhen [1996]. 
 
 
 
1.2.1.16 Methods for the measurement of respirable dust  
 
Due to the uncertainties surrounding the effectiveness of the OEL to prevent silicosis, it is 
vital that the methods used to measure the amount of respirable crystalline silica containing 
dust are accurate. 
 
 Currently, the instrument used for the measurement of respirable dust in field operations is 
the personal gravimetric dust sampler. The sampler consists of a cyclone assembly and 
filter holder, which contains a pre-weighed millipore filter and is attached to a battery-
             Kreiss & Zhen  
             Steenland & Brown 
             Hnizdo & Sluis-Cremer 
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powered pump. As the pump draws air through the assembly the larger particles are 
discarded while the smaller particles stay on the filter. The dust can then be analyzed in a 
number of ways, including: examination under a polarizing microscope, roentgenographic 
diffraction; colorimetry; infra-red spectrophotometry and X-Ray Diffraction (XRD). 
[Ziskind et al., 1976].  
 
The use of dosimetric readings to estimate immediate exposure to harmful dust is routinely 
used by the mines, however, these readings are often unreliable. For instance, the levels 
recorded have been found to be quite variable even within groups working closely 
together. In addition, the equipment is sometimes not worn correctly or it is allowed to get 
wet (since the mining areas are often sprayed with water to decrease the levels of dust). It 
is often difficult in practice to measure the exposure over a full 8-hour shift, and this leads 
to problems when estimating the cumulative exposure levels. Also, miners may move 
around and change their activities during a shift, so compliance and interpretation become 
problematic. [Girdler-Brown et al., 2006].  
 
1.2.1.17 Compensation of silicosis afflicted individuals 
 
It is estimated that there are nearly half a million ex-mineworkers suffering from 
compensatable lung disease in southern Africa, and that there is approximately 2.8 billion 
rand worth of unpaid compensation [Marks, 2006]. The enormous problems encountered in 
the compensation of miners could also be resolved if early biomarkers could be identified 
that would prevent silicosis from occurring.  
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1.2.1.18 Biomarkers for crystalline silica exposure 
 
The high silicosis prevalence rate (despite the implemented dust control measures), the 
limitations of the use of chest radiographs for the early detection of silicosis, the lack of an 
effective treatment for silicosis, the uncertainties regarding the OEL level, the problems 
involved in the measurement of dust exposure, the potential financial issues regarding 
compensation and the association of crystalline silica exposure with other diseases, 
emphasize the need for more effective silicosis prevention methods (both locally and 
globally).  
 
Since silicosis can be prevented by limiting the inhalation of crystalline silica dust [Rimal 
et al., 2005], it is important to be able to reliably assess the effectiveness of dust control 
measures currently employed.  
 
If scientifically acceptable biomarkers were found that could allow the measurement of 
changes that occur immediately after exposure to crystalline silica but prior to the 
appearance of abnormalities on chest radiographs, they could be used to detect early 
adverse effects of silica exposure and also to evaluate efficacy of dust-control methods 
implemented [Gulumian et al., 2006].  
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1.2.2 Biomarkers 
 
In the past, relationships were observed between exposure and disease even though the 
mechanisms of action or the intervening steps were not often understood (refer to figure 
1.2.2). However, this approach is not very useful in situations with low levels of exposure, 
intermittent exposure, a mixture of exposures, or for diseases with long latency periods 
(such as silicosis). This approach is also problematic as there is a tendency to misclassify 
people as to their exposures and it does not take into account acquired or genetic host 
factors. Biological markers (biomarkers) may, potentially, address these problems. [NRC, 
1987, Schulte, 1995]. 
 
 
 
 
 
 
 
 
Figure 1.2.2: The traditional view of the relationship between exposure and disease. Adapted 
from [Schulte, 1995]. 
 
 
1.2.2.1 Definition of biomarkers 
 
The Committee on Biological Markers of the National Research Council (NRC) in the 
United States of America has defined biomarkers as “Indicators of variation in cellular or 
biochemical components or processes, structure or function that are measurable in biologic 
systems or samples” [NRC, 1989]. Therefore, biomarkers may represent signals in the 
intervening steps between exposure and resultant disease [Schulte, 1989]. 
 
 
       EXPOSURE                        DISEASE 
 
Black Box 
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Biomarkers can be classified into three main types: biomarkers of exposure, biomarkers of 
effect and biomarkers of susceptibility [NRC, 1987]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2.2.1: Flow chart of the position of different types of biomarkers in the pathway 
from exposure to disease. Solid arrows indicate progression. The pathway is a temporal 
sequence where the higher event generally precedes the lower event. Biomarkers in the first three 
blocks can be considered biomarkers of exposure and biomarkers in the lower four blocks can be 
considered biomarkers of effect. Biomarkers of susceptibility can occur at any stage in the 
pathway. Adapted from [NRC, 1987].  
 
 
 
For any given toxicant exposure, there may therefore be several biomarkers with different 
levels of sensitivity and specificity that can be measured in different body fluids and 
tissues [Timbrell, 1998]. 
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1.2.2.2 Biomarkers of exposure 
 
These are the xenobiotic substance of interest or a metabolite(s) or product of its 
interaction with a biological molecule or cell, that are measured in a compartment within 
an organism [NRC, 1989]. They can be divided into two types: markers of internal dose or 
markers of effective dose.  
 
While external exposure is the level of xenobiotic substances an organism is exposed to, 
the internal dose is the amount of the xenobiotic compound that is actually absorbed into 
the organism and effective dose is the amount of the xenobiotic compound that interacts 
with critical subcellular, cellular and tissue targets [NRC, 1987]. Biomarkers of internal 
dose therefore indicate that exposure to a xenobiotic compound has taken place by 
measuring the compound or its metabolite(s) in body fluids. Biomarkers of effective dose 
indicate that exposure to a xenobiotic compound has resulted in the compound or its 
metabolite(s) reaching a toxicologically significant target [Timbrell, 1998]. 
 
Examples of biomarkers of exposure in the occupational health setting include urinary 
cadmium as a long term marker of cadmium exposure, urinary methylhippuric acid as a 
marker of recent xylene exposure and the DNA adduct Styrene oxide-O6 guanine as a 
marker of styrene exposure [Waterfield and Timbrell, 2000].  
 
1.2.2.3 Biomarkers of effect 
 
These are measurable physiologic, biochemical, or other changes within an organism that 
can be recognized as a potential or established health impairment or disease [NRC, 1989].  
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In the case of biomarkers of effect, an effect is defined as a recognized disease, an early 
precursor of a disease process, or an event that is nonessential to any disease process but is 
correlated with one and is thus predictive of the development of the disease. A biological 
marker of effect can therefore be any change that is quantitatively or qualitatively 
predictive of a disease associated with exposure. [NRC, 1987, NRC, 1989].  
 
As far as exposure is concerned, biomarkers of effect are, in theory, non-specific. 
However, in occupational situations it is often possible to exclude other factors affecting 
the biomarker levels and therefore a relative specificity is possible [Aitio, 1999].  
 
Biomarkers of effect range from simple (for example body weight) to complex (for 
example determination of specific isoenzymes). They can also be divided into those that 
detect biochemical changes or those that indicate pathological damage; and those that can 
be accessed through invasive or non-invasive procedures. [Timbrell, 1998]. In addition, 
biomarkers of effect can be classified as either early or late biomarkers. Early biomarkers 
of effect can indicate the extent of the initial interaction of the toxic substance (for example 
crystalline silica) with the cellular systems while late biomarkers of effect can indicate 
early minimum damage to the lung. An ideal biomarker of effect would be able to indicate 
early reversible events [Gulumian et al., 2006].  
 
Examples of biomarkers of effect include the enzyme aspartate aminotransferase (AST) as 
a measure of myocardial damage, induction of cytochrome P450 isoenzymes as a marker 
of exposure to polycyclic aromatic hydrocarbons (PAHs) and organochlorine compounds, 
and increased metallothionein levels as a marker of heavy metal exposure (such as 
cadmium) [Waterfield and Timbrell, 2000]. 
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1.2.2.4 Biomarkers of susceptibility 
 
These indicate an acquired or inherent limitation in the ability of an organism to respond to 
the exposure to specific xenobiotic substance [NRC, 1989]. Therefore, any variation in the 
response of an individual to identical exposures could indicate a difference in susceptibility 
due to either the genetic make-up of the individual or to factors or environmental 
influences such as diet or the uptake and absorption of the xenobiotic substance. However, 
the most likely source of variability is due to the metabolism of the substance by the 
organism, which may be genetically determined. [Waterfield and Timbrell, 2000]. 
 
Biomarkers of susceptibility include, among others, polymorphisms in genes responsible 
for DNA repair, genomic stability and chemical activation or detoxification [Schulte and 
Rothman, 1998].  
There are however numerous ethical, legal and social issues surrounding the use of 
biomarkers of susceptibility [Schulte, 1991].  
 
1.2.2.5 Applications of biomarkers 
 
The different types of biomarkers can be used to 1) assess exposure, 2) identify effects or 
changes that occur as a result of the exposure, 3) identify the start of pathological changes 
before the development of the disease, and 4) predict susceptibility of individuals to 
disease [Gulumian et al., 2006]. Therefore, the ultimate objective of biomarkers is to 
identify problems as early as possible to avoid adverse effects [Waterfield and Timbrell, 
2000].  
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The most important prerequisite for a biomarker to be practically useful is that enough 
information is available to translate the observed changes in terms of health significance 
and clinical relevance. The most challenging part of achieving this is to distinguish 
between adaptive and toxic effects, reversible and irreversible effects, and adverse from 
non-adverse effects [Bernard and Hermans, 1997].  
 
In population studies, the potential uses of biomarkers include: 1) mechanistic studies (i.e. 
the identification of the mechanism); 2) as a “gold standard” in validation studies; and 3) to 
monitor compliance to a prescribed regime [Howe, 1998]. 
 
One application for biomarkers of exposure is in biological monitoring (which involves the 
periodic measurement of a biomarker of exposure). Biological monitoring aims to quantify 
the amount of chemical absorbed; transformed into an active metabolite or accumulated in 
organs, tissues or cells when exposure to a chemical occurs. In epidemiological research, 
this can help to overcome the limitations of crude markers of exposure such as job titles or 
point estimates of airborne pollution. [Mutti, 1999].  
 
1.2.2.6 Limitations of biomarkers 
 
Potential limitations of the use of biomarkers include: 1) the high cost of assaying many 
biomarkers may mean that only a small sample size can be used (which results in an 
increase in random error and a decrease in study power); 2) in case-control studies many 
biomarkers may only reflect recent exposures and may not reflect exposure at the time 
relevant to the aetiology of the disease; 3) in case-control studies the disease process and/or 
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treatment may affect the biomarker in an unpredictable manner; and 4) in cohort studies 
longitudinal exposure data may not be available [Howe, 1998]. 
 
1.2.2.7 Ideal characteristics of biomarkers 
 
Ideally, a biomarker should be 1) specific, 2) sensitive, 3) quantitative, 4) in-expensive, 5) 
easily measurable, 6) related to the biochemical mechanism, 7) detectable at realistic 
exposure doses and 8) assessed by non-invasive procedures [Timbrell, 1998]. However, all 
these characteristics will rarely be available in one biomarker [NRC, 1989]. 
 
1.2.2.8 Validation of biomarkers 
 
Before a biomarker can be used as an independent or dependent variable for medical 
screening, surveillance, or intervention, it must be validated [Schulte, 2005]. An essential 
step in the validation process is establishing that a relationship between an environmental 
exposure and the biological change of interest (the biomarker) exists [NRC, 1989]. 
Validation can also include the determination of the specificity and sensitivity of the 
biomarker, characterization of all variability sources (analytical, biological) and 
characterization of the background levels [Manini et al., 2007]. 
 
Validation of biomarkers involves both laboratory and population requirements. The 
laboratory requirements include the analytical validity of the assay or test and an 
understanding of the biology of the biomarker. The population requirements include 
describing the performance of the test in populations and the factors that affect the test or 
biomarker (for example pre-existing medical conditions, lifestyle choices, or 
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environmental factors). [Schulte, 2005]. It is also important to consider the stability of the 
biomarker during the sampling process and storage (for example the storage temperature 
and duration) [Kang et al., 2005].  
 
In order to evaluate the health risks arising from exposure to xenobiotic substances, 
reference values (called Biological Exposure Indices or BEI) for the general population are 
determined in order to identify individuals with an increased exposure compared to the 
background level [Morgan, 1997]. However, biomarkers are subject to biological 
variability. As a result, reference values (RVs) for biomarkers should be defined at a local 
level since they are influenced by environmental exposure levels in that country, biological 
conditions (age, sex, diseases), metabolic interferences due to lifestyle choices (such as 
tobacco and alcohol consumption, use of drugs), genetic polymorphisms, and improvement 
in analytical procedures [Manini et al., 2007].    
 
1.2.2.10 Potential biomarkers of crystalline silica exposure 
 
Ever since the pathogenic pathway of silicosis was elucidated, attempts have been made to 
identify suitable biomarkers to detect exposure to high levels of crystalline silica and/or to 
predict the development of silicosis.  
 
In terms of crystalline silica as a biomarker of exposure, the major problem is that silica 
cannot be measured directly in blood, unlike other chemicals such as lead. It can however 
be measured in lung tissue and in bronchoalveolar lavage fluid (BALF) but these methods 
are invasive and expensive and therefore not practical for exposure studies. In addition, 
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neither the presence nor elemental analysis of crystalline silica has produced an accurate 
estimation of internal dose in relation to disease. [Gulumian et al., 2006].  
 
A number of polymorphisms, such as TNF-α and IL-1 polymorphisms, have been 
investigated as possible biomarkers of susceptibility for silicosis in crystalline silica 
exposed individuals. One of these investigations [McCanlies et al., 2002] has however 
suggested that although this genetic information is valuable in characterising risk, it is not 
a useful tool for individual classification. In addition, such biomarkers would indicate 
susceptibility to silicosis rather than indicating recent exposure to crystalline silica 
exposure [Corbett et al., 2002]. Finally, there may be ethical, social, and legal problems 
associated with the use of biomarkers of susceptibility [Schulte, 1991].  
 
Due to the limitations associated with the biomarkers of exposure and susceptibility, it is 
preferable to investigate silica exposure indirectly by identifying and measuring 
biomarkers of effect of crystalline silica exposure in the blood or other easily accessible 
body fluids.  
 
The first phase of this project identified ten potential biomarkers of effect that were 
considered worthy of further investigation [Gulumian et al., 2006]. The ten biomarkers 
identified were: reactive oxygen species (ROS) measurement by chemiluminescence 
(neutrophil release), erythrocyte glutathione (GSH), erythrocyte glutathione-S-transferase 
(GST), erythrocyte glutathione peroxidase (GPx), n-8 isoprostane, tumour necrosis factor 
alpha (TNF-α), platelet-derived growth factor (PDGF), interleukin-8 (IL-8), Clara cell 
protein 16 (CC16), and total antioxidant status as a trolox equivalent (TAS).  
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The second phase of this project evaluated the ten biomarkers to determine the influence (if 
any) of Human Immunodeficiency Virus (HIV) infection, anti retroviral (ARV) treatment, 
smoking, age and the ability to discriminate between crystalline silica exposed and 
unexposed individuals. Two of the ten biomarkers investigated, namely erythrocyte GPx 
and serum CC16, were found to be significantly decreased in the silica dust-exposed 
subjects. In addition, the two biomarkers were found to be unaffected by HIV infection, 
ARV treatment, smoking, age and the presence of radiological silicosis. [Murray et al., 
2006].   
  
 This third phase of the project aimed to confirm the levels of and further analyze CC16 
and GPx in relation to the levels and duration of crystalline silica exposure. GPx and CC16 
are both biomarkers of effect; erythrocyte GPx is a marker of oxidative stress while serum 
CC16 is a marker of Clara cell (lung) damage.  
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1.2.3 Oxidative Stress markers 
 
1.2.3.1 Reactive oxygen species  
 
Reactive oxygen species (ROS) is the term given to oxygen free radicals and their 
metabolites. Free radicals are atoms or molecules with one or more unpaired electrons. 
Oxygen-centred free radicals contain the unpaired electron on the oxygen atom. 
[Vallyathan and Shi, 1997].  
 
In the lungs, ROS can be produced by both endogenous and exogenous sources:  
 
Endogenous sources:  
Oxygen free radicals, which are usually beneficial to metabolic processes, are constantly 
produced by living cells. The main sources for the endogenous production of ROS are the 
mitochondria (during energy production), microsomes, endoplasmic reticulum, endothelial 
cells, nuclei, and phagocytic cells (such as AMs and neutrophils).  
 
Exogenous sources:  
These include physical and chemical agents such as tobacco smoke, toxic gases, vapours, 
chemicals, dust particles (such as asbestos and crystalline silica), and ambient air 
containing toxicants. [Vallyathan and Shi, 1997]. 
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1.2.3.2 The involvement of ROS in silica exposure 
 
As was previously described in sections 1.2.1.3 and 1.2.1.9, crystalline silica is able to 
produce ROS directly and/or by the stimulation of inflammatory cells (such as AMs). The 
ROS produced directly by freshly fractured crystalline silica include silicon-based radicals 
(Si•, SiO•, and SiOO•) in air [Ding et al., 2002], as well as hydroxyl radical (OH•), 
hydrogen peroxide (H2O2), superoxide anion radical (O2•-), and singlet oxygen (O2) in 
aqueous medium [Shi et al., 1995]. The ROS produced by the immune response to 
crystalline silica inhalation include the superoxide anion radical (O2•-), hydroxyl radical 
(OH•), hydrogen peroxide (H2O2) and hypochlorous acid (HOCl) [Engelen et al., 1990]. 
 
Reactive oxygen species may be involved in a number of silica-induced responses such as 
inflammation, fibrosis [Mossman and Churg, 1998], cell injury and proliferation 
[Vallyathan et al., 1998], and DNA modifications [Shi et al., 1995]. 
 
1.2.3.3 Oxidative stress 
 
Oxidative stress has been defined as “An imbalance between oxidants and antioxidants in 
favour of the oxidants, potentially leading to damage” [Sies, 1997]. As described earlier, 
oxidants such as ROS are continuously generated by both endogenous and exogenous 
sources. While low doses of radicals can be valuable or essential (for example in 
intracellular messaging and defence against micro-organisms), high doses can result in 
oxidative stress [Mates et al., 1999]. 
 
  
 
 41 
Oxidative stress plays a key role in the pathogenesis of many lung diseases both directly or 
indirectly [MacNee, 2000]. In the case of silicosis, exposure to crystalline silica causes an 
overwhelming production of ROS, which causes an imbalance in oxidant/antioxidant state 
and therefore oxidative stress [Zhang et al., 1999]. 
 
1.2.3.4 The lungs’ defence against oxidative stress  
 
The lung is the primary interface between the organism and the inhaled toxicants and it 
therefore plays a vital role in protecting against the ROS produced by these toxicants 
[Rahman et al., 1999]. The large epithelial surface area of the lung (including the 
tracheobronchial tree and the alveolar space) is particularly at risk to attack from ROS 
produced by inhaled toxicants [Comhair and Erzurum, 2005].  
 
The lungs’ main defence against inhaled ROS is an antioxidant system, which consists of a 
range of enzymatic and non-enzymatic molecules [Rahman et al., 1999]. The antioxidant 
system is normally able to cope with the continuous stream of free radicals [Borm et al., 
1986]. Antioxidants exert their protective effect by: 1) preventing free radical production, 
2) intercepting free radicals that have already been produced, 3) repairing oxidative 
damage caused by free radicals and 4) helping to eliminate damaged molecules 
[Gutteridge, 1995].  
 
1.2.3.5 The non-enzymatic antioxidant defence system 
 
One of the most important antioxidant defence mechanisms is the non-enzymatic 
glutathione (GSH) redox system.  
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Glutathione is a tripeptide consisting of γ-glutamic acid, cysteine and glycine, and it is 
present in all tissues. Reduced glutathione (GSH) can react with oxidants to form the 
oxidized form, glutathione disulphide (GSSG), or a mixed disulphide (RSSG) [Moldeus 
and Jiang, 1987].  
 
The susceptibility and tolerance of lung epithelial cells to oxidative stress are strongly 
affected by their intracellular redox status (GSH/GSSG) [Rahman et al., 2005]. Normally 
the cells of the lung contain a high concentration of GSH to help protect the lung from 
oxidative stress. Glutathione limits the oxidative stress induced by toxicants by 1) 
returning cellular constituents to their normal reduced forms and thereby restoring their 
normal physiological function and 2) assisting in the detoxification of oxidants thereby 
preventing cellular injury. A decrease in GSH levels may therefore contribute to the 
development of lung injury and disease. [Rahman et al., 1999] 
 
Besides GSH, the GSH redox system consists of a number of antioxidant enzymes, 
namely, glutathione peroxidase (GPx), glutathione reductase (GR), glutathione S-
transferase (GST), and glucose 6-phosphate dehydrogenase (G6PD). While GSH and GPx 
function to detoxify exogeneous toxicants and their reactive intermediates, GR reduces 
GSSG back to GSH (using reduced nicotinamide adenine dinucleotide phosphate, 
NADPH) and G6PD helps maintain the NADPH in its reduced form. [Rahman et al., 
1999]. 
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1.2.3.6 The enzymatic antioxidant defense system  
 
The main antioxidant enzymes are catalase (CAT), manganese and copper-zinc superoxide 
dismutase (SOD), and glutathione peroxidase (GPx). They frequently act in a coordinated 
manner to protect the lungs or other tissues from damage caused by oxidative stress. 
[Quinlan et al., 1994]. Superoxide dismutase converts the toxic superoxide anion radical 
(O2•-) into hydrogen peroxide (H2O2) as follows: 
 
2 O2•-   +  2 H+    H2O2 + O2 
 
In order to prevent hydrogen peroxide from forming the highly toxic hydroxyl radical 
(OH•), CAT and GPx catalyze the conversion of hydrogen peroxide to other non-toxic 
products (such as water) as follows [Rahman et al., 2005]: 
 
2 H2O2    O2  +  2 H2O 
 
H2O2  +  2GSH   2 H2O +  GSSG   
 
These three antioxidant enzymes are all found in human erythrocytes [Andersen et al., 
1997], and for a long time CAT and GPx were considered the erythrocyte’s main defense 
against hydrogen peroxide. Recently, however, more attention is being paid to the 
antioxidant role of a family of peroxidases, called peroxiredoxins, in erythrocytes [Low et 
al., 2007]. 
 
SOD 
CAT 
GPx 
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Peroxiredoxins (Prxs) are a group of antioxidant enzymes that reduce H2O2 and alkyl 
hydroperoxides to water and alcohol, respectively [Jara et al., 2007]. They rely on a 
conserved cysteine residue to catalyze the reduction. Six mammalian isoforms (Prx1-6) 
have been identified with erythrocytes possessing in abundance Prx2 and a small amount 
of Prx1 and Prx6. [Low et al., 2007]. Except for Prx6 which uses GSH as a co-substrate , 
Prxs use thioredoxin (Trx) as a co-substrate and therefore the reduction of hydrogen 
peroxide by most Prxs can be illustrated as follows [Rahman et al., 2005]:  
 
H2O2  +  Trx(SH)2     H2O  +  TrxS2 
   
1.2.3.7 Characteristics of GPx 
 
Glutathione peroxidase (E.C.1.11.1.9) was first described by Mills in erythrocytes [Mills, 
1957]. It was shown to be essential for the protection of erythrocytes from oxidative 
breakdown, for example from hydrogen peroxide or ascorbic acid  [Mills, 1957, Mills and 
Randall, 1958].  
 
Glutathione peroxidase exists as two forms, selenium (Se)-dependent GPx and Se-
independent GPx. Approximately one third of the lung GPx activity is Se-independent. 
[Rahman et al., 1999]. 
 
There are four types of selenium-dependent GPx (that result from the expression of 
different genes): the classic cellular GPx (cGPx), the gastrointestinal GPx (giGPx), the 
extracellular or plasma GPx (eGPx or pGPx), and the phospholipid hydroperoxide GPx 
Prx 
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(PHGPx) [Brigelius-Floche, 1993], also referred to as GPx-1 to GPx-4, respectively 
[Toppo et al., 2008]. 
 
Erythrocyte (cellular) GPx is a 85 kDa protein [Rahman et al., 1999] that forms a tetramer 
of four identical subunits each with a selenocysteine in their active site [Forstrom et al., 
1978]. It plays a significant role in the protection of lungs against oxidative damage 
(caused by ROS) [Nadif et al., 2001]. This may be due to the fact that erythrocytes can act 
as a circulating antioxidant system in the lung. They are able to penetrate into the smallest 
blood vessels, which allows them to reach the sites of inflammation [Borm et al., 1986].  
 
1.2.3.8 Function of GPx 
 
Glutathione peroxidases catalyze the reduction of hydrogen peroxide (H2O2), lipid 
hydroperoxides, and organic hydroperoxides; such as cumene hydroperoxide (CUOOH) 
[Saint-Denis et al., 1998] and tert-butyl hydroperoxide (t-BOOH) [Brigelius-Floche et al., 
2002]; to water (H2O) and alcohol (ROH) using reduced glutathione (GSH) as a co-
substrate [Mannervik, 1985]: 
 
ROOH  +  2 GSH
  
H2O  +  ROH  +  GSSG 
 
The oxidised glutathione (GSSG) is recycled to its original state by reduced nicotinamide 
adenine dinucleotide phosphate (NADPH) in a reaction catalyzed by glutathione reductase 
(GR) [Brigelius-Floche et al., 2002]:  
 
GSSG  +  NADPH  +  H+                        2 GSH  +   NADP+ 
GPx 
GR 
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The primary function of glutathione peroxidase is therefore the in vivo detoxification of 
toxic hydrogen peroxide to less toxic products. Evidence reveals that cellular GPx (in 
conjunction with the pentose phosphate cycle and glutathione reductase) efficiently 
metabolizes intracellular hydrogen peroxide. The cellular GPx system is therefore a highly 
efficient and indispensable part of the cells’ protection against oxidative stress. [Ursini et 
al., 1995].  
 
1.2.3.9 Research involving GPx and exposure to crystalline silica and 
other toxicants  
 
The activity of GPx has been shown to be affected by exposure to a number of toxicants, 
such as cigarette smoke [Li et al., 1994, Gilks et al., 1998, Vallyathan and Shi, 1997, 
Duthie et al., 1991, Kondo et al., 1994, Ho et al., 2005] and cadmium [Babu et al., 2006], 
and in a number of diseases including chronic obstructive pulmonary disease (COPD) 
[MacNee, 2000, Kluchova et al., 2007], asthma [Misso et al., 1996, Powell et al., 1994], 
and bronchopulmonary dysplasia [Fu et al., 2008].  
 
Since crystalline silica exposure causes oxidative stress and GPx activity is considered a 
marker of oxidative stress, a number of studies have examined the effect of crystalline 
silica exposure (and/or silicosis) on the activity of GPx.  
 
In two studies involving silicosis patients and unexposed controls, one study found a 
significant decrease in GPx activity in the silicosis patients versus controls (p < 0.001) 
[Zhou et al., 1999] while the other found a non-significant decrease (2.44 U/g Hb versus 
2.86 U/g Hb,  p < 0.1)[Borm et al., 1986]. A decrease in GPx activity has also been 
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observed in coal mine workers.  A study of active and retired French coal miners showed a 
significant decrease in mean GPx activity in the active miners compared to the retired 
miners (38.8 ± 12.5 U/g Hb versus 44.6 ± 13.7 U/g Hb,  p = 0.01) [Nadif et al., 2001]. A 
similar study of coal miners from three French regions found that the retired miners with 
coal workers’ pneumoconiosis (CWP) had a lower GPx activity than those without CWP; 
however, the study also found that the GPx activity of active underground miners with 
CWP was slightly higher than those without CWP. Engelen and colleagues [1990] also 
showed that mean GPx activity was higher in Belgian coal miners with CWP than those 
without CWP (9.80 ± 0.05 U/g Hb versus 9.58 ± 0.08 U/g Hb, p = 0.04). A later study of 
rats acutely exposed to quartz  also found a significantly higher level of GPx activity in the 
exposed rats compared to the controls [Vallyathan et al., 1995].  
 
The large variation in GPx activity values obtained in the aforementioned Borm et al 
[1986], Nadif et al [2001] and Engelen et al [1990] studies may have been due to the fact 
that different assays were used and the study participants were from different geographical 
regions. Although an accepted range of GPx activity for healthy silica exposed workers 
could not be found, a study on the biological variability of erythrocyte GPx [Guemouri et 
al., 1991] reported erythrocyte GPx activity levels of between 22.5 and 67.0 U/g Hb in 
healthy unexposed adult males and between 24.4 and 68.1 U/g Hb in healthy adult females. 
 
Due to the uncertainty surrounding the effect of crystalline silica exposure on GPx activity, 
further investigation was warranted. In addition, none of the above mentioned studies 
involved South African subjects or gold miners and none examined the effect of HIV 
infection or ARV treatment on GPx activity. Phase two of this project on biomarkers 
therefore aimed to investigate the levels of GPx activity in silica exposed gold miners and 
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controls from South Africa and determine if the levels were affected by HIV infection or 
ARV treatment. It showed that the GPx activity was significantly lower in the subjects 
exposed to crystalline silica compared to those with no exposure. It also found that there 
was no significant effect of HIV infection or ARV treatment on GPx activity. [Murray et 
al., 2006] 
 
The third phase of this project therefore aimed to further investigate the levels of 
erythrocyte GPx activity in relation to crystalline silica exposure. 
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1.2.4 Lung damage markers 
 
The lung is a highly complex organ that contains over 40 different cell types [Bernard and 
Hermans, 1997], including Clara cells.  
 
1.2.4.1 Clara cells 
 
Although Clara cells were first recognised as a morphologically distinct cell type by 
Kölliker in 1881, Max Clara described the same cells in 1937 and the cells were named 
after him [Singh and Katyal, 1997]. Clara cells are nonciliated secretory epithelial cells 
(with diameters of 5 mm or less) that line the pulmonary airways (figure 1.2.4.1), in 
particular the respiratory and terminal bronchioles [Singh et al., 1988b].  
 
Clara cells are one of the most multifunctional and heterogeneous cell types in the 
mammalian lung, with their main function being the protection of the respiratory tract 
[Broeckaert and Bernard, 2000].  
 
One of the proteins secreted by Clara Cells is a 16 kDa protein known as Clara Cell Protein 
16 or CC16 [Singh and Katyal, 1997]. In literature, the different CC16 homologues have 
been referred to by a number of different names which indicate their molecular weight 
(CC16, and Clara cell 10 kDa protein (CC10)), their origin (human protein-1, urine 
protein-1, uteroglobin (UG), and Clara cell secretory protein (CCSP)), or their function 
(blastokinin, Clara cell phospholipid-binding protein, and PCB-binding protein) 
[Broeckaert and Bernard, 2000]. 
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Figure 1.2.4.1: A schematic diagram of the distal pulmonary epithelium (A) with an enlarged 
view of a Clara cell (B). sER= smooth endoplasmic reticulum, rER= rough endoplasmic 
reticulum. Adapted from [Matthay et al., 2002] and 
http://anatomy.iupui.edu/courses/histo_D502/D502f04/lecture.f04/Respsystemf04/respiratory.html  
 
1.2.4.2 History of CC16 
 
In 1988, Jackson described the purification of a protein (called urine protein-1) from the 
urine of patients with renal failure [Jackson et al., 1988]. A protein, that was specifically 
localised to Clara cells in the lung, was then identified in rats [Singh and Katyal, 1984, 
Singh et al., 1985], rabbits [Gupta et al., 1987] and humans [Singh et al., 1988b]. It was 
determined, by means of sodium dodecyl sulphate-polycrylamide gel electrophoresis 
(SDS-PAGE), that the protein had a molecular weight of 10 kDa and was composed of two 
5 kDa subunits [Singh et al., 1987]. Because the protein was the major secretory protein of 
the Clara cell, it was called Clara cell 10 kDa protein (CC10). Later studies showed that 
CC10 was identical to urine protein-1 [Bernard et al., 1992c, Bernard et al., 1992b] and 
that it was also the counterpart of rabbit uteroglobin [Mantile et al., 1993]. In 1993, 
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electrospray ionization/mass spectrometry showed that the molecular mass of the protein 
was actually 15 840 Da (16 kDa) which lead to the more common term of CC16 [Bernard 
et al., 1993].  
 
1.2.4.3 Structure of CC16 
 
Clara cell protein 16 is a homodimer of two identical 70 amino acid subunits (in 
antiparallel orientation) that are connected by two disulphide bonds [Singh et al., 1988a]. 
The early studies of CC16 showed that it is rich in glutamic acid, leucine, serine, and 
aspartic acid amino acids [Singh et al., 1988b] .  
 
1.2.4.4 Function of CC16 
 
The exact function of CC16 is still unknown, however, research indicates that it plays a 
key role in the lung as an anti-inflammatory, immunosuppressive, and antifibrotic agent 
[Wang et al., 2007]. This research includes: 
1)  The entire human CC16 gene has been sequenced and localized to chromosome 11, in 
particular the p12-p13 region. This region is occupied by several genes involved in the 
regulation of inflammation and allergy [Hay et al., 1995]. This lead to the suggestion 
that CC16 plays an important role in the regulation of inflammation in the lungs [Singh 
and Katyal, 1997].  
1) Clara cell protein 16 has been shown to inhibit the production and biological activity of 
inflammatory cytokines [Broeckaert and Bernard, 2000, Wang et al., 2007]. 
2) Clara cell protein 16 has been found to inhibit cytosolic phospholipase A2 (PLA2, an 
important enzyme in the inflammatory process) and this may be important in 
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controlling the inflammatory responses in the lung [Singh et al., 1990, Lesur et al., 
1995]. Since inhibitors of PLA2 have been shown to inhibit superoxide anion 
generation [Henderson et al., 1989], this may form part of CC16’s anti-inflammatory 
activity.  
3) Clara cell protein 16 is also able to inhibit PDGF-induced fibroblast chemotaxis 
(probably by inhibition of cytosolic PLA2) and it has been suggested that a decrease in 
CC16 may allow the recruitment of fibroblasts (and therefore fibroblast activation and 
overgrowth) in fibrosing lung diseases [Lesur et al., 1995]. 
4) Clara cell protein 16 could play an important role in the sequestration or clearance of 
toxic substances that have been deposited in the respiratory tract [Singh and Katyal, 
1997].  
5) It has also been suggested that CC16 protects the respiratory tract against oxidative 
stress [Broeckaert and Bernard, 2000]. 
 
1.2.4.5 Characteristics of CC16 
 
Although it was initially thought that CC16 was produced exclusively by Clara cells 
[Singh et al., 1988b], it was later shown that CC16 is also secreted in the male urogenital 
tract (in particular the prostate) [Bernard et al., 1991] as well as in the thyroid, mammary 
gland, and the pituitary [Peri et al., 1993]. As a result, in addition to the BALF, CC16 has 
been detected in a number of body fluids including urine, sperm, amniotic fluid and serum 
[Bernard et al., 1993].   
 
The presence of CC16 in serum can only be explained by assuming that it moves from the 
lung into the bloodstream [Hermans and Bernard, 1999].  Although the exact mechanism 
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by which this happens and the exact sites of their passage are unknown, the most likely 
explanation is passive diffusion across the bronchoalveolar-blood barrier. This theory has 
been supported by studies that show a positive correlation between the CC16 concentration 
in serum and BALF [Petrek et al., 2002]. The most likely driving force for this diffusion is 
the large CC16 concentration gradient that exists across the bronchoalveolar-blood barrier 
[Bernard et al., 1998].  In addition, because CC16 is small (molecular radius ∼1.9 nm) and 
because of the sieving properties of the alveolar barrier, CC16 is likely to move across the 
bronchoalveolar-blood barrier with little hindrance [Hermans and Bernard, 1998].  
 
Once in the bloodstream, CC16 can rapidly be eliminated by glomerular filtration in the 
kidneys before being collected and catabolised in the proximal tubule cells [Bernard and 
Hermans, 1997].  
 
The concentration of CC16 in serum is therefore determined by a number of factors. 
 
 
Figure 1.2.4.5: Schematic diagram of factors affecting the concentration of CC16 in serum. 
CC16 moves from the lung into serum and is then eliminated by the kidneys. GFR= glomerular 
filtration rate, ELF=epithelial lining fluid, BALF = bronchoalveolar lavage fluid. [Hermans and 
Bernard, 1998] 
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1.2.4.6 Applications of CC16 as a lung damage marker 
 
If this theory of the movement of CC16 from the lung to the bloodstream is accepted, the 
assessment of the levels of CC16 in serum could be used for two important applications:  
1) It could be used to assess the integrity of the bronchoalveolar-blood barrier (which can 
be compromised in a number of diseases)  
2) It could be used to assess the changes in the number and/or integrity of the lung 
epithelial cells (when the bronchoalveolar-blood barrier is intact or slightly impaired). 
[Hermans and Bernard, 1998].  
 
In fact, studies on experimental animals and occupationally exposed workers indicate that 
serum CC16 may be a relatively specific and sensitive biomarker for detecting early acute 
or chronic effects of toxicants on the tracheobronchial tree [Bernard and Hermans, 1997]. 
This is important as early lung injury is difficult to identify [Waterfield, 2000] and, at 
present, no toxicity biomarker is in place to monitor populations exposed to occupational 
or environmental pneumotoxins [Bernard and Hermans, 1997].  
 
1.2.4.7 Research involving CC16 and exposure to crystalline silica and 
other toxicants 
 
Levels of CC16 have been shown to increase in individuals exposed to toxicants such as 
asbestos [Petrek et al., 2002], polypropylene combustion products [Bernard et al., 1997], 
and ozone [Arsalane et al., 1999, Blomberg et al., 2003] and in patients suffering from 
sarcoidosis [Bernard et al., 1992a] and idiopathic pulmonary fibrosis [Lesur et al., 1995]. 
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This increase has been attributed to an increase in the permeability of the bronchoalveolar-
blood barrier and therefore an increase in the movement of CC16 into the bloodstream.  
 
However, the few studies that have examined the effect of crystalline silica dust exposure 
on the concentration of CC16 in serum have found decreased CC16 levels. Bernard and 
colleagues [1994a] measured the levels of CC16 in the serum of asymptomatic quarry 
miners exposed to silica dust and control subjects and found a significant decrease in the 
mean CC16 levels in the miners (16.3 ng/ml for controls versus 12.3 ng/ml for miners,      
p = 0.001). Later, Wang et al [2007] studied the role of serum CC16 as a biomarker for the 
early diagnosis and the pathogenesis of silicosis. They also found that the serum CC16 
concentration was significantly reduced in the silica-exposed pyrite mine workers 
compared to the controls   (4.42 ± 1.83 ng/ml versus 12.59 ± 3.85 ng/ml, p < 0.01). The 
authors proposed that the decrease in CC16 levels in serum was as a result of a decreased 
secretion or production of CC16 due to the destruction of Clara cells by silica. 
 
The results obtained for the aforementioned studies indicated that CC16 may be a 
promising marker of early lung injury caused by crystalline silica exposure. The second 
phase of this project on biomarkers therefore aimed to investigate the effect of crystalline 
silica exposure on the levels of serum CC16 in gold miners and controls from South 
Africa. It also aimed to determine if the CC16 levels were affected by HIV infection or 
ARV treatment. The study found that the CC16 levels were significantly lower in the 
subjects exposed to silica than those with no exposure (4.87 ± 1.69 ng/ml versus 5.77 ± 
1.64 ng/ml, p = 0.02) and it also found that there was no significant effect of HIV infection 
or ARV treatment on the CC16 levels [Murray et al., 2006][see Appendix A]. 
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The third phase of this project therefore aimed to further investigate the levels of serum 
CC16 concentration in relation to crystalline silica exposure. 
 
There was a large variation in the mean CC16 levels in the control groups of the Bernard et 
al [1994a], Wang et al [2001] and Murray et al [2006] studies. This large variation may be 
due to population differences. Other studies have reported serum CC16 levels of between 
6.6 and 23.2 µg/l in healthy adult males and between 3.7 and 22.9 µg/l in healthy adult 
females [Shijubo et al., 2003]. A study on the effect of geographical location on CC16 
levels would therefore be worthwhile; however, this was not investigated in the current 
study. 
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1.3 Aims and Objectives 
 
The overall aim of this project on biomarkers is to identify, confirm and operationalise 
biomarkers for crystalline silica dust exposure that could be used for surveillance of dust 
exposure levels in South African mines and thereby assess the success of dust control 
measures. This third phase of the project aimed to confirm the levels of, and further 
analyze, two biomarkers, GPx and CC16, in miners exposed to low and high levels of 
crystalline silica dust. It also aimed to develop Standard Operating Procedures (SOPs) for 
biomarker specimen handling and storage under field conditions, and also for their assay in 
the laboratory.  
 
In order to accomplish these aims, the following objectives needed to be completed: 
• To classify the study participants into high and low dust exposure groups according to 
their current job description.  
• To measure the levels of GPx and CC16 in the study participants after their return 
from a period of leave and again following their exposure to crystalline silica. 
• To investigate the relationship between the levels of GPx and CC16 and the duration 
of exposure to crystalline silica. 
• To record chest radiological evidence of silicosis. 
• To determine the effect of storage temperature, delay time between blood sample 
collection and separation, ambient laboratory temperature and storage duration on the 
levels of GPx and CC16. 
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Chapter 2:  
Materials and Methods 
The protocol for this study was peer-reviewed by international collaborators prior to the 
commencement of the study. 
 
The diagram below outlines the three main steps involved in this phase of the project, 
which are described in sections 2.1 to 2.4: 
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2.1 Protocol for the assay of glutathione peroxidase 
 
Analysis of the activity of glutathione peroxidase (GPx) was performed using a 
Glutathione Peroxidase Assay Kit (Cayman Chemical Company, Ann Arbor, MI, U.S.A) 
according to the manufacturer’s instructions. 
 
2.1.1 Principle of the Glutathione peroxidase Assay Kit 
 
The GPx assay kit measures GPx activity indirectly by a coupled reaction with glutathione 
reductase (GR). During the assay, GPx catalyzes the reduction of cumene hydroperoxide 
(CUOOH) to water (H2O) and alcohol (CUOH) using reduced glutathione (GSH) as a     
co-substrate [Saint-Denis et al., 1998]: 
 
CUOOH  +  2 GSH    
   
H2O  +  CUOH  +  GSSG 
 
The oxidised glutathione (GSSG) is recycled to its original state by reduced nicotinamide 
adenine dinucleotide phosphate (NADPH) in a reaction catalyzed by glutathione reductase 
(GR) [Brigelius-Floche et al., 2002]: 
 
GSSG  +  NADPH  +  H+                         2 GSH  +   NADP+ 
 
The oxidation of NADPH to NADP+ is accompanied by a decrease in absorbance at       
340 nm (A340). Under the assay conditions, the GPx activity is rate limiting and therefore 
the rate of decrease in the absorbance at 340 nm is directly proportional to the GPx activity 
GR 
GPx 
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in the sample [Paglia and Valentine, 1967]. The Cayman GPx Assay Kit can be used to 
measure all of the glutathione-dependent peroxidases in plasma, erythrocyte lysate, tissue 
homogenate, and cell lysate [CaymanChemical, 2004]. 
 
Since the kit uses cumene hydroperoxide as the substrate, the total GPx activity is 
measured. However, human lungs and erythrocytes only contain Se-dependent GPx 
[Carmagnol et al., 1983] and since the current study used erythrocyte lysate samples, only 
the Se-dependent GPx activity was being measured.  
 
Although GPx is not the only hydroperoxide reducing enzyme in cells, the assay is specific 
to GPx since the assay of catalase activity involves measuring the decomposition of 
hydrogen peroxide at a wavelength of 240 nm [Andersen et al., 1997], the assay of 
peroxiredoxin activity uses the thioredoxin reductase system [Kim et al., 2005] and neither 
of catalase nor peroxiredoxin use GSH as a co-substrate.  
 
2.1.2 Glutathione peroxidase assay kit specifications 
 
Each kit contained one vial of assay buffer concentrate (10 X), one vial of sample buffer 
concentrate (10 X), one vial of GPx control (consisting of a solution of bovine erythrocyte 
GPx), three vials of co-substrate mixture (consisting of a lyophilized powder of NADPH, 
glutathione and glutathione reductase), one vial of cumene hydroperoxide, one 96 well 
plate and one plate cover.  
 
The kits were stored at -20 oC until the indicated expiration date.  
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2.1.3 Reagent preparation  
 
The kit was removed from the -20 oC freezer and the components were brought to 25 oC.  
 
The assay buffer was prepared by transferring 2 ml of assay buffer concentrate into a 
clearly labelled sterile 50 ml Falcon tube (Greiner Bio-One GmbH, Germany) containing 
18 ml of HPLC-grade water, and gently mixing. The diluted assay buffer was stable for 
two months if stored at 4 oC. The sample buffer was prepared by transferring 2 ml of 
sample buffer concentrate into a clearly labelled sterile 50 ml Falcon tube containing 18 ml 
of HPLC-grade water, and gently mixing. The diluted sample buffer was stable for one 
month if stored at 4 oC. 
 
The co-substrate mixture was prepared by adding 2 ml of HPLC-grade water to the vial 
provided and vortexing gently to mix. Each reconstituted vial of co-substrate mixture was 
enough for approximately forty wells. It was therefore only necessary to reconstitute the 
number of vials needed to supply the number of wells that were being used. The 
reconstituted co-substrate mixture was stable for two days if stored at 4 oC. 
 
The GPx control was prepared by pipetting 10 µl of the GPx control into a 1.5 ml 
microcentrifuge tube containing 490 µl of diluted sample buffer, and gently mixing. The 
GPx control was only stable for four hours when stored at 4 oC and therefore it was only 
prepared after the sample preparation was complete (refer to section 2.1.4).  According to 
the kit protocol, a 20 µl aliquot of the diluted GPx control should cause a decrease of 
approximately 0.051 absorbance units per minute under standard assay conditions 
[CaymanChemical, 2004].  
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2.1.4 Sample preparation 
 
The thawed erythrocyte lysate samples (the preparation of which is described in sections 
2.3.2.1, 2.3.3.1, 2.3.4.1, 2.3.5.1 and 2.4.4.1) were diluted 30 X by transferring 10 µl lysate 
into a 1.5 ml microcentrifuge tube containing 145 µl of diluted sample buffer, and gently 
mixing. According to the kit protocol, a 20 µl aliquot of diluted sample should have an 
initial absorbance of between 1.2 and 0.5 and should cause an absorbance decrease of 
between 0.02 and 0.135 per minute [CaymanChemical, 2004].  
 
2.1.5 Assay procedure 
 
Into each well, 100 µl of diluted assay buffer and 50 µl co-substrate mixture were added. 
The blank (non-enzymatic) wells were prepared by adding 20 µl of diluted assay buffer in 
triplicate into the designated wells. The positive control wells were prepared by adding    
20 µl of diluted GPx control in triplicate into the designated wells. The sample wells were 
prepared by adding 20 µl of 30 X diluted erythrocyte lysate sample into the designated 
wells. Finally, to initiate the reaction, 20 µl of cumene hydroperoxide was added to each 
well. 
  
The plate was gently shaken and placed in the plate holder of the automated BioTek 
ELx800TM microplate reader (BioTek Instruments, Inc., USA). The GPx activity was then 
measured.  
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2.1.6 Plate analysis 
 
To measure the absorbance of the samples, an automated microplate reader was used in 
conjunction with KC4TMv3.4 software (BioTek Instruments, Inc., USA). 
 
The microplate reader was set up while the reagents and samples were thawed. A laptop 
installed with KC4TMv3.4 software and a HP LaserJet 1010 printer were connected to the 
microplate reader. Using the KC4TMv3.4 program and the accompanying manufacturers’ 
instructions, a new protocol was designed for each experiment. Each protocol included 
details about the layout of samples, controls and blanks in the plate; the wavelength to be 
used; and the results needed in the printed report.  
 
When the plate was ready to be analyzed, the absorbance of each well was measured at       
340 nm every minute for a total of five minutes.  The resulting absorbance data was printed 
and used to calculate the GPx activity (see Appendix B). 
 
2.1.7 Calculation of GPx activity  
 
To ensure accuracy, two different methods of calculating the GPx activity (using the 
absorbance data obtained) were used. The first method involved an automated analysis tool 
provided by Cayman Chemical Company while the second involved a manually designed 
spreadsheet in Microsoft Excel.  
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2.1.7.1 Analysis tool 
 
The Cayman Chemical Company website (www.caymanchem.com) provides access to an 
analysis tool that allows the GPx activity to be calculated automatically from the 
absorbance data obtained. A document entitled “GSHases Triple’’ was downloaded and in 
the worksheet entitled “Analysis” (see Appendix C), the absorbance data obtained were 
entered into the appropriate fields. The GPx activity in each well was automatically 
calculated. The corresponding graphs of absorbance versus time for each sample were also 
automatically constructed and illustrated in a worksheet entitled “Graphs” (Appendix D). 
 
2.1.7.2 Microsoft Excel calculations 
 
Using the absorbance data obtained, the change in absorbance (∆A340) per minute of the 
blanks, positive controls and samples was calculated using the formula: 
 
 ∆A340/ min = (A340 (at 5 minutes) – A340 (at 0 minutes)) / (5 Minutes – 0 Minutes) 
 
The average rate of ∆A340/min of the blank wells was calculated and subtracted from the 
rate of ∆A340/min of the positive control wells and the sample wells. The GPx activity in 
each well was then calculated using the formula: 
 
 GPx Activity = ((∆A340/ min)/ 0.00373 µM-1) x (0.19 ml/0.02 ml) x Sample Dilution = nmol/min/ml 
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Where: 0.00373 µM-1 is the NADPH extinction coefficient; 0.19 ml is the final assay 
volume in each well; 0.02 ml is the volume of sample in each well; and the sample dilution 
is 30 X. 
 
In order to ensure reproducibility, Microsoft Excel was used to design a spreadsheet into 
which the formulae were entered. The absorbance values were then entered into the 
spreadsheet and the GPx activity was calculated.  
 
For both methods the GPx activity results were reported in units of nmol of NADPH 
oxidized to NADP+ per minute per ml (nmol/min/ml). The units were then manually 
converted, using Microsoft Excel, to units per millilitre (U/ml) where one unit (U) is 
defined as the enzyme activity that catalyzes the oxidation of 1 µmol of NADPH to 
NADP+ per minute. In order to report the GPx activity results, for the field work samples, 
in the standard SI units of Units per gram haemoglobin (U/g Hb), the haemoglobin 
concentration of the samples was measured.  
 
2.1.8 Measurement of haemoglobin  
 
The haemoglobin concentration (in g Hb/dl) of the erythrocyte lysate samples was 
measured using a Coulter ® LH500 Hematology Analyzer (Beckman Coulter, Inc, USA). 
Since the replicate erythrocyte lysate samples used in the optimization of GPx 
methodology experiments (see section 2.3.1) were prepared from the same blood sample it 
was not necessary to measure the haemoglobin concentration of these samples. Therefore, 
haemoglobin concentration was only measured in the erythrocyte lysate samples collected 
during the field work (see section 2.4.4). 
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2.2 Protocol for the assay of Clara Cell Protein 16  
 
The Clara cell protein 16 (CC16) concentration was determined using a Human Clara Cell 
Protein ELISA kit (BioVendor Laboratory Medicine, Inc; Czech Republic) according to 
the manufacturer’s instructions.  
 
2.2.1 Principle of the Human Clara Cell Protein ELISA Kit  
 
The Human Clara Cell Protein ELISA kit is a biotin labelled antibody based sandwich 
enzyme immunoassay for the quantitative measurement of human CC16 in serum, plasma, 
tissue culture medium and bronchoalveolar lavage fluid. Standards, quality controls or 
samples are incubated with rabbit polyclonal anti-human Clara Cell Protein antibody 
coated in microtiter wells. A washing step is then performed and biotin-labelled polyclonal 
anti-human Clara Cell Protein antibody is added to bind with the captured CC16. After 
incubation and washing, streptavidin-horseradish peroxidase conjugate is added to bind to 
the biotin attached to the captured CC16 via the polyclonal anti-human Clara Cell Protein 
antibody. Following a final incubation and washing, the remaining conjugate is allowed to 
react with the substrate H2O2-tetramethylbenzidine. The reaction is stopped by addition of 
acidic solution and absorbance of the resulting yellow product is measured at 450 nm. The 
absorbance is proportional to the concentration of Clara Cell Protein. A standard curve is 
constructed by plotting absorbance values versus Clara Cell Protein concentrations of 
calibrators, and concentrations of the unknown samples are determined using the standard 
curve. [BioVendor, 2006]. 
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2.2.2 Human Clara Cell Protein ELISA Kit specifications 
 
Each kit contained 100 ml of wash solution concentrate (10 X), 20 ml of dilution buffer,    
13 ml of biotin labelled antibody solution, 13 ml of streptavidin- horseradish peroxidase 
(HRP) conjugate, 13 ml of substrate solution (TMB), 13 ml of stop solution (0.2 M 
H2SO4), two vials of quality control (QC) high (lyophilized), two vials of QC low 
(lyophilized), one vial of Clara Cell Protein master calibrator (purified from human urine 
and then lyophilized), and sealed antibody coated microtitier strips (96 wells). An 
instruction manual and a certificate of analysis were also included with the kit. 
 
The kits were stored at between 2 oC and 8 oC until the indicated expiration date. 
 
2.2.3 Reagent preparation  
 
Before performing the assay, the kit was removed from the 4 oC fridge and the components 
were brought to room temperature (approximately 25 oC).  
 
Diluted wash solution was prepared by adding 100 ml of the wash solution concentrate into 
a clearly labelled 1 L Schott laboratory bottle (Schott UK Ltd, UK) containing 900 ml of 
HPLC-grade water, and gently mixing. The diluted wash solution was stable for one month 
if stored at 4 oC. 
 
The Clara Cell Protein Master Calibrator was reconstituted by the addition of 0.5 ml 
dilution buffer and mixed gently. The concentration of human Clara Cell Protein in the 
  
 
 68 
stock solution was 100 ng/ml. The 100 ng/ml stock solution was serially diluted to prepare 
a 40, 20, 10, 5 and 2 ng/ml standard according to table 2.2.3.a.  
 
Table 2.2.3.a: Preparation of Clara Cell Protein standards by serial dilution of 100 ng/ml 
Clara Cell Protein stock solution 
 
Volume of standard Volume of dilution buffer 
Final concentration  
of standard 
200 µl of 100 ng/ml stock 300 µl 40 ng/ml 
200 µl of 40 ng/ml standard 200 µl 20 ng/ml 
200 µl of 20 ng/ml standard 200 µl 10 ng/ml 
200 µl of 10 ng/ml standard 200 µl 5 ng/ml 
200 µl of 50 ng/ml standard 300 µl 2 ng/ml 
 
 
The QC high, QC low and the six standards were diluted 25 X by pipetting 10 µl of the 
reagent into a 1.5 ml microcentrifuge tube containing 240 µl dilution buffer and were 
mixed gently. 
 
Each Human Clara Cell Protein ELISA kit contains a certificate of analysis stating the 
expected results for the provided standards and quality controls (refer to table 2.2.3.b 
below and Appendix E). 
 
Table 2.2.3.b: Expected ELISA results for standards and quality controls (QCs) as specified 
by the certificate of analysis (for lot no RD-1276R1) 
Standards/ QC Average A450 Expected CC16  concentration (ng/ml) 
Standard 1 3.245 100 
Standard 2 2.482 40 
Standard 3 1.637 20 
Standard 4 0.987 10 
Standard 5 0.569 5 
Standard 6 0.264 2 
Blank 0.011 - 
QC High 1.913 23.09 (18.5-27.7) 
QC Low 0.546 4.46 (3.6-5.3) 
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2.2.4 Sample preparation 
 
The thawed serum samples (the preparation of which is described in sections 2.3.2.2, 
2.3.3.2, 2.3.4.2, 2.3.5.2 and 2.4.4.1) were diluted 25 X by transferring 5 µl sample into a 
1.5 ml microcentrifuge tube containing 120 µl of dilution buffer and mixed gently.  
 
2.2.5 Assay procedure 
 
The blank wells were prepared by pipetting 100 µl dilution buffer in the designated wells 
in duplicate. The quality control wells were prepared by pipetting 100 µl diluted QC high 
and diluted QC low into the designated wells in duplicate. The standard wells were 
prepared by pipetting 100µl of the diluted 100, 40, 20, 10, 5 and 2 ng/ml CC16 standards 
into the designated wells in duplicate. The sample wells were prepared by pipetting 100 µl 
of diluted serum sample into the designated wells. 
 
The plate was wrapped in foil and incubated at room temperature for 75 minutes. The plate 
was washed five times with 1 X wash solution using an automated microplate washer. 
Biotin labelled antibody solution (100 µl) was then added to each well and the plate was 
wrapped in foil and incubated at room temperature for 75 minutes. Following a second 
washing step, a 100 µl streptavidin-HRP conjugate solution was added to each well. The 
plate was wrapped in foil and incubated at room temperature for a further 75 minutes. A 
third washing step was performed after which 100 µl substrate solution was added to each 
well. The plate was wrapped in foil and incubated, in the dark, at room temperature for an 
additional 10 minutes (the incubation time was increased to 20 minutes if the room 
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temperature was lower than 20 oC). The colour development was stopped by the addition 
of 100 µl stop solution. The plate was analyzed immediately.  
 
2.2.6 Plate analysis 
 
Analysis of the plate involved the measurement of the absorbance of the blanks, quality 
controls, standards and samples at 450 nm using an automated BioTek ELx800TM 
microplate reader in conjunction with KC4TMv3.4 software. 
 
The microplate reader was set up while the reagents and samples were thawed. A laptop 
installed with KC4TMv3.4 software and a HP LaserJet 1010 printer were connected to the 
microplate reader. Using the KC4TMv3.4 program and the accompanying manufacturers’ 
instructions, a new protocol was designed for each experiment. Each protocol included 
details of the layout of blanks, quality controls, standards and samples in the plate; the 
wavelength to be used; the type of standard curve, and the results required in the printed 
report. 
 
2.2.7 Calculation of CC16 concentration 
 
The absorbance values, corrected absorbance values, CC16 concentrations and a standard 
curve (refer to figure 2.2.7) were automatically calculated by the KC4TMv3.4 software and 
the results were presented in a report that was printed (see Appendix F). In order to allow 
statistical analysis of the results, they were entered into a spreadsheet in Microsoft Excel. 
 
  
 
 71 
 
Figure 2.2.7: Example of the CC16 standard curve obtained using the KC4TMv3.4 software. 
The curve was constructed by plotting the absorbance at 450 nm (Y) obtained for the standards 
versus the log of the known CC16 concentration (X) of the standards, using the four-parameter 
function. 
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2.3 Optimization of operational parameters 
 
Before the field work could commence, it was essential to determine the optimal 
conditions for the handling, storage and assaying of the GPx and CC16 samples in order to 
ensure reliable and reproducible results. A series of four optimization experiments were 
carried out to investigate the effects of storage temperature, time between blood collection 
and separation, ambient laboratory temperature and storage duration on the assessed levels 
of erythrocyte GPx and serum CC16.  
 
2.3.1 Study sample 
 
Willing volunteers were recruited from the National Institute for Occupational Health 
(NIOH). After reading the information sheet (Appendix G) and signing the necessary 
consent forms (Appendix H), blood specimens were collected from the volunteers. Five 
volunteers were used for the GPx experiments (one male and four females) and four 
volunteers were used for the CC16 experiments (three males and one female). 
 
2.3.2 The effect of storage temperature 
 
2.3.2.1 Erythrocyte GPx 
 
Venous blood was collected from two volunteers into two 6 ml BD Vacutainer tubes 
containing Lithium heparin as an anti-coagulant (Becton, Dickinson and Company, 
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U.S.A.). The bloods were immediately centrifuged at 1300 x g for 10 minutes at room 
temperature (approximately 25 oC). The upper plasma layer and buffy coat (leukocytes) 
were discarded and forty five 50 µl aliquots of packed erythrocytes were pipetted into     
1.5 ml microcentrifuge tubes containing 200 µl ice-cold distilled water (in order to lyse the 
erythrocytes). The samples were inverted gently to mix and centrifuged at 10 000 x g for 
15 minutes at 4 oC. The erythrocyte lysate supernatant (100 µl) was pipetted into clearly 
labelled 1.8 ml CryoTubes. Fifteen aliquots each were stored at 4 oC, -20 oC or -80 oC, 
respectively. 
 
At the end of three weeks storage, the 45 erythrocyte lysate samples were thawed at room 
temperature. The GPx activity in the samples was then determined using the Glutathione 
Peroxidase Assay Kit as described in section 2.1.  
 
2.3.2.2 Serum CC16  
 
Venous blood was collected from two volunteers into two 6 ml BD Vacutainer tubes 
containing Clot Act (Becton, Dickinson and Company, U.S.A.). The bloods were left to 
coagulate at room temperature for 10 minutes and then centrifuged at 1300 x g for 10 
minutes at room temperature. Forty five aliquots of 50 µl serum were pipetted into clearly 
labelled 1.8 ml CryoTubes. Fifteen aliquots each were stored at 4 oC, -20 oC or -80 oC, 
respectively. 
 
Following three weeks of storage, the 45 serum samples were thawed at room temperature. 
The CC16 concentration in the serum samples was then determined using a Clara Cell 
Protein Human ELISA Kit as detailed in section 2.2. 
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2.3.3 The effect of a delay in time between blood sample 
collection and separation 
 
2.3.3.1 Erythrocyte GPx  
 
Venous blood was collected from two volunteers into two 6 ml BD Vacutainer tubes 
containing Lithium heparin. One of the 6 ml tubes was immediately centrifuged at 1300 x g 
for 10 minutes at room temperature. From the remaining 6 ml tube, half the blood was 
transferred into a new BD Vacutainer tube. The two tubes containing 3 ml blood were left 
at room temperature for 1 and 2 hours, respectively, before centrifugation at   1300 x g for 
10 minutes at room temperature.  
 
Following centrifugation, the upper plasma layer and buffy coat were discarded and fifteen  
50 µl aliquots of packed erythrocytes were pipetted into 1.5 ml microcentrifuge tubes 
containing 200 µl ice-cold distilled water. The samples were gently inverted to mix and 
centrifuged at 10 000 x g for 15 minutes at 4oC. The erythrocyte lysate supernatant (100 µl) 
was pipetted into clearly labelled 1.8 ml CryoTubes and frozen at -80 oC.  
 
After two weeks of storage, the 45 erythrocyte lysate samples were thawed at room 
temperature. The GPx activity in the samples was then determined using a Glutathione 
Peroxidase Assay kit as described in section 2.1. 
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2.3.3.2 Serum CC16 
 
Venous blood was collected from two volunteers into two 6 ml BD Vacutainer tubes 
containing Clot Act. The bloods were left to coagulate at room temperature. Half the blood 
from one tube was transferred to a new BD Vacutainer tube. The two tubes, containing  
3 ml blood, were left at room temperature for 1 and 2 hours (respectively) before 
centrifugation at 1300 x g for 10 minutes at room temperature. After only 10 minutes, the 
remaining 6 ml tube was centrifuged at 1300 x g for 10 minutes at room temperature. 
Fifteen aliquots of 50 µl serum were pipetted from each tube into clearly labelled 1.8 ml 
CryoTubes and frozen at -80 oC.  
 
At the end of two weeks of storage, the 45 serum samples were thawed at room 
temperature. The CC16 concentration in the serum samples was then determined using a 
Clara Cell Protein Human ELISA Kit as detailed in section 2.2. 
 
2.3.4 The effect of ambient laboratory temperature 
 
2.3.4.1 Erythrocyte GPx 
 
Venous blood was collected from two volunteers into two 6 ml BD Vacutainer tubes 
containing Lithium heparin. The bloods were immediately centrifuged at 1300 x g for            
10 minutes at room temperature. During the subsequent erythrocyte lysate preparation 
steps, one tube of separated blood (and resulting samples) was kept at 25 oC while the 
  
 
 76 
other tube (and resulting samples) was kept at 35 oC using a Labnet AccuBlock Digital Dry 
Bath (Labnet International, Inc., USA).  
 
Following centrifugation, the upper plasma layer and buffy coat were discarded and fifteen  
50 µl aliquots of packed erythrocytes were pipetted from each tube into 1.5 ml 
microcentrifuge tubes containing 200 µl ice-cold distilled water. The samples were gently 
mixed and centrifuged at 10 000 x g for 15 minutes at 4 oC. The erythrocyte lysate 
supernatant (100 µl) was pipetted into clearly labelled 1.8 ml CryoTubes and frozen at    
-80 oC.  
 
After two weeks of storage, the 30 erythrocyte lysate samples were thawed and the GPx 
activity in the samples was then determined using a Glutathione Peroxidase Assay Kit as 
described in section 2.1. During the thawing and assay preparation steps, one set of 15 
erythrocyte lysate aliquots was kept at 25 oC while the other was kept at 35 oC using the 
Labnet AccuBlock Digital Dry Bath.  
 
2.3.4.2 Serum CC16 
 
Venous blood was collected from two volunteers into two 6 ml BD Vacutainer tubes 
containing Clot Act. During the subsequent serum sample preparation, thawing and assay 
preparation steps, one tube of blood (and resulting serum samples) was kept at 25 oC while 
the other tube (and resulting serum samples) was kept at 35 oC using a Labnet AccuBlock 
Digital Dry Bath.  
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The collected bloods were left to coagulate (at the different temperature) for 10 minutes 
and then centrifuged at 1300 x g for 10 minutes at room temperature. Fifteen aliquots of  
50 µl serum were collected from each tube of separated blood into clearly labelled 1.8 ml 
CryoTubes and frozen at -80 oC.  
 
Following two weeks of storage, the 30 serum samples were thawed and the CC16 
concentration in the serum samples was then determined using a Clara Cell Protein Human 
ELISA Kit as detailed in section 2.2.  
 
2.3.5 The effect of storage duration 
 
2.3.5.1 Erythrocyte GPx 
 
Venous blood was collected from two volunteers into two 6 ml BD Vacutainer tubes 
containing Lithium heparin. The bloods were immediately centrifuged at 1300 x g for            
10 minutes at room temperature. The upper plasma layer and buffy coat were discarded 
and 60 aliquots of 50 µl packed erythrocytes were pipetted into 1.5 ml microcentrifuge 
tubes containing 200 µl ice-cold distilled water. After gentle mixing, the samples were 
centrifuged at 10 000 x g for 15 minutes at 4 oC. The erythrocyte lysate supernatant      
(100 µl) was pipetted into clearly labelled 1.8 ml CryoTubes. Fifteen erythrocyte lysate 
aliquots were assayed immediately. The remaining 45 erythrocyte lysate aliquots were 
stored at -80 oC for three, six, and nine weeks respectively. At the end of the specified 
storage period, 15 frozen erythrocyte lysate aliquots were thawed at room temperature 
(approximately 25 oC) and the GPx activity in the samples was then determined using a 
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Glutathione Peroxidase Assay Kit as described in section 2.1. As a result each frozen 
erythrocyte lysate aliquot was assayed and then discarded.  
 
2.3.5.2 Serum CC16  
 
Venous blood was collected from two volunteers into two 6 ml BD Vacutainer tubes 
containing Clot Act. The bloods were left to coagulate at room temperature for ten minutes 
and then centrifuged at 1300 x g for 10 minutes at room temperature. Sixty aliquots of     
50 µl serum were pipetted into clearly labelled 1.8 ml CryoTubes. Fifteen serum aliquots 
were assayed immediately. The remaining 45 serum aliquots were stored at -80 oC for 
three, six, and nine weeks respectively. At the end of the specified storage period, 15 
frozen serum aliquots were thawed at room temperature (approximately 25 oC) and the 
CC16 concentration in the serum samples was then determined using a Clara Cell Protein 
Human ELISA Kit as detailed in section 2.2. As a result each frozen serum aliquot was 
assayed and then discarded.  
 
The results obtained from the optimization experiments were then used to develop 
Standard Operating Procedures (SOPs) for the handling, processing and analysis of GPx 
CC16 samples. The SOPs are attached as Appendix I and J, respectively.  
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2.4 Field work 
 
2.4.1 Study design 
 
2.4.1.1. Study population 
 
The study population consisted of volunteer male underground mine workers at a 
Goldfields gold mine in North West province, South Africa. 
 
2.4.1.2. Study sample 
 
The sample consisted of volunteers who met the inclusion criteria for the study.  
 
2.4.1.3. Inclusion criteria 
 
 Adult males 
 Volunteers 
 Underground mine workers 
 New employees or returning from two or more weeks leave at the time of study 
recruitment 
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2.4.1.4. Exclusion criteria 
 
 Difficult to contact telephonically to arrange follow-up visits 
 Taking medication for pulmonary tuberculosis  
 Unwilling to give blood specimens 
 
The HIV sero-status of the volunteers was not sought since the second phase of the project 
had previously shown that GPx and CC16 levels were not affected by HIV sero-status, or 
by the taking of ARV treatment.  
 
2.4.1.5. Study design 
 
A series of cross-sectional studies of 80 mine workers exposed to low and high levels of 
dust (determined by current job description as described in section 2.4.6).   
 
2.4.2 Recruitment of participants 
 
Prior to commencing the recruitment of the study participants, written permission was 
obtained from the management of the mine involved to be able to conduct the study on 
their premises without hindrance. A meeting was also held with the representatives of all 
the Unions active in the mine who expressed their satisfaction and support for the study.  
  
 
 81 
Additional assistance for the recruitment of participants and collection of field work 
samples was provided by Professor Brendan Girdler-Brown (a qualified medical 
practitioner) who was responsible for blood sample collection and by Miss Lerato Kaphe 
and Miss Thoko Ndlovu (Diploma in Technology students) who assisted with language 
interpretation. 
 
All miners undergo an induction course after their annual leave that includes a routine 
medical examination (including chest radiography) and training or re-training, which takes 
place at the mines’ Training Academy. For the current study, a temporary field laboratory 
was set up in a room in this Training Academy. Every morning (between 9 am and 1 pm) 
the employees undergoing training were given a brief multi-lingual presentation informing 
them about the project and its requirements and that their participation was voluntary. 
Those who agreed to participate were asked to meet the research team in the temporary 
laboratory at their convenience, but prior to their return to underground work. 
 
Volunteers who agreed to participate were asked to review a short information sheet 
(Appendix K), sign a consent form (Appendix L) as well as to complete a short 
questionnaire (Appendix M) (figure 2.4.2). Those volunteers, who agreed to have their 
photographs taken to be used in scientific publications and reports, were asked to sign an 
additional consent form (Appendix N). Thereafter, 15 ml of venous blood, representing the 
returning from leave (ex-leave) sample, was drawn by the qualified medical practitioner 
who is registered as such with the Health Professions Council of South Africa (HPCSA).  
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Figure 2.4.2: Prof Girdler-Brown, (left) and Miss Kaphe (middle) help a volunteer (right) to 
fill out the consent form and questionnaire. The photograph was taken after obtaining written 
consent. 
 
A total of 80 volunteers were recruited between the period of February and April 2007. 
 
2.4.3 Collection of specimens from volunteers 
 
The project protocol called for the collection of two sets of blood specimens from the 
volunteers, return from leave (ex-leave) and return to work (follow up) specimens. The 
purpose of this collection procedure was to examine the levels of GPx and CC16 before 
and after occupational exposure to crystalline silica. 
 
As stated in section 2.4.2, the return from leave (ex-leave) specimens were collected from 
the volunteers at the time of recruitment when the volunteers had been on leave for a 
period of at least two weeks. Venous blood was collected from volunteers into three 6 ml 
BD Vacutainer tubes, two containing Lithium Heparin and one containing Clot Act. 
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Once ex-leave blood specimens were collected from a total of 80 volunteers, the same 
volunteers were contacted telephonically to arrange the collection of the return to work 
(follow up) specimens. Collection of follow up samples was carried out between May and 
August 2007.  Due to the complexity of the follow up specimen collection procedure, the 
time between the collection of the ex-leave and follow up samples (i.e. the time of 
exposure to crystalline silica-containing dust) could not be kept constant. The silica 
exposure time therefore ranged from 8 to 25 weeks (i.e. two to six months).  
 
The collection of the follow up specimens was carried out at the mine shafts in a 
designated room (figure 2.4.3). The shafts in operation at the mine during the study period 
were shafts one, three, four, seven and eight. In order to make the collection of follow up 
samples efficient, the volunteers were grouped according to the shaft at which they worked 
and a timetable of which shafts would be visited on which dates was prepared. Since the 
original protocol stated that the return to work specimens would be collected from each 
volunteer on a Monday (pre-shift), a Wednesday (pre- and post-shift), and a Friday (post-
shift), it was decided that one full week would need to spent at each shaft. The first two 
weeks were spent at shafts one and three. During that time, even though they had been 
informed and had agreed at the time of recruitment, all but one volunteer decided that they 
were not willing to give a blood specimen four times in one week. Because of the difficulty 
experienced, the specimen collection procedure was then revised so that specimens were 
collected either on a Monday (pre-shift), a Wednesday (pre- and post-shift), or a Friday 
(post-shift). When the miners were contacted and informed of the dates the research team 
would be at their shaft, they were asked whether they would be prepared to give two 
specimens on a Wednesday (pre- and post-shift). Those who said they were not prepared to 
do so were randomly (by tossing a coin) allocated to a single specimen collected either on 
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a Monday (pre-shift) or on a Friday (post-shift). There was only one volunteer from whom 
a return to work sample was collected on a Monday, Wednesday and Friday and three 
volunteers from whom a return to work sample was collected on two of the days. With the 
exception of the few volunteers who worked afternoon or evening shifts, the pre-shift 
samples were collected between 4:30 am and 7:30 am while the post-shift samples were 
collected between 12 noon and 3 pm. 
 
The collection of the follow up specimens involved the collection of venous blood into two     
6 ml BD Vacutainer tubes, one containing Lithium Heparin and the other containing Clot 
Act. 
 
 
Figure 2.4.3: Prof Girdler-Brown, (left) draws a follow up blood sample from a volunteer 
(right) in the mine shaft computer room. The photograph was taken after obtaining written 
consent. 
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2.4.4 Processing of specimens 
 
2.4.4.1 Processing of bloods 
 
Immediately after blood collection, the BD Vacutainer tubes containing Lithium Heparin 
were centrifuged at 1300 x g for 10 minutes at room temperature. The upper plasma layer 
and buffy coat were discarded and triplicate aliquots of 0.3 ml packed erythrocytes were 
added to 1.2 ml cold distilled water in 1.5 ml microcentrifuge tubes. The samples were 
inverted gently to mix and centrifuged at 10 000 x g for 15 minutes at 4 oC. Aliquots of      
1 ml erythrocyte lysate (i.e. the supernatant) were pipetted in triplicate into clearly labelled 
1.8 ml CryoTubes and shock frozen in a Dewar tank of liquid nitrogen. The erythrocyte 
lysate was used to determine GPx activity.  
 
After being left to clot for 10 minutes, the BD Vacutainer tube containing Clot Act was 
centrifuged at 1300 x g for 10 minutes at room temperature. Aliquots of 300 µl serum were 
pipetted in triplicate into clearly labelled 1.8 ml CryoTubes and shock frozen in a Dewar 
tank of liquid nitrogen.  The serum was used to determine CC16 concentration.  
 
2.4.4.2 Transport and storage of samples 
 
The samples were placed in cooler boxes with ice packs (± 4 oC), transported back to the 
NIOH laboratory within 1 hour and placed in a -80 oC freezer (as recommended by the 
assay kit manufacturers and optimization experiment results) until assayed in batches. 
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2.4.4.3 Assay of Glutathione Peroxidase (GPx) 
 
Following storage for four to six weeks, the triplicate erythrocyte lysate samples were 
thawed and assayed using the Glutathione Peroxidase Assay Kit as described in section 
2.1. In the assay, the samples and controls were randomly allocated to wells using a table 
of random numbers.  
 
2.4.4.4 Assay of Clara Cell protein 16 (CC16) 
 
After storage for eight to ten weeks, the triplicate serum aliquots were thawed and assayed 
using a Clara Cell Protein Human ELISA Kit as described in section 2.2. For the assay the 
standards, samples and controls were randomly allocated to wells using a table of random 
numbers.  
 
2.4.5 Chest radiography 
 
The volunteers signed a consent form (Appendix L) giving the research team permission to 
examine their most recent chest radiographs collected at the Occupational Health Centre. 
The radiographs were obtained as digital images and were independently assessed for 
silicosis by two experienced readers (Prof A Solomons and Prof D Rees of the National 
Institute for Occupational Health) with the aid of DigiRad Imaging Solutions software. 
International Labour Organisation (ILO) category scores of 1/1 or greater were considered 
to be indicative of silicosis for the purpose of this study.  
  
 
 87 
2.4.6 Dust exposure classification of jobs 
 
The volunteers were asked to sign a consent form (Appendix L) giving the research team 
permission to access their occupational history, in particular their job title and code, from 
the human resources department.  
 
In a previous study carried out by Aurum Health Research (Pty) Ltd at a similar gold mine 
[Churchyard et al., 2003], the mine jobs were classified into high, medium and low dust 
exposure categories based on the judgment of two experienced hygienists who were 
familiar with the mine.  The lists of jobs and corresponding dust exposure levels, used for 
that study, were obtained by personal correspondence with Professor G. Churchyard. The 
lists were used to classify the jobs of this study’s volunteers into high or low dust exposure 
categories as summarised in table 2.4.6.  
 
It is important to note that using current job descriptions to classify dust exposure levels is 
not a reliable or accurate measure of a volunteers personal dust exposure. Therefore, in the 
current study, these job classifications were merely used as an indication of dust exposure 
levels and all results based on these classifications should be treated with caution. 
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Table 2.4.6: Summary of the job categories and corresponding dust exposure levels of 
volunteers in the study 
 
Occupation Dust exposure level High=H, Low=L n 
Aquajet operator H 2 
Banksman L 1 
Chief safety officer L 1 
Developer H 1 
Electrician L 5 
Fitter and turner L 2 
General miner H 11 
Grade officer L 1 
Loader operator H 2 
Loco Driver L 6 
Mine overseer L 1 
Night shift cleaner H 3 
Onsetter L 1 
Plant manager L 1 
Pump attendant L 3 
Rigger L 3 
Safety officer L 1 
Scraper winch driver H 3 
Section engineer L 1 
Senior surveyor (uncertified) L 1 
Shaft and construction timberman  L 1 
Shaft foreman L 1 
Shift boss L 6 
Stoper H 12 
Survey leading hand L 1 
Surveyor (uncertified) L 3 
Wining engine driver (U/G) L 2 
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2.5 Ethical issues 
 
This study protocol was approved by the University of the Witwatersrand Human Research 
Ethics Committees (Clearance number: R14/49 Makinson) (Attached as Appendix O). 
 
The study was funded in full by the Mines Health and Safety Council and was approved by 
employers, government and labour union representatives. 
 
Participation was entirely voluntary.  
 
Volunteers were given an information leaflet and a copy of the informed consent form in 
the language of their choice (English, Afrikaans or Zulu) to keep. The participant 
information leaflet advised participants that the test results had no diagnostic value and that 
individual results could not be used to indicate (in an absolute sense) their individual dust 
exposure levels.  
 
All venesections were performed by a medical practitioner registered with the HPCSA and 
there was 24 hour medical attention available for miners who might have suffered 
discomfort or anxiety following the venesection (none did). There was no testing of blood 
for HIV, neither were participants asked about their HIV infection status at any time. If any 
volunteer had medical questions they were generally answered by the medical practitioner 
who drew their blood specimen and they were told to obtain medical follow up. In cases 
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where abnormalities were detected on the chest radiographs, the identities of the miners 
concerned were communicated to the mines medical staff for follow-up. 
 
Individual results were kept confidential and were not divulged to any person other than 
the individual miner at his specific request. When requested, the meaning of their 
individual results was carefully explained and it was emphasized that each person has his 
own “normal” level for biomarkers tested and that no individual result could be used to 
indicate disease, freedom from disease, or over or under-exposure to silica either 
chronically or acutely. 
 
A feed-back session for participating miners, accompanied by a lunch, was held on the 24th 
November 2007 and again on 8th December 2007. During these sessions miners were 
provided with a summary of the findings, and the overall results were explained. Miners 
who wanted their individual results were supplied with their results (in writing) along with 
a one-to-one explanation regarding interpretation at the time of the feed-back session.  
 
When a photograph(s) of a volunteer was taken, their written permission was obtained 
beforehand on a consent form that also indicated whether they were willing to have the 
photograph(s) published.  
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2.6 Statistical methods 
 
The data provided in the questionnaire by the volunteers were entered into Microsoft Excel 
and exported to Stata version 9 (StataCorp LP, USA) where all the statistical analyses were 
performed. The data were manually double-checked for the correctness of entries. Any 
data observation which was greater than 2.IQR (interquartile range) above or below the 
median was considered an outlier and was excluded from the data set.  
Unless otherwise stated, for hypotheses tests the critical value for rejecting a null 
hypothesis was adopted as p ≤ 0.05. 
Box-plots were used to portray the data distributions.  
 
When the data sets being compared showed compatibility with having been drawn at 
random from a normally distributed population based on the results of the Shapiro-Wilk W 
test [Shapiro and Wilk, 1965], t-tests were used to evaluate differences between means 
provided.  
 
Paired t-tests were performed for paired data (for example for comparisons of the ex-leave 
specimens with the follow up specimens as well as for comparisons of the Wednesday pre-
shift and Wednesday post-shift specimens). For paired t-tests, before the test was carried 
out, the differences were first checked by means of the Shapiro-Wilk W test to ensure that 
they were compatible with having been drawn at random from a normally distributed 
population. The Bonferroni adjusted critical alpha-value (α*) was then manually 
calculated, as α*= 0.05/x where x= k!/2!*(k-2)! (for example, for three pair wise 
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comparisons α* = 0.05/3 = 0.017) [Pagano and Gauvreau, 2000], and used to determine 
the level of significance for the pair-wise comparisons. 
 
Unpaired t-tests were performed where data were not from the same miner (for example 
comparisons of the Monday pre-shift and Friday post-shift specimens). The F-test (Stata 
command “sdtest”) was used to assess the equivalence of sample variances prior to 
performance of the unpaired t-tests. In cases where the sample variances were unequal, the 
variation of the t-test for samples with unequal variances was used. Interpretation of these 
tests with unequal variances was carried out using Satterthwaite’s method [Satterthwaite, 
1946]. 
 
In cases where the data were not compatible with having been drawn at random from a 
normally distributed population, comparisons were carried out using the two sample rank-
sum test for unpaired data (Stata command “ranksum”), or the signed-rank test (Stata 
command “signrank”) for paired data as applicable. If possible, the data were also 
transformed to achieve a normal distribution and allow parametric tests to be performed.  
 
Where multiple comparisons were made (for data that were compatible with being drawn 
at random from normally distributed populations) ANOVA was used with Bonferroni-
adjusted p-values being used for interpretation of individual pair-wise comparisons. The 
Kruskal-Wallis test of equality of populations was used for multiple comparisons in 
instances in which the sample data were not compatible with having been drawn at random 
from a normally distributed population [Kruskal and Wallis, 1952a; Kruskal and Wallis, 
1952b].  
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Since only a single set of ex-leave and follow-up samples were collected for each volunteer 
and due to the high variability of some biomarker levels it was not possible to reliably 
compare biomarker levels on an individual basis. As a result all analysis involved 
population-based average readings and all individual results were treated with caution. 
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Chapter 3: 
RESULTS 
 
This third phase of the project on biomarkers consisted of two parts: 
The first part involved optimisation of the operational parameters for the establishment of 
the Standard Operating Procedures (SOPs). Four separate experiments were performed in 
which the effects of storage temperature, a delay in time between blood collection and 
separation, ambient laboratory temperature and storage duration on the levels of 
erythrocyte GPx activity and serum CC16 concentration were investigated (the results are 
presented in section 3.1). 
 
The second part involved field work during which adult male miners were recruited from a 
gold mine in North West province, South Africa. Blood specimens were collected from the 
mine volunteers after their return from leave (at the time of recruitment), and then again 
after their return to work on a Monday (pre-shift), a Wednesday (pre- and post-shift), 
and/or on a Friday (post-shift) (the results of which are presented in section 3.2).  
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3.1 Optimization of the operational parameters 
 
These optimization experiments were performed with the intention of developing SOPs for 
the handling, processing and analysis of GPx and CC16 samples to ensure optimum 
precision and reproducibility during the field work and also during future research. (The 
SOPs are attached as Appendices I and J). 
 
3.1.1 Effect of storage temperature  
 
The effect of storage temperature on erythrocyte GPx activity and serum CC16 
concentration was evaluated by storing erythrocyte lysate and serum samples, collected 
from two volunteers, at 4 oC, -20 oC and -80 oC for 3 weeks. The GPx activity of the 
erythrocyte lysate samples was then determined using a Glutathione Peroxidase Assay Kit 
and the CC16 concentration of the serum samples was determined using a Clara Cell 
Protein Human ELISA Kit. 
 
3.1.1.1 Erythrocyte GPx 
 
For volunteer one and two, there was a slight decrease in median GPx activity as the 
storage temperature was lowered (figure 3.1.1.1 below). 
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Figure 3.1.1.1: GPx activity of erythrocyte lysate samples (from two volunteers) stored for 3 
weeks at 4 oC, -20 oC and -80 oC. The GPx activity was measured (in a total of 15 replicates per 
condition) using a Glutathione Peroxidase Assay Kit. The CV ranged from 18.7%-28.5% for 
volunteer 1 and 49.5%-69.0% for volunteer 2. In the box-and-whisker plot the line through the 
middle of the boxes represents the median GPx activity. The top and bottom of each box is the 75th 
and the 25th percentile, respectively. The top and bottom of each bar is the 90th and 10th percentile, 
respectively. The solid dot represents a data observation greater than 1.5 IQR above or below the 
median. 
 
 
Analysis revealed that, for both volunteers, the differences between the mean GPx 
activities of the samples were compatible with a normal distribution (Shapiro-Wilk W test 
for normal data, p > 0.05). This allowed paired t-tests to be used to compare the mean GPx 
activities of the samples and the results of those tests are summarised in table 3.1.1.1 
below.  
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Table 3.1.1.1: P-values obtained from the pair-wise comparison of the mean erythrocyte GPx 
activity of samples stored at various temperatures (level of significance is p ≤ 0.017)  
 
 
 
 
The pair-wise comparison of the means (table 3.1.1.1) revealed that the slight decrease in 
mean GPx activity observed at the lower storage temperatures (figure 3.1.1.1) was not 
statistically significant (p > Bonferonni adjusted α of 0.017).  
 
It was therefore concluded the temperature at which the erythrocyte lysate samples were 
stored had no significant effect on the GPx activity of the samples.  
 
 
3.1.1.2 Serum CC16 
 
As observed in figure 3.1.1.2 below, for both volunteers there was a decrease in the median 
CC16 concentration with a decrease in storage temperature.  
 
Volunteer 4 oC -20 oC -80 oC 
   4 oC p = 1.00   
-20 oC p = 0.13 p = 1.00  1 
-80 oC p = 0.09 p = 0.74 p = 1.00 
   4 oC  p = 1.00   
-20 oC  p = 0.47  p = 1.00  2 
-80 oC  p = 0.78  p = 0.77 p = 1.00 
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Figure 3.1.1.2: CC16 concentration of serum samples (from two volunteers) stored for 3 
weeks at 4 oC, -20 oC and -80 oC. The CC16 concentration was measured (in 15 replicates per 
condition) using a Clara Cell Protein Human ELISA Kit. The CV ranged from 8.5%-9.6% for 
volunteer 1 and 8.3%-11.4% for volunteer 2. In the box-and-whisker plot the black line through the 
middle of the boxes represents the median CC16 concentration. The top and bottom of each box is 
the 75th and the 25th percentile, respectively. The top and bottom of each bar is the 90th and 10th 
percentile, respectively. The solid dots represent data observations greater than 1.5 IQR above or 
below the median. 
 
  
 
 
The differences between the mean CC16 concentrations of the samples were compatible 
with a normal distribution, for volunteer one and two (Shapiro-Wilk W test for normal 
data, p > 0.05). The mean CC16 concentrations of the samples were therefore compared 
using the paired t-test, the results of which are summarised in table 3.1.1.2 below. 
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Table 3.1.1.2: P-values obtained from the pair-wise comparison of the mean CC16 
concentration of samples stored at various temperatures (level of significance is p ≤ 0.017)  
 
Volunteer 4 oC -20 oC -80 oC 
   4 oC        p = 1.00   
-20 oC     p = 0.00* p = 1.00  1 
-80 oC     p = 0.00* p = 0.46 p = 1.0 
   4 oC       p = 1.00   
-20 oC p = 0.05 p = 1.00  2 
-80 oC   p = 0.00* p = 0.38 p = 1.0 
* Indicates p-value less than level of significance 
 
 
The pair-wise comparison of the means (table 3.1.1.2) indicated that the mean CC16 
concentration of the samples collected from volunteer one and stored at 4 oC was 
significantly higher than the mean CC16 concentration of the samples stored at -20 oC and 
-80 oC (p = 0.00 for both). It also indicated that there was a significant difference between 
the mean CC16 concentration of the samples collected from volunteer two and stored at    
4 oC and those stored at -80 oC (p = 0.00). For both volunteers there was no significant 
difference between the mean CC16 concentration of the samples stored at -20oC and -80oC 
(p > Bonferonni adjusted α of 0.017).  
 
Unlike the GPx results, these results indicated that the temperature at which the serum 
samples were stored did have a significant effect on the CC16 concentration of the 
samples. 
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3.1.2 Effect of a delay in time between blood sample collection 
and separation 
 
In order to determine the effect of a delay in time (between blood sample collection and 
separation) on erythrocyte GPx activity and serum CC16 concentration, blood samples 
were collected (from two volunteers) and left to stand for 0, 1 and 2 hours prior to 
separation. The resultant erythrocyte lysate and serum samples were frozen at -80 oC for    
2 weeks.  The GPx activity of the erythrocyte lysate samples was then measured using a 
Glutathione Peroxidase Assay Kit while the CC16 concentration of the serum samples was 
measured using a Clara Cell Protein Human ELISA Kit. 
 
3.1.2.1 Erythrocyte GPx 
 
 
An increase in delay time between blood sample collection and separation caused an 
increase in the median GPx activity of samples collected from volunteer one and a 
decrease in the median GPx activity of samples collected from volunteer two, as shown in 
figure 3.1.2.1 below.  
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Figure 3.1.2.1: GPx activity of erythrocyte lysate samples (from two volunteers) obtained 
from blood samples separated 0, 1 and 2 hours after collection.  The GPx activity was 
measured (in a total of 15 replicates per condition) after 2 weeks of storage at -80 oC using a 
Glutathione Peroxidase Assay Kit. The CV ranged from 11.2%-15.2% for volunteer 1 and 15.8%-
22.2% for volunteer 2. In the box-and-whisker plot the black line through the middle of the boxes 
represents the median GPx activity. The top and bottom of each box is the 75th and the 25th 
percentile, respectively. The top and bottom of each bar is the 90th and 10th percentile, respectively. 
The solid dots represent data observations greater than 1.5 IQR above or below the median. 
 
 
 
The differences between the mean GPx activities of the samples were compatible with a 
normal distribution (Shapiro-Wilk W test for normal data, p > 0.05), except for the 
difference between the mean GPx activity of the one and two hour samples of volunteer 
two (p = 0.00). As a result, the Wilcoxon signed-rank test was used to compare the mean 
GPx activities of the one and two hour samples of volunteer two while the paired t-test was 
used to compare the mean GPx activities of the other samples. The results of these 
comparisons are summarised in table 3.1.2.1 below.   
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Table 3.1.2.1: P-values obtained from the pair-wise comparison of the mean erythrocyte GPx 
activity of samples prepared after various delay times (level of significance is p ≤ 0.017)  
 
Volunteer 0 hour 1 hour 2 hour 
0 hour p = 1.00   
1 hour p = 0.78 p = 1.00  1 
2 hour p = 0.78 p = 0.88 p = 1.00 
0 hour p = 1.00   
1 hour p = 0.76 p = 1.00  2 
2 hour p = 0.03 p = 0.05 p = 1.00 
 
 
 
The pair-wise comparison of the mean GPx activities (table 3.1.2.1) indicated that the 
changes in mean GPx activity observed in figure 3.1.2.1 were not statistically significant  
(p > Bonferonni adjusted α of 0.017).  
 
It was therefore concluded that leaving the blood specimens to stand for up to two hours 
before their separation did not have a significant effect on the GPx activity of the resulting 
erythrocyte lysate samples. 
 
3.1.2.2 Serum CC16 
 
For volunteer one and two, a decrease in median CC16 concentration was observed with an 
increase in delay time from zero to two hours (figure 3.1.2.2 below).  
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Figure 3.1.2.2: CC16 concentration of serum samples (from two volunteers) obtained from 
blood samples separated 0, 1 and 2 hours after collection.  The CC16 concentration was 
measured (in 15 replicates per condition) after storage of the serum samples at -80 oC for 2 weeks 
using a Clara Cell Protein Human ELISA Kit. The CV ranged from 20.3%-40.2% for volunteer 1 
and 26.8%-47.5% for volunteer 2. In the box-and-whisker plot the black line through the middle of 
the boxes represents the median CC16 concentration. The top and bottom of each box is the 75th 
and the 25th percentile, respectively. The top and bottom of each bar is the 90th and 10th percentile, 
respectively. The solid dots represent data observations greater than 1.5 IQR above or below the 
median. 
 
 
 
The differences between the mean CC16 concentration of the samples were compatible 
with a normal distribution (Shapiro-Wilk W test for normal data, p > 0.05), except for the 
difference between the mean CC16 concentration of the zero and one hour samples 
collected from volunteer two (p = 0.03). As a result, the mean CC16 concentration of the 
zero and one hour samples collected from volunteer two were compared using the 
Wilcoxon signed-rank test while the mean CC16 concentration of the other samples were 
compared using the paired t-test. The results of these comparisons are shown in table 
3.1.2.2 below.  
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Table 3.1.2.2: P-values obtained from the pair-wise comparison of the mean CC16 
concentration of samples prepared after various delay times (level of significance is p ≤ 0.017)  
 
Volunteer 0 hour 1 hour 2 hour 
0 hour p = 1.00   
1 hour p = 0.06 p = 1.00  1 
2 hour p = 0.02 p = 0.67 p = 1.00 
0 hour p = 1.00   
1 hour p = 0.92 p = 1.00  2 
2 hour p = 0.11 p = 0.15 p = 1.00 
 
 
The pair-wise comparison of the mean CC16 concentrations (table 3.1.2.2) indicated that 
decrease in mean CC16 concentration observed in figure 3.1.2.2 was not statistically 
significant (p > Bonferonni adjusted α of 0.017).  
 
Similar to the GPx results, these results indicated that a delay time of up to two hours had 
no significant effect on the CC16 concentration of the serum samples.   
 
 
3.1.3 Effect of ambient laboratory temperature 
 
The effect of ambient laboratory temperature on erythrocyte GPx activity and serum CC16 
concentration was determined, for two volunteers, by processing one set of blood samples 
and resulting erythrocyte lysate and serum samples at 25 oC and another set at 35 oC. After 
storage for 2 weeks at -80 oC, the GPx activity of the erythrocyte lysate samples was 
determined using a Glutathione Peroxidase Assay Kit and the CC16 concentration of the 
serum samples was determined using a Clara Cell Protein Human ELISA Kit.  
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3.1.3.1 Erythrocyte GPx 
 
 
As demonstrated in figure 3.1.3.1, an increase in ambient laboratory temperature (from    
25 oC to 35 oC) caused an increase in the median GPx activity of samples collected from 
volunteer one and a slight decrease in the median GPx activity of samples collected from 
volunteer two.  
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Figure 3.1.3.1: GPx activity of erythrocyte lysate samples (from two volunteers) processed at   
25 oC and 35 oC. The GPx activity was measured (in a total of 15 replicates per condition) after 2 
weeks of storage at -80 oC using a Glutathione Peroxidase Assay Kit. The CV ranged from 11.0%-
16.6% for volunteer 1 and 12.1%-19.9% for volunteer 2. In the box-and-whisker plot the black line 
through the middle of the boxes represents the median GPx activity. The top and bottom of each 
box is the 75th and the 25th percentile, respectively. The top and bottom of each bar is the 90th and 
10th percentile, respectively. 
 
 
The difference between the mean GPx activities of the samples prepared at different 
laboratory temperatures was compatible with a normal distribution for both volunteer one 
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and two (Shapiro-Wilk W test for normal data, p > 0.05). The mean GPx activities of the 
samples were therefore compared using the paired t-test and the results summarised in 
table 3.1.3.1.  
 
Table 3.1.3.1: P-values obtained from the pair-wise comparison of the mean erythrocyte GPx 
activity of samples prepared at different temperatures (level of significance is p ≤ 0.05)  
 
Volunteer 25 oC 35 oC 
25 oC p = 1.00  1 35 oC   p = 0.00* p = 1.00 
25 oC p = 1.00  2 35 oC p = 0.37 p = 1.00 
* Indicates p-value less than level of significance 
 
For volunteer one, pair-wise comparison of the means (table 3.1.3.1) indicated that the 
increased GPx activity observed at the higher ambient laboratory temperature of 35 oC was 
statistically significant (p=0.00). For volunteer two, however, pair-wise comparison of the 
means indicated that the decreased GPx activity observed at the higher ambient laboratory 
temperature was not statistically significant (p=0.37).  
 
Therefore, the results of the current study suggest that the laboratory temperature at which 
the erythrocyte lysate samples are processed may affect the GPx activity. 
 
3.1.3.2 Serum CC16 
 
The median CC16 concentration of the samples prepared at an ambient laboratory 
temperature of 35 oC was higher than that of the samples prepared at 25 oC for both 
volunteers (figure 3.1.3.2 below).  
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Figure 3.1.3.2: CC16 concentration of serum samples (from two volunteers) processed at      
25 oC and 35 oC. The CC16 concentration was measured (in 15 replicates per condition) after 
storage of the serum samples at -80 oC for 2 weeks using a Clara Cell Protein Human ELISA Kit. 
The CV ranged from 10.3%-11.8% for volunteer 1 and 7.5%-16.2% for volunteer 2. In the box-
and-whisker plot the black line through the middle of the boxes represents the median CC16 
concentration. The top and bottom of each box is the 75th and the 25th percentile, respectively. The 
top and bottom of each bar is the 90th and 10th percentile, respectively.  
 
 
Since the differences between the mean CC16 concentrations of the samples prepared at 
different laboratory temperatures were compatible with a normal distribution for both 
volunteers (Shapiro-Wilk W test for normal data, p > 0.05), the mean CC16 concentrations 
of the samples were compared using paired t-tests. The results of these comparisons are 
presented in table 3.1.3.2 below. 
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Table 3.1.3.2: P-values obtained from the pair-wise comparison of the mean serum CC16 
concentration of samples prepared at different temperatures (level of significance is p ≤ 0.05)  
 
Volunteer 25 oC 35 oC 
25 oC p = 1.00  1 35 oC   p = 0.01* p = 1.00 
25 oC p = 1.00  2 35 oC p = 0.10 p = 1.00 
* Indicates p-value less than level of significance 
 
For volunteer one, pair-wise comparison of the means (table 3.1.3.2) indicated that the 
mean CC16 concentration of the samples processed at 35 oC was significantly higher        
(p = 0.01) than that of the samples processed at 25 oC. On the other hand, for volunteer 
two, pair-wise comparison of the means indicated that there was no significant difference 
(p = 0.10) between the mean CC16 concentration of the samples processed at 25 oC and   
35 oC.  
 
Therefore, the current investigation also indicated that the temperature at which the serum 
samples are processed may have a significant effect on the CC16 concentration of the 
samples.  
 
 
3.1.4 Effect of storage duration 
 
The effect of storage duration on erythrocyte GPx activity and serum CC16 concentration 
was determined by storing erythrocyte lysate and serum samples, collected from two 
volunteers, at -80 oC for 0, 3, 6 and 9 weeks. The GPx activity of the erythrocyte lysate 
samples was then measured using a Glutathione Peroxidase Assay Kit while the CC16 
  
 
 109 
concentration of the serum samples was measured using a Clara Cell Protein Human 
ELISA Kit and 
 
3.1.4.1 Erythrocyte GPx 
 
Except for a decrease in the median GPx activity of the three week samples collected from 
volunteer two, an increase in storage duration appeared to have no effect on the median 
GPx activities of the samples collected from volunteer one and two (figure 3.1.4.1). 
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Figure 3.1.4.1: GPx activity of erythrocyte lysate samples (from two volunteers) stored at      
-80 oC for 0, 3, 6 and 9 weeks. The GPx activity was measured (in 15 replicates per condition) 
using a Glutathione Peroxidase Assay Kit. In the box-and-whisker plot the black line through the 
middle of the boxes represents the median GPx activity. The CV ranged from 49.5%-63.7% for 
volunteer 1 and 46.1%-126.3% for volunteer 2. The top and bottom of each box is the 75th and the 
25th percentile, respectively. The top and bottom of each bar is the 90th and 10th percentile, 
respectively. The solid dots represent data observations greater than 1.5 IQR above or below the 
median. 
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Since the difference between the mean GPx activity of the zero and six week samples of 
both volunteers were not compatible with a normal distribution (Shapiro-Wilk W test for 
normal data, p = 0.03 for both), the mean GPx activities of these samples were compared 
using the Wilcoxon signed-rank test. The paired t-test was used to compare the mean GPx 
activities of the other samples since the differences between the mean GPx activities were 
all compatible with a normal distribution (p > 0.05). These comparison results are shown in 
table 3.1.4.1.  
 
Table 3.1.4.1: P-values obtained from the pair-wise comparison of the mean erythrocyte GPx 
activity of samples stored for various durations (level of significance is p ≤ 0.008)  
 
Volunteer 0 weeks 3 weeks 6 weeks 9 weeks 
0 weeks p = 1.00    
3 weeks p = 0.95 p = 1.00   
6 weeks p = 0.25 p = 0.11 p = 1.00  1 
9 weeks p = 0.02 p = 0.05 p = 0.82 p = 1.00 
0 weeks p = 1.00    
3 weeks p = 0.14 p = 1.00   
6 weeks p = 0.83 p = 0.07 p = 1.00  2 
9 weeks p = 0.78 p = 0.15 p = 0.54 p = 1.00 
 
The pair-wise comparison of the mean GPx activities (table 3.1.4.1) indicated that there 
was no significant difference between the mean GPx activity of the samples assayed 
immediately and those assayed 3, 6 and 9 weeks after storage (p > Bonferonni adjusted α 
of 0.008) for both volunteers.  
 
It was therefore concluded that the erythrocyte lysate samples could be stored for up to 
nine weeks without there being a significant effect on the GPx activity of the samples. 
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3.1.4.2 Serum CC16 
 
 
As illustrated in figure 3.1.4.2 below, there was a decrease in median CC16 concentration 
between the samples assayed immediately (the 0 week samples) and those stored for 3, 6 
and 9 weeks, for both volunteers.  
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Figure 3.1.4.2: CC16 concentration of samples (from two volunteers) stored at -80 oC for 0, 3, 
6 and 9 weeks. The CC16 concentration was measured (in 15 replicates per condition) using a 
Clara Cell Protein Human ELISA Kit. The CV ranged from 9.6%-26.2% for volunteer 1 and 8.3%-
12.2% for volunteer 2. In the box-and-whisker plot the black line through the middle of the boxes 
represents the median CC16 concentration. The top and bottom of each box is the 75th and the 25th 
percentile, respectively. The top and bottom of each bar is the 90th and 10th percentile, respectively. 
The solid dots represent data observations greater than 1.5 IQR above or below the median. 
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The difference between the mean CC16 concentration of the three and nine week samples 
collected from volunteer one and the zero and three week samples collected from volunteer 
two were not compatible with a normal distribution both volunteers (Shapiro-Wilk W test 
for normal data, p = 0.023 for both). As a result the mean CC16 concentrations of these 
samples were compared using the Wilcoxon signed-rank test. Since the rest of the 
differences between the mean CC16 concentration of the samples were compatible with a 
normal distribution (p > 0.05), paired t-tests were used to compare the mean CC16 
concentrations of those samples. The results of these comparisons are presented in table 
3.1.4.2. 
  
Table 3.1.4.2: P-values obtained from the pair-wise comparison of the mean CC16 level in 
serum samples stored for various durations (level of significance is p ≤ 0.008)  
 
Volunteer 0 weeks 3 weeks 6 weeks 9 weeks 
0 weeks p = 1.00    
3 weeks   p = 0.00* p = 1.00   
6 weeks   p = 0.00* p = 0.37 p = 1.00  1 
9 weeks p = 0.06 p = 0.14 p = 0.03 p = 1.0 
0 weeks p = 1.00    
3 weeks p = 0.10 p = 1.00   
6 weeks p = 0.01 p = 0.12 p = 1.00  2 
9 weeks p = 0.69 p = 0.20   p = 0.01* p = 1.0 
* Indicates p-value less than level of significance 
 
For volunteer one, pair-wise comparison of the means (table 3.1.4.2) indicated that the 
mean CC16 concentration of the samples stored for 0 weeks was significantly higher than 
the mean CC16 concentration of the samples stored for 3 and 6 weeks (p = 0.00 for both). 
There was, however, no significant difference between the mean CC16 concentrations of 
the samples assayed immediately (0 weeks) and those stored for 9 weeks (p > Bonferonni 
adjusted α of 0.008). 
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For volunteer two, pair-wise comparison of the means (table 3.1.4.2) indicated that there 
was no significant difference between the mean CC16 concentration of the 0 week samples 
and those stored for 3, 6 or 9 weeks (p > Bonferonni adjusted α of 0.008). There was, 
however, a significant difference between the mean CC16 concentration of the samples 
stored for 6 weeks and the samples stored for 9 weeks (p = 0.00). 
 
It was therefore concluded that the CC16 concentration of the serum samples may have 
been affected by the duration of storage. 
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3.2 Field work 
 
As previously described in section 2.4 and in the introduction to chapter 3, the field work 
was conducted with adult male miners recruited from a gold mine in North West province, 
South Africa. Blood specimens were collected from the volunteers after their return from 
leave (at the time of recruitment), and then again after their return to work on either a 
Monday (pre-shift), a Wednesday (pre- and post-shift), and/or a Friday (post-shift). It is 
important to state at this point that it was not possible to collect return to work blood 
specimens (also referred to as follow up samples) from all of the initial volunteers for a 
number of reasons. The field work sample collection procedure and the reasons why follow 
up samples were not collected from all of the initial volunteers are detailed in figure 3.2.1 
below.  
 
The demographics of the group of volunteers are summarised in the next section. The 
influence of age, race group, cigarette smoking habit and silicosis on the levels of 
erythrocyte GPx activity and serum CC16 concentration were then evaluated and the 
results are presented in sections 3.2.2 and 3.2.3. The subsequent comparison of the GPx 
and CC16 results obtained for the return from leave (ex-leave) and return to work (follow 
up) are summarized in sections 3.2.4. Finally, the effect of the estimated level and duration 
of crystalline silica exposure on the changes in GPx activity and CC16 concentration was 
evaluated and these results are presented in section 3.2.5.  
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Figure 3.2: Outline of the field work sample collection procedure. The initial group of 80 
volunteers were sorted into two groups according to whether the researchers were able to collect a 
follow up sample from the volunteer. Follow up samples were collected on either a Monday (pre-
shift), Wednesday (pre- and post-shift) or Friday (post-shift) during morning, afternoon and 
evening shifts. The reasons why follow up samples were not collected from some volunteers are 
also described (*For example the volunteer was the only miner working a night shift at a particular 
shaft and it was therefore logistically difficult and expensive to collect that one specimen).   
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shift workers 
 
n=0 (0%) 
Afternoon  
shift workers 
 
n=0 (0%) 
Night shift 
Workers 
 
n=1 (1%) 
Night shift 
Workers 
 
n=3 (4%) 
No longer at 
the mine 
 
n =4 (5%) 
 
Difficult 
shift/shaft to 
follow up * 
 
 n =11 (14%) 
 
Refused to 
continue 
 
n =7 (9%) 
 
Follow up sample collected 
 
n=53 (66%) 
8 to 25 weeks after returning to work 
OR OR 
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3.2.1 Demographics of the study population 
 
At the time of recruitment, the volunteers were requested to complete a general 
questionnaire (regarding their age, smoking history and current working conditions) and 
these results are summarised in table 3.2.1.a. In order to determine if there were any 
demographic differences between the group of volunteers who agreed to give follow up 
samples and the group from whom no follow up sample could be collected, the 
demographic data for the whole group of volunteers was sorted into two groups according 
to this follow up status. The characteristics of these two groups are also presented in table 
3.2.1.a.  
 
Table 3.2.1.a: Demographics of the study population as a whole as well as for those volunteers 
from whom follow up samples could and could not be collected  
 
Characteristic Whole group 
Group from 
whom follow up 
sample collected 
Group from whom 
no follow up 
sample collected 
Age (years) mean (± SD) 39.97 (± 9.09) 40.44 (± 8.50) 39.09 (± 10.21) 
% Black 72.5 69.8 77.8 Race group % White 27.5 30.2 22.2 
% Current smokers 31.7 35.8 23.1 
% Ex-smokers 24.0 18.9 34.6 Smoking 
% Non-smokers 44.3 45.3 42.3 
% Low dust exposure 56.0 58.5 50.0 Job 
classification  % High dust exposure 44.0 41.5 50.0 
Silicosis 
(grade ≥ 1/1) % Silicosis 11.1 9.4 15.8 
Ex-leave GPx 
activity  
(U/g Hb) 
mean (± SD) 26.30 (± 6.50) 26.51 (±5.41) 25.56 (±6.99) 
Ex-leave CC16 
concentration 
(ng/ml) 
mean (± SD) 6.82 (±2.83) 6.89 (±2.65) 6.78 (±2.94) 
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As shown in table 3.2.1.a, the group of volunteers as a whole (n = 80) had an average age 
of 40 years, consisted of a majority of black individuals, had an approximately equal 
number of non-smokers and ever smokers (current and ex-smokers), consisted of an 
approximately equal number of individuals in high and low dust exposure jobs, and had a 
radiological silicosis prevalence of 11%.   
 
 While the overall prevalence of radiological silicosis is given in table 3.2.1.a above, table 
3.2.1.b below gives more detailed results of the radiological silicosis assessments.  As 
previously described in section 2.4.5, chest radiographs were obtained for the study 
volunteers and assessed for silicosis (defined as an ILO category score of 1/1 or greater) by 
two experienced readers. 
 
Table 3.2.1.b: Number of study volunteers in each ILO category, as diagnosed by chest 
radiographs read by two readers (with silicosis defined as ILO ≥ 1/1) 
 
Reader 1 
ILO category 0 1 2 3 Total 
0 64 3 0 0 67 
1 1 1 0 0 2 
2 0 1 1 0 2 
3 0 0 0 1 1 
R
ea
de
r 
2 
Total 65 5 1 1 72 
 
The agreement between the two readers, in terms of silicosis classification, was determined 
by means of the kappa score which had a value of 0.64 indicating good agreement. 
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In order to determine if there had been a selection bias in the miners from whom follow up 
blood specimens were collected (n = 53) and those from whom no follow up blood 
specimen could be collected (n = 27), the characteristics of the two groups were compared 
by statistical analysis to detect any significant differences.  
 
The age data for the two groups as well as the return from leave GPx activity and CC16 
concentration data for the group of volunteers who did not give follow up samples were 
compatible with having been drawn at random from a population with a normal 
distribution (Shapiro-Wilk W test for normal data, p > 0.5). The data were therefore 
compared using the t-test. On the other hand, the return from leave GPx activity and CC16 
concentration data for the group of volunteers who gave follow up samples were not 
compatible with having been drawn at random from a population with a normal 
distribution (Shapiro-Wilk W test for normal data, p = 0.01 and p = 0.04 respectively) and 
therefore these data were compared using the two-sample Wilcoxon rank-sum test.  
 
It was thereby determined that there was no significant difference between the group of 
volunteers who donated follow up samples and the group who could not donate follow up 
samples in regards to age (t-test with equal variances, p = 0.54), race group composition 
(chi square p-value = 0.45), current smoking status (chi square p-value = 0.25), ex-
smoking status (chi square p-value = 0.12), job classification (chi square p-value = 0.50), 
silicosis prevalence (chi square p-value = 0.45), return from leave GPx activity (two-
sample Wilcoxon rank-sum test, p = 0.34) or return from leave CC16 concentration (two-
sample Wilcoxon rank-sum test, p = 0.71). Since there were no significant differences 
between the characteristics of two groups, it was concluded that there was no selection bias 
in the miners who donated follow up blood specimens. This in turn, allowed the ex-leave 
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results obtained from the two groups of miners to be combined to investigate the 
parameters affecting GPx activity and CC16 concentration (sections 3.2.2 and 3.2.3, 
respectively).  The combined ex-leave results were also used later to compare those levels 
of GPx activity and CC16 concentration to those obtained from the miners who donated 
the follow up samples (sections 3.2.4).  
 
 
3.2.2 Parameters affecting GPx activity in ex-leave miners 
 
In order to determine if the age, race group, or cigarette smoking habits of the study 
volunteers (n = 80) had influenced the results obtained in section 3.2.4, the effect of these 
factors on the levels of erythrocyte GPx activity was investigated. In addition, the effect of 
the presence of radiological silicosis on the levels of GPx activity was examined.  
 
3.2.2.1 Age 
 
The return from leave (ex-leave) GPx activity data collected from all of the initial 80 study 
volunteers were used to determine the effect of age on GPx activity. This ex-leave GPx 
activity data were not compatible with having been drawn at random from a population 
with a normal distribution (Shapiro-Wilk W test for normal data, p=0.00), however the age 
data were compatible with a normal distribution (p=0.08).  
 
When the age data were compared with the GPx activity data, no significant correlation 
was found (Spearman’s correlation r = -0.08, p = 0.47). This non-significant result was 
confirmed by parametric tests performed on the log transformed data (Pearson’s 
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correlation r = -0.03, p = 0.78). These results indicate that the GPx activity of the ex-leave 
samples was not affected by the age of the study volunteers.   
 
3.2.2.2 Race group 
 
The mean return from leave GPx activities of the study volunteers, sorted according to 
apparent race group, are summarised in table 3.2.2.2.  
 
Table 3.2.2.2: Mean GPx activity of the return from leave samples collected from the black 
and white study volunteers 
 
 
Race group n Mean GPx activity (U/g Hb) Standard deviation 
Black 58 26.19 6.97 
White 22 26.60 5.12 
 
The ex-leave GPx activity data of the black race group were not compatible with having 
been drawn at random from a population with a normal distribution (Shapiro-Wilk W test 
for normal data, p = 0.00) while that of the white race group were compatible (p = 0.56).  
 
Although a slight increase in mean GPx activity between the black and white race groups  
(0.41 U/g Hb) was observed (table 3.2.2.2) this increase was not statistically significant 
(two-sample Wilcoxon rank-sum test, p = 0.58). This non-significant result was confirmed 
by parametric tests performed on the log transformed data (two-sample t test, p=0.61).  
 
These results indicate that the GPx activity of the ex-leave samples was also not affected 
by the race of the study volunteers. 
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3.2.2.3 Cigarette smoking 
 
Table 3.2.2.3 illustrates the mean return from leave GPx activities of the study volunteers 
sorted according to their cigarette smoking habits. 
 
Table 3.2.2.3: Mean GPx activity of the return from leave samples divided into three groups 
according to the cigarette smoking status of the volunteer at the time of sample collection 
 
 
Smoking status n Mean GPx activity (U/g Hb) Standard deviation 
Current smoker 25 27.48 7.13 
Ex-smoker 19 25.58 5.89 
Non-smoker 35 25.64 6.33 
 
The ex-leave GPx activity data of the non-smoker group were not compatible with having 
been drawn at random from a population with a normal distribution (Shapiro-Wilk W test 
for normal data, p = 0.00) while that of the current smoker and ex-smoker groups were 
compatible (p = 0.19 and p = 0.99, respectively).  
 
The decrease in the mean GPx activity between the current smokers and the ex-smokers 
and non-smokers (table 3.2.2.3) was not statistically significant (Kruskal-Wallis test,         
p = 0.52). This non-significant result was confirmed by parametric tests performed on the 
log transformed data (one-way analysis of variance with comparisons of the means,           
p = 0.61).  
 
These results indicate that the GPx activity of the ex-leave samples was also not affected 
by cigarette smoking. 
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3.2.2.4 Silicosis 
 
The mean return from leave GPx activities of the study volunteers with and without 
radiological silicosis (of ILO grade ≥ 1/1) are shown in table 3.2.2.4.  
 
 
Table 3.2.2.4: Mean GPx activity of the return from leave samples collected from the study 
participants with and without radiological silicosis (of ILO grade ≥ 1/1)  
 
Silicosis n Mean GPx activity (U/g Hb) Standard deviation 
No silicosis 64 26.68 6.72 
Silicosis   8 21.42 2.31 
 
 
 
The ex-leave GPx activity data of the group with no signs of radiological silicosis were not 
compatible with having been drawn at random from a population with a normal 
distribution (Shapiro-Wilk W test for normal data, p = 0.01) while that of the group with 
silicosis were compatible with a normal distribution (p = 0.41).  
 
As illustrated in table 3.2.2.4, the mean GPx activity of the individuals with no silicosis 
was higher that the mean GPx activity of the individuals with silicosis (approximately    
5.3 U/g Hb). It was determined that this difference was statistically significant (two-sample 
Wilcoxon rank-sum test, p = 0.01) and the result was confirmed by parametric tests 
performed on the log transformed data (two-sample t test with unequal variances,               
p = 0.00).  
 
These results indicate that the GPx activity of the ex-leave samples was significantly 
affected by the presence of radiological silicosis (of ILO grade ≥ 1/1) in the study 
volunteers. 
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3.2.3 Parameters affecting CC16 concentration in ex-leave 
miners 
 
The effect of age, race, cigarette smoking and silicosis on the levels of serum CC16 
concentration was examined to determine if these factors may have influenced the results 
obtained in section 3.2.4.  
 
  
3.2.3.1 Age 
 
Similar to the GPx activity results, the return from leave (ex-leave) CC16 concentration 
data were used to determine the effect of age on CC16 concentration. The ex-leave CC16 
concentration data for the whole group were not compatible with having been drawn at 
random from a population with a normal distribution (Shapiro-Wilk W test for normal 
data, p = 0.01) while the age data were compatible with a normal distribution (p = 0.08). 
 
When the age data were compared with the CC16 concentration data, no significant 
correlation was found (Spearman’s correlation r = 0.11, p = 0.35). This non-significant 
result was confirmed by parametric tests performed on the log transformed data (Pearson’s 
correlation r = 0.06, p = 0.58).  
 
These results indicate that the CC16 concentration of the ex-leave samples was not 
affected by the age of the study participants.  
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3.2.3.2 Race group 
 
Table 3.2.3.2 summarises the return from leave CC16 concentration data for the two main 
race groups involved in the study. 
 
 
Table 3.2.3.2: Mean CC16 concentration of the return from leave samples collected from the 
black and white study volunteers 
 
Race group n Mean CC16 concentration (ng/ml) Standard deviation 
Black 58 6.80 3.00 
White 22 6.84 2.36 
 
The ex-leave CC16 concentration data of the white race group were not compatible with 
being drawn at random from a population with a normal distribution (Shapiro-Wilk W test 
for normal data, p = 0.01) while that of the black race group were compatible (p = 0.05).  
 
As shown in table 3.2.3.2, there was a slight increase in mean CC16 concentration between 
the black and white race groups (0.04 ng/ml), however it was not statistically significant 
(two-sample Wilcoxon rank-sum test, p = 0.85). This non-significant result was confirmed 
by parametric tests performed on the log transformed data (the two-sample t test with 
unequal variances p = 0.53).  
 
These results indicate that the CC16 concentration of the ex-leave samples was also not 
affected by the race of the study volunteer. 
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3.2.3.3 Cigarette smoking 
 
The mean return from leave CC16 concentrations of the ex-leave samples collected from 
the current smokers, ex-smokers and non-smokers who volunteered for the study are 
shown in table 3.2.3.3.  
 
Table 3.2.3.3: Mean CC16 concentration of the ex-leave samples divided into three groups 
according to the cigarette smoking status of the volunteer at the time of sample collection 
 
Smoking status n Mean CC16 concentration (ng/ml) Standard deviation 
Current smoker 25 6.59 2.50 
Ex-smoker 19 7.63 2.74 
Non-smoker 35 6.50 3.10 
 
The ex-leave CC16 concentration data of the non-smoker group were not compatible with 
having been drawn at random from a population with a normal distribution (Shapiro-Wilk 
W test for normal data, p = 0.01) while that of the current smoker and ex-smoker groups 
were compatible with a normal distribution (p = 0.09 and p = 0.37, respectively).  
 
As shown in table 3.2.3.3, the mean CC16 concentration of the group of ex-smokers was 
higher than that current smokers and non-smokers. However, analysis revealed that the 
difference between the mean CC16 concentration of the three groups was not statistically 
significant (Kruskal-Wallis test, p = 0.15). This non-significant result was confirmed by 
parametric tests performed on the log transformed data (one-way analysis of variance with 
comparisons of the means, p = 0.32).  
 
These results indicate that the cigarette smoking habits of the study volunteers did not 
affect the CC16 concentration of the ex-leave samples. 
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3.2.3.4 Silicosis 
 
The return from leave CC16 concentration results for the study volunteers with and 
without signs of radiological silicosis (of ILO grade ≥ 1/1) are illustrated in table 3.2.3.4.  
 
 
Table 3.2.3.4: Mean CC16 concentration of the return from leave samples collected from the 
study participants with and without radiological silicosis (of ILO grade ≥ 1/1)  
 
Silicosis n Mean CC16 concentration (ng/ml) Standard deviation 
No silicosis 64 6.59 2.77 
Silicosis   8 8.61 3.12 
 
The ex-leave CC16 concentration data of the group with no signs of radiological silicosis 
were not compatible with having been drawn at random from a population with a normal 
distribution (Shapiro-Wilk W test for normal data, p = 0.01) while that of the group with 
silicosis were compatible with a normal distribution (p = 0.44).  
 
The increase in the mean CC16 concentration between the individuals with no silicosis and 
those with silicosis (2.02 ng/ml) observed in table 3.2.3.4 was just statistically significant 
(two-sample Wilcoxon rank-sum test, p = 0.05). This significant result was contradicted by 
parametric tests performed on the log transformed data (two-sample t test, p = 0.10).  
 
These results indicate that the CC16 concentration of the ex-leave samples may have been 
affected by whether the study volunteers had radiological silicosis (of ILO grade ≥ 1/1). 
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3.2.4 Comparison between biomarker levels in the return from 
leave (ex-leave) and return to work (follow up) samples  
 
Blood specimens were collected from the study volunteers after their return from leave (at 
the time of recruitment), and then again 8 to 25 weeks after their return to work on either a 
Monday (pre-shift), a Wednesday (pre- and post-shift), or a Friday (post-shift). In order to 
determine the effect of crystalline silica exposure on the levels of erythrocyte GPx activity 
and serum CC16 concentration, the levels of these biomarkers in the ex-leave and follow 
up samples were statistically compared.  
 
3.2.4.1 Erythrocyte GPx 
 
The median erythrocyte GPx activity results obtained for the ex-leave and follow up 
samples are illustrated in figure 3.2.4.1.a below. In addition, the mean erythrocyte GPx 
activities of the different groups and a statistical comparison of the differences between the 
mean GPx activities of the groups are given in table 3.2.4.1.a and table 3.2.4.1.b, 
respectively.  
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Figure 3.2.4.1.a: Erythrocyte GPx activities of the ex-leave and follow up samples (collected 
after 8 to 25 weeks on either a Monday, Wednesday (pre- and post-shift), or Friday). The GPx 
activity was measured using a Glutathione Peroxidase Assay Kit. In the box-and-whisker plot the 
line through the middle of the boxes represents the median GPx activity. The top and bottom of 
each box is the 75th and the 25th percentile, respectively. The top and bottom of each bar is the 90th 
and 10th percentile, respectively.  
 
 
Table 3.2.4.1.a: Mean erythrocyte GPx activities of the ex-leave samples and the follow up 
samples (combined and individually) 
Group n Mean GPx activity (U/g Hb) 
Standard 
deviation 
Ex-leave  80 26.30 6.49 
Combined follow up  53 22.48 5.78 
Monday  18 21.23 4.09 
Wednesday pre-shift 23 23.01 7.02 
Wednesday post-shift  22 23.78 7.42 
Friday  16 21.68 4.72 
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Table 3.2.4.1.b: Comparison between the mean erythrocyte GPx activities of the ex-leave and 
follow up samples (the level of significance is p ≤ 0.01) 
Groups being compared 
Difference between  
mean GPx activities 
(U/g Hb) 
Significance  
(p-value) 
Ex-leave versus combined follow up -3.82  0.00* 
Ex-leave versus Monday -5.07  0.00* 
Ex-leave versus Wednesday (pre-shift) -3.29  0.01* 
Ex-leave versus Wednesday (post-shift) -2.52  0.00* 
Ex-leave versus Friday -4.62  0.00* 
Monday versus Wednesday (pre-shift)  1.78 0.27 
Monday versus Wednesday (post-shift)  2.55 0.18 
Monday versus Friday  0.45 0.94 
Wednesday (pre-shift) versus Wednesday (post-shift) -0.77 0.91 
Wednesday (pre-shift) versus Friday -1.33 0.64 
Wednesday (post-shift) versus Friday -2.10 0.38 
*Indicates p-value less than level of significance 
  
As observed in figure 3.2.4.1.a, the median GPx activity of the ex-leave samples was 
higher than the median GPx activities of all of the follow up samples. The same results 
were observed in tables 3.2.4.1.a and 3.2.4.1.b with regards to the mean GPx activities. 
 
The differences between the mean GPx activity of the ex-leave samples and the follow up 
samples (including the combined follow up data) were all compatible with having been 
drawn at random from a population with a normal distribution (Shapiro-Wilk W test for 
normal data, p > 0.05). The paired t-test (with Bonferonni adjusted α of 0.01) was 
therefore performed to compare the mean GPx activity of the ex-leave samples with that of 
the Monday, Wednesday (pre- and post-shift) and Friday samples. The test indicated a 
significant decrease between the mean GPx activity of the ex-leave samples and the 
Monday, Wednesday (pre- and post-shift) and Friday follow up samples (table 3.2.4.1.b). 
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These results indicated that exposure to crystalline silica caused a decrease in the level of 
erythrocyte GPx activity. 
 
The GPx activities of the follow up samples were then compared with each other to 
determine any significant differences. The GPx activity data for the Wednesday (pre-shift) 
and Friday follow up samples were not compatible with having been drawn at random 
from a population with a normal distribution (Shapiro-Wilk W test for normal data, p = 
0.02 and p = 0.04 respectively), while the data for the Monday and Wednesday (pre-shift) 
follow up samples were compatible (p > 0.05). The two sample t-test indicated that there 
was no significant difference between the mean GPx activities of the Monday and 
Wednesday (post-shift) and the Wednesday pre-shift and post-shift follow up samples 
(table 3.2.4.1.b). The two-sample Wilcoxon rank-sum test (for unmatched data) indicated 
that there was no significant difference between the mean GPx activities of the Monday 
and Wednesday (pre- shift), the Monday and Friday, and the Wednesday (pre-and post-
shift) and Friday follow up samples (table 3.2.4.1.b). These non-significant results were 
confirmed by parametric tests (two-sample t-test) performed on the log transformed data. 
There were therefore no significant differences between the GPx activities of the follow up 
samples. 
 
The non-significant result obtained for the comparison of the mean GPx activities of the 
different follow up samples enabled a mean GPx activity to be determined for all the 
follow up samples combined.  The paired t-test (with Bonferonni adjusted α of 0.01) was 
performed to compare the mean GPx activity of ex-leave samples with that of the 
combined follow up samples. The test indicated a significant decrease between the mean 
GPx activity of the ex-leave samples and the combined follow up samples.   
  
 
 131 
The results presented in figure 3.2.4.1.a and tables 3.2.4.1.a and 3.2.4.1.b are combined 
results for all the volunteers. Since there were three miners from whom more than one set 
of follow up samples were collected, it was possible to illustrate the ex-leave and follow up 
results for these individual volunteers. Figure 3.2.4.1.b below compares the GPx activity of 
the ex-leave and follow up samples collected from these three miners.   
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Figure 3.2.4.1.b: Erythrocyte GPx activities of three volunteers from whom ex-leave and 
multiple follow up samples were collected. The follow up samples were collected 11 to 13 weeks 
after the ex-leave samples on a Monday, Wednesday (pre- and post-shift) and/or Friday.                                 
(Miner 8         ; miner 11          ; miner 43        ). All three volunteers had low dust exposure job 
classifications and only Miner 43 had a silicosis score ≥ 1/1.  
 
 
As was observed with the group of volunteers as a whole, the three individual volunteers 
all showed a decrease in mean GPx activity between their ex-leave and follow up samples 
(figure 3.2.4.1.b). While there was a large increase in mean GPx activity between the 
Monday and Friday samples of miner 8, there was a large decrease in the mean GPx 
activity between the Wednesday and Friday samples of miner 11. These individual results 
cannot, however, be considered an accurate representation of the effect of silica exposure 
on GPx activity since they are based on single samples which show high variation. 
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3.2.4.2 Serum CC16 
 
The median serum CC16 concentration results obtained for the ex-leave and follow up 
samples are illustrated in figure 3.2.4.2.a.  
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Figure 3.2.4.2.a: CC16 concentrations of the ex-leave and follow up samples (collected after 8 
to 25 weeks on either a Monday, Wednesday (pre- and post-shift), or Friday). The CC16 
concentration was measured using a Clara Cell Protein Human ELISA Kit. In the box-and-whisker 
plot the line through the middle of the boxes represents the median CC16 concentration. The top 
and bottom of each box is the 75th and the 25th percentile, respectively. The top and bottom of each 
bar is the 90th and 10th percentile, respectively.  
 
 
In addition, the mean serum CC16 concentrations of the different groups and a statistical 
comparison of the differences between the mean CC16 concentrations of the groups are 
given in table 3.2.4.2.a and table 3.2.4.2.b, respectively.  
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Table 3.2.4.2.a: Mean CC16 concentrations of the ex-leave and the follow up samples  
Group n Mean CC16 
concentration (ng/ml) 
Standard 
deviation 
Ex-leave  80 6.82 2.83 
Monday  18 6.97 2.55 
Wednesday pre-shift 23 6.75 3.96 
Wednesday post-shift  22 5.15 3.10 
Friday  16 5.59 2.23 
 
 
Table 3.2.4.2.b: Comparisons of the mean CC16 concentrations of the ex-leave and follow up 
samples (level of significance is p ≤ 0.01) 
Groups being compared 
Difference between  
CC16 concentrations 
(ng/ml) 
Significance 
(p-value) 
Ex-leave versus Monday  0.15 0.74 
Ex-leave versus Wednesday (pre-shift) -0.07 0.52 
Ex-leave versus Wednesday (post-shift) -1.67   0.00* 
Ex-leave versus Friday -1.23 0.02 
Monday versus Wednesday (pre-shift) -0.22 0.12 
Monday versus Wednesday (post-shift) -1.82 0.04 
Monday versus Friday -1.38 0.11 
Wednesday (pre-shift) versus Wednesday (post-shift) -1.60   0.01* 
Wednesday (pre-shift) versus Friday -1.16 0.76 
Wednesday (post-shift) versus Friday  0.44 0.31 
* Indicates p-value less than level of significance 
 
There was increase in median CC16 concentration (figure 3.2.4.2.a) and mean CC16 
concentration (table 3.2.4.2.a and 3.2.4.2.b) between the ex-leave and Monday follow up 
samples and a decrease in median CC16 concentration (figure 3.2.4.2.a) and mean CC16 
concentration (table 3.2.4.2.a and 3.2.4.2.b) between the ex-leave and Wednesday (pre- 
and post-shift) and Friday follow up samples.  
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Unlike the differences between the mean CC16 concentration of the ex-leave samples and 
the Monday and Wednesday (pre-shift) follow up samples which were compatible with 
having been drawn at random from a population with a normal distribution (Shapiro-Wilk 
W test for normal data, p > 0.05), the differences between the mean CC16 concentrations 
of the ex-leave and Wednesday (post-shift) (p = 0.02) and Friday (p = 0.02) follow up 
samples were not compatible. As a result, the paired t-test (with Bonferonni adjusted α of 
0.01) was used to compare the mean CC16 concentration of ex-leave samples with that of 
the Monday and Wednesday (pre-shift) follow up samples, and the Wednesday pre-shift 
and post-shift samples. The Wilcoxon signed-rank test (for matched data) was used to 
compare the mean CC16 concentration of ex-leave samples with that of the Wednesday 
(post-shift) and Friday follow up samples. As demonstrated in table 3.2.4.2.b, the tests 
indicated a significant difference between the mean CC16 concentration of the ex-leave 
samples and the Wednesday post-shift (p = 0.00), but no significant difference between the 
mean CC16 concentration of the ex-leave samples and the Monday, Wednesday (pre-shift) 
or Friday follow up samples (p > 0.01).   
 
The CC16 concentration data for the Wednesday (pre- and post-shift) follow up samples 
were not compatible with having been drawn at random from a population with a normal 
distribution (Shapiro-Wilk W test for normal data, p = 0.01 and p = 0.00 respectively), 
while the data for the Monday and Friday follow up samples were compatible (p > 0.05). 
As shown in table 3.2.4.2.b, there was no significant difference between the mean CC16 
concentration of the Monday and Wednesday (pre- and post-shift) samples, the Wednesday 
(pre- and post-shift) and Friday samples (the two-sample Wilcoxon rank-sum test for 
unmatched data, p > 0.01) or the Monday and Friday samples (two-sample t-test, p > 0.01). 
There was however, a significant difference between the mean CC16 concentration of the 
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Wednesday pre-shift and post-shift samples (the Wilcoxon signed-rank test for matched 
data, p = 0.01).  
 
The significant results obtained for some of the comparisons between the mean CC16 
concentrations of the different follow up samples meant that a mean CC16 concentration 
could not be determined for all the follow up samples combined.  
 
The results presented in figure 3.2.4.2.a and tables 3.2.4.2.a and 3.2.4.2.b are a 
combination of all the results obtained. Since there were three miners from whom more 
than one set of follow up samples were collected, it was possible to examine the ex-leave 
and follow up results for these individual volunteers. Figure 3.2.4.2.b below compares the 
CC16 concentration of the ex-leave and follow up samples for these three miners.  
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Figure 3.2.4.2.b: Serum CC16 concentrations of three volunteers from whom ex-leave and 
multiple follow up samples were collected. The follow up samples were collected 11 to 13 weeks 
after the ex-leave samples on a Monday, Wednesday (pre- and post-shift) and/or Friday.                                 
(Miner 8         ; miner 11          ; miner 43        ). All three volunteers had low dust exposure job 
classifications and only Miner 43 had a silicosis score ≥ 1/1.  
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As illustrated in figure 3.2.4.2.b, for miner 43, there was a decrease in CC16 concentration 
between the ex-leave and Monday follow up samples and the CC16 concentration 
continued to decrease throughout the week. For miner 8 there was a decrease in CC16 
concentration between the ex-leave and Friday samples, which was in accordance with the 
results obtained for the entire group of volunteers (figure 3.2.4.2.a), however there was an 
increase in CC16 concentration between the ex-leave and Monday samples. A similar 
contradictory result was observed for miner 11 in that the CC16 concentration increased 
between the ex-leave and Wednesday (pre-and post-shift) samples and between the ex-
leave and Friday samples. As with the GPx results, these individual results should be 
treated with caution as they are based on single samples which show high variation. 
 
 
3.2.5 Effect of crystalline silica exposure on the change in 
biomarker levels 
 
In an attempt to explain the changes in GPx activity and CC16 concentration (between the 
ex-leave and follow up samples) observed in section 3.2.4, the correlation between the job 
classification (an estimate of the level of crystalline silica exposure) of the study volunteers 
and the changes in biomarker levels was investigated. In addition, the correlation between 
the duration of crystalline silica exposure (i.e. the time between the collection of the ex-
leave and follow up samples) and the changes in biomarker levels was examined.   
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3.2.5.1 Erythrocyte GPx 
 
As previously stated in section 3.2.4, the mean GPx activity for the combined follow up 
samples was determined. The changes in mean GPx activity for the volunteers with high 
and low dust exposure job classifications are presented in table 3.2.5.1.a. 
 
Table 3.2.5.1.a: Change in mean GPx activity (between the ex-leave and combined follow up 
samples) divided into two groups according to the job classification of the study volunteers  
 
Job classification n Change in mean GPx 
activity (U/g Hb) Standard deviation 
Low dust exposure 31 -5.12 4.04 
High dust exposure 22 -2.91 5.40 
 
The change in GPx activity data of the groups with low and high dust exposure jobs were 
compatible with having been drawn at random from a population with a normal 
distribution (Shapiro-Wilk W test for normal data, p > 0.05).  
 
Although the change in mean GPx activity was greater for the group of volunteers with 
low dust exposure jobs than those with high dust exposure jobs (table 3.2.5.1.a), the 
difference proved not to be statistically significant (two-sample t test, p = 0.09).  This was 
confirmed by the finding of no significant correlation between the job dust exposure 
classification and the change in GPx activity (Pearson’s correlation r = -0.23, p = 0.09).  
 
These results indicate that the changes in GPx activity (between the ex-leave and follow up 
samples) observed in the current study were not affected by the job classification (i.e. the 
estimated dust exposure level) of the study volunteers. 
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To determine if there was a connection between the duration of crystalline silica exposure 
and the observed changes in GPx activity, the change in GPx activity results were sorted 
according to the duration of exposure .These results are presented in table 3.2.5.1.b. 
 
Table 3.2.5.1.b: Summary of the change in GPx activity (between the ex-leave and combined 
follow up samples) arranged according to the crystalline silica exposure duration   
 
Crystalline 
silica exposure 
duration 
(weeks) 
 
 
n 
GPx activity of 
ex-leave samples, 
mean ± SD 
(U/g Hb) 
GPx activity of combined 
follow up samples,  
mean ± SD 
(U/g Hb) 
Change in mean  
GPx activity,  
mean ± SD 
(U/g Hb) 
8 1 30.21 (± 0.00) 34.79 (± 0.00)   4.58 (± 0.00) 
9 2 28.32 (± 4.04) 22.82 (± 3.93) -5.49 (± 0.10) 
11 2 20.86 (± 1.44) 16.97 (± 2.40) -3.88 (± 0.96) 
13 6 25.98 (± 4.33) 21.93 (± 2.46)   -4.05 (± 2.71) 
14 2 29.68 (± 3.59) 17.67 (± 0.08) -12.01 (± 3.68) 
15 5 22.55 (± 3.15) 22.38 (± 4.84)   -0.17 (± 3.12) 
16 5 25.81 (± 8.99) 20.56 (± 9.31) -5.25 (± 1.38) 
17 3 28.30 (± 5.41) 23.52 (± 2.64) -4.78 (± 2.77) 
18 9 25.39 (± 5.59) 22.72 (± 6.96) -2.68 (± 5.76) 
20 4 26.10 (± 5.34) 21.73 (± 1.75) -4.36 (± 7.04) 
21 4 31.00 (± 4.72) 21.75 (± 4.16) -9.25 (± 2.75) 
22 2 19.79 (± 4.25) 22.68 (± 8.10)   2.88 (± 3.84) 
23 3 24.84 (± 0.85) 19.93 (± 3.07) -4.91 (± 3.62) 
25 5 34.50 (± 9.46) 28.23 (± 7.52) -6.27 (± 3.10) 
 
 
There was no apparent trend between the change in GPx activity and the duration of 
exposure to crystalline silica (table 3.2.5.1.b). This was confirmed by the finding of no 
significant correlation between the crystalline silica exposure duration and the change in 
GPx activity (Pearson’s correlation r = 0.14, p = 0.33).  
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3.2.5.2 Serum CC16 
 
Because the mean CC16 concentrations of all the follow up samples could not be 
combined to form a single follow up CC16 concentration variable, the change in CC16 
concentration (between the ex-leave and follow up samples) was calculated for each of the 
follow up groups separately. The changes in mean CC16 concentration for the volunteers 
with high and low dust exposure job classifications are presented in table 3.2.5.2.a. 
 
Table 3.2.5.2.a: Change in mean CC16 concentration (between the ex-leave and follow up 
samples) sorted according to the job classification of the study participants 
 
Job 
classification 
Change in mean 
CC16 level for 
the Monday 
follow up group, 
mean ± SD 
(ng/ml) 
Change in mean 
CC16 level for 
the Wednesday 
(pre-shift) follow 
up group, mean ± 
SD (ng/ml) 
Change in mean 
CC16 level for 
the Wednesday 
(post-shift) follow 
up group, mean ± 
SD (ng/ml) 
Change in mean 
CC16 level for 
the Friday follow 
up group, mean 
± SD (ng/ml) 
Low dust 
exposure  0.44 (± 1.93) -0.81 (± 2.64) -2.13 (± 2.25) -1.76 (± 2.50) 
 
High dust 
exposure 
-0.53 (± 2.81) -0.51 (± 1.45) -1.53 (± 1.73) -0.98 (± 2.06) 
 
 
There was a slight increase in the mean CC16 concentration between the ex-leave and 
Monday follow up samples for the group of volunteers with low dust exposure jobs and a 
slight decrease for the group of volunteers with high dust exposure jobs (table 3.2.5.2.a), 
however, the difference between the change in mean CC16 concentration in the two dust 
exposure groups was not significant (two-sample t test, p = 0.41).  This was confirmed by 
the finding of no significant correlation between the job dust exposure classification and 
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the change in mean CC16 concentration for the Monday follow up group (Pearson’s 
correlation p = 0.41).  
 
 
Although the decrease in CC16 concentration between the ex-leave and Wednesday (pre-
shift), Wednesday (post-shift) and Friday follow up samples was greater for the group of 
volunteers with low dust exposure jobs than those with high exposure jobs (table 3.2.5.2.a), 
the difference between the change in mean CC16 concentration in the two dust exposure 
groups was not significant (two-sample t test p = 0.64, two-sample Wilcoxon rank-sum           
p = 0.53 and p = 0.52 respectively).  This was confirmed by the finding of no significant 
correlation between the job classification and the change in mean CC16 concentration for 
the Wednesday (pre-shift), Wednesday (post-shift) and Friday follow up groups (Pearson’s 
correlation p = 0.64 and p = 0.49 and Spearman’s correlation p = 0.54, respectively).  
 
These results indicate that the change in CC16 concentration (between the ex-leave and 
follow up samples) was more than likely not affected by the job classification (i.e. the 
estimated dust exposure level) of the study volunteers. 
 
Similar to GPx, the change in mean CC16 concentration results (for each follow up group) 
were sorted according to the duration of crystalline silica exposure to establish if there was 
a connection between the duration of exposure and the observed changes in CC16 
concentration. These results are presented in table 3.2.5.2.b below. 
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Table 3.2.5.2.b: Summary of the change in CC16 concentration (between the ex-leave and 
follow up samples) arranged according to the duration of crystalline silica exposure  
 
Crystalline 
silica 
exposure 
duration 
(weeks) 
Change in mean 
CC16 level for 
the Monday 
follow up group, 
mean ± SD 
(ng/ml) 
Change in mean 
CC16 level for the 
Wednesday (pre-
shift) follow up 
group, mean ± SD 
(ng/ml) 
Change in mean 
CC16 level for the  
Wednesday (post-
shift) follow up 
group, mean ± SD 
(ng/ml) 
Change in mean 
CC16 level for the  
Friday follow up 
group, mean ± SD 
(ng/ml) 
8 - - - -1.01 (±0.00) 
9 - -1.43 (± 0.66) -1.67 (± 1.32) - 
11 -1.04 (± 3.71) -3.72 (± 0.00) -7.84 (± 0.00) -7.23 (± 0.00) 
13  2.38 (± 0.70)  2.45 (± 1.52) -0.11 (± 0.08) -0.47 (± 2.14) 
14 - 
 0.37 (± 0.00)   0.54 (± 0.00) -0.32 (± 0.00) 
15 -1.83 (± 0.19)  0.46 (± 5.01) -2.53 (± 0.86) -4.96 (± 0.00) 
16  3.69 (± 0.00)  0.90 (± 1.19) -0.44 (± 0.87) - 
17 
 0.81 (± 0.00) -2.43 (± 0.00) -4.38 (± 0.00) -0.34 (± 0.00) 
18 - -0.36 (± 1.33) -1.06 (± 1.38) -0.59 (± 0.74) 
20 -1.43 (± 0.00) -0.19 (± 0.92) -1.54 (± 0.40) -0.67 (± 0.00) 
21 -0.52 (± 1.03) -1.09 (± 0.00) -3.22 (± 0.00)   0.93 (± 0.00) 
22 -3.47 (± 0.00) -1.94 (± 0.00) -3.83 (± 0.00) - 
23 -0.15 (± 1.63) - - -4.65 (± 0.00) 
25 
 0.53 (± 0.23) -1.65 (± 2.43) -2.44 (± 1.54) -2.03 (± 0.00) 
 
 
 
There was no apparent trend between the change in CC16 concentration (between the ex-
leave and follow up samples) and the duration of exposure to crystalline silica. This was 
confirmed by the finding of no significant correlation between the duration of exposure to 
crystalline silica and the change in CC16 concentration between the ex-leave and Monday, 
Wednesday (pre-shift), Wednesday (post-shift) and Friday follow up samples (Pearson’s 
correlation p = 0.34 and p = 0.46, Spearman’s correlation p = 0.28 and p = 0.93).  
 
Therefore, the changes in GPx activity and CC16 concentration observed in the current 
study could not be correlated to the estimated dust exposure level (job classification) or the 
duration of crystalline silica exposure. 
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Chapter 4: 
DISCUSSION 
 
Despite the dust control methods currently being employed, silicosis continues to pose a 
significant threat to the health of South African gold miners. This is possibly due to 
inadequate occupational exposure limit enforcement and unreliable methods of 
determination of personal dust exposure. In addition, due to the long latency period of 
silicosis, the chest radiographs that are used to diagnose silicosis are a late indicator of 
harmful dust exposure and therefore do not provide an effective way to measure and 
control the dust exposure.   
 
It is therefore clear that a more effective means of monitoring dust control methods is 
needed if silicosis is to be eliminated. One promising field is that of biomarkers of effect, 
which are measurable changes within an organism that may indicate either early processes 
preceding disease or predict the advance and presence of disease [Bennett and Waters, 
2000]. 
 
As a result, a project on biomarkers was initiated which aimed to identify and 
operationalise biomarkers for crystalline silica dust exposure that could then be used to 
assess the success of the implemented dust exposure control measures in South African 
mines. The project was not intended to produce a diagnostic test for silicosis in individuals 
as biomarkers identified would probably be too non-specific for such a definitive 
diagnostic purpose [Aitio, 1999].  
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The current investigation is the third phase of this project on biomarkers and is aimed to 
confirm the levels of and further analyze erythrocyte glutathione peroxidase (GPx) and 
serum Clara cell protein 16 (CC16) in miners exposed to crystalline silica dust. Prior to 
their analysis in blood specimens collected from these miners, the optimal operational 
parameters for these biomarkers were investigated and the relevant Standard Operating 
Procedures (SOPs) were established.  
 
4.1 Optimization of the operational parameters 
 
In order to limit pre-analytical variability as a result of storage conditions and sample 
processing, the effect of different operational parameters on the levels of GPx activity and 
CC16 concentration was investigated.  
 
Firstly, the effect of temperature and duration of storage on the levels of GPx activity and 
CC16 concentration needed to be determined as the assay of these two biomarkers were 
time intensive and could not be performed immediately under field conditions. Secondly, 
the effect of a delay in time between blood sample collection and separation needed to be 
investigated due to the fact that the follow up samples were collected at different times 
from different mine shafts and were then transported back to the temporary laboratory for 
their separation. Lastly, the effect of ambient room temperature on GPx activity and CC16 
concentration needed to be determined because, despite the availability of heaters and fans, 
the temporary field laboratory did not have an adequate air conditioning system to ensure 
constant ambient temperature. Each of these investigations was performed with blood 
specimens obtained from two volunteers with no history of exposure to crystalline silica. 
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4.1.1 Effect of storage temperature 
 
In order to determine the effect of storage temperature on the levels of GPx activity and 
CC16 concentration, replicate erythrocyte lysate and serum samples were stored at 4 oC 
(common fridge temperature), -20 oC (common freezer temperature) and -80 oC 
(specialised freezer temperature) before being assayed. 
 
4.1.1.1 Erythrocyte GPx 
 
For both volunteers there was a decrease in mean GPx activity with a decrease in storage 
temperature however, the decrease was not statistically significant. This indicated that the 
temperature at which the GPx samples were stored after separation did not have a 
significant effect on the GPx activities.  
 
The results obtained were not expected as a number of studies have shown that GPx 
activity decreases with an increase in storage temperature. For instance, Zhang and 
colleagues [1986] examined the effect of storage temperature and storage duration on 
swine plasma GPx activity. They found a significant decrease in GPx activity after storage 
for two days and more at either 4 oC or -15 oC, with the decrease in GPx activity much 
greater in samples stored at 4 oC than in those stored at -15 oC. Saint-Denis and co-workers 
[1998] investigated the effect of storage temperature on GPx activity (of the cytosolic 
fraction) in the Earthworm Eisenia fetida andrei. They found that while storage for two 
months at 4 oC caused a decrease in GPx activity, the GPx activity of samples stored at      
-20 oC was relatively stable (although there was a slight decrease of activity). The GPx 
activity of the samples stored at -80 oC was the most stable. Other studies have also 
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suggested that the GPx activity of samples is more stable when the samples are frozen 
rather than refrigerated [Wahdati et al., 1992, Miranda et al., 2004]. 
  
An additional observation with our results was that the mean GPx activity in the 
erythrocyte lysate samples from volunteer two was approximately three times lower than 
that of volunteer one. Since the two volunteers were both females of similar age, the 
difference observed may just have been due to lifestyle factors [Andersen et al., 1997] or 
hormonal differences [Pinto and Bartley, 1969]. 
 
4.1.1.2 Serum CC16 
 
The concentration of CC16 measured in the serum of both volunteers decreased with a 
decrease in storage temperature, with the largest statistically significant decrease occurring 
in the samples stored at -80 oC compared to those stored at 4 oC. On the other hand, no 
statistically significant difference could be observed between the mean CC16 concentration 
of the samples stored at -20 oC and -80 oC.  
 
The higher CC16 concentration measured in the serum samples stored at 4 oC was not 
expected. Changes in volume observed in these samples, possibly due to evaporation 
despite the use of sealed CryoTubes, could have resulted in the higher concentrations of 
CC16 measured in these samples.  
 
Therefore, although the present investigation could not confirm the results of reported 
studies, a storage temperature of -80 oC was chosen for the erythrocyte lysate and serum 
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samples as it was the temperature recommended by the GPx and CC16 assay kit 
manufacturers and it was the temperature used in other investigations of erythrocyte GPx 
activity [Engelen et al., 1990, Ho et al., 2005, Borm et al., 1986] and serum CC16 
concentration [Halatek et al., 2004, Wang et al., 2007].  
 
4.1.2 Effect of a delay in time between blood sample collection 
and separation 
 
During the field work, the blood specimens could be left for up to two hours before being 
separated and therefore the effect of this delay in time on the levels of GPx activity and 
CC16 concentration was investigated. 
 
4.1.2.1 Erythrocyte GPx 
 
As the time interval between blood sample collection and separation increased (from zero 
to two hours), there was a slight increase in mean GPx activity of the erythrocyte lysate 
samples obtained from volunteer one and a slight decrease in mean GPx activity of the 
samples collected from volunteer two. However statistical analysis revealed that, for both 
volunteers, these observed changes in GPx activity were not statistically significant.  
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4.1.2.2 Serum CC16 
 
There was a decrease in mean CC16 concentration as the time between sample collection 
and separation increased (from zero to two hours) for both volunteer one and two. 
However statistical analysis revealed that, for both volunteers, the decrease observed was 
not statistically significant. In another study on the effect of time between blood collection 
and centrifugation, the researchers found no significant difference between samples 
separated immediately and samples left for 30 minutes, 24, 48 and 96 hours before 
separation [Kenis et al., 2002]. 
 
It was therefore decided that the blood samples collected during the field work could be 
left for up to two hours (at approximately 25 oC) before being separated without a 
significant effect on the GPx activity of the resulting lysate samples or on the CC16 
concentration of the resulting serum samples. 
 
4.1.3 Effect of ambient laboratory temperature 
 
The levels of GPx activity and CC16 concentration were assessed in samples processed at     
25 oC (the common laboratory temperature) and 35 oC (a temperature close to 
physiological temperature) to establish the effect of ambient laboratory temperature.  
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4.1.3.1 Erythrocyte GPx 
 
For volunteer one, processing of the erythrocyte lysate samples at the higher laboratory 
temperature of 35 oC, rather than the common laboratory temperature of 25 oC, caused a 
significant increase in the mean GPx activity of the samples. A similar result was found by 
Saint Denis and colleagues [Saint-Denis et al., 1998] who showed that maximum GPx 
activity occurred at a temperature of 40 oC.  Since the normal human physiological body 
temperature is approximately 37 oC, one would expect enzymes such as GPx to function 
optimally at that temperature or temperatures close to it. 
 
In contrast, for volunteer two there was a slight decrease in mean GPx activity at the higher 
laboratory temperature, however this decrease was not statistically significant.   
 
4.1.3.2 Serum CC16 
 
For both volunteer one and two, there was an increase in the mean CC16 concentration 
when the serum samples were processed at the higher laboratory temperature of 35oC. This 
increase was statistically significant for volunteer one and only just non-significant for 
volunteer two.  
 
The significant results obtained for volunteer one indicated that the laboratory temperature 
at which the samples are processed may affect the GPx activity and CC16 concentration of 
the samples. It was therefore important that the erythrocyte lysate and serum samples be 
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processed and assayed at a constant temperature to ensure reproducibility and allow the 
GPx activity and CC16 concentration of the samples to be reliably compared. Although a 
higher GPx activity and CC16 concentration was found at a temperature of 35 oC, the GPx 
and CC16 assay kit instructions recommended an assay temperature of 25 oC. It was 
therefore decided that during the field work the ambient temperature of the temporary field 
laboratory and the NIOH laboratory would be maintained as close to 25 oC as possible.  
 
4.1.4 Effect of storage duration 
 
The effect of increasing duration of storage on the levels of GPx activity and CC16 
concentration was investigated as the erythrocyte lysate and serum samples could not be 
assayed immediately after their preparation.  
 
4.1.4.1 Erythrocyte GPx 
 
Although there was a slight increase in mean GPx activity with an increase in storage 
duration for volunteer one, analysis revealed that, for both volunteers, there was no 
significant difference between the mean GPx activities of the samples stored for increasing 
storage durations. A non-significant effect of storage temperature on GPx activity was also 
found by Andersen and colleagues [1997] who stored erythrocyte lysate samples at -80 oC 
for six months. 
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It was therefore decided that the erythrocyte lysate samples, collected during the field 
work, could be stored for up to nine weeks without there being a significant effect on the 
GPx activity of the samples.  
 
Similar to the results obtained with the effect of storage temperature (section 4.1.1.1), 
storage duration also affected differently the GPx activities of the erythrocyte lysate 
samples collected from two different donors in that the mean GPx activity of the samples 
obtained from volunteer two were almost double that of the samples obtained from 
volunteer one.  In this latter experiment however, the volunteers were of different sexes 
and the differences in mean GPx activities observed may therefore be attributed to gender 
differences as confirmed by observations by Bolzan et al [1997]. 
 
4.1.4.2 Serum CC16  
 
For both volunteer one and two, the mean CC16 concentration of the samples decreased 
after three and six weeks but then recovered slightly after nine weeks of storage. While the 
decrease in the mean CC16 concentrations between the zero week and the three and six 
week samples was significant for volunteer one it was not significant for volunteer two.  
 
Since there was no significant difference between the mean CC16 concentration of the 
serum samples assayed immediately and those stored for nine weeks, for both volunteers, it 
was decided that the serum samples collected during the field work would be stored for 
approximately nine weeks before being assayed.  This decision was also based on the 
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recommendations of the kit manufacturers which claimed that the serum CC16 samples 
could be stored for up to two years at -80 oC.  
 
4.1.5 Comparison of GPx activity and CC16 concentration 
results of NIOH volunteers with results reported for 
healthy adults 
 
As previously mentioned in section 2.1.8, the haemoglobin concentration of the 
erythrocyte lysate samples used in the GPx optimisation experiments was not measured 
because the replicate samples were prepared from the same blood specimen. The GPx 
activity results obtained for the GPx optimisation experiments were therefore reported as 
nmol/min/ml. The GPx activity levels, obtained in the optimisation experiments, ranged 
from 20.4 to 1726.8 nmol/min/ml (or 0.002 to 1.727 Units). Using the average 
haemoglobin concentration obtained for the miner’s erythrocyte lysate samples (0.05 g 
Hb/ml); the GPx activity results for the optimisation experiments were estimated to be 
between 0.42 and 35.36 U/g Hb.  A study on the biological variability of erythrocyte GPx 
[Guemouri et al., 1991], conducted in France, reported erythrocyte GPx activity levels of 
between 22.5 and 67.0 U/g Hb in healthy adult males and between 24.4 and 68.1 U/g Hb in 
healthy adult females.  In terms of the South African population, Janse van Rensburg et al 
[2005] reported erythrocyte GPx levels of 22.1 ± 3.5 U/g Hb in healthy adult controls; 
however their sample numbers were low. Therefore, although some of the NIOH 
volunteers had estimated GPx activity results well below the reported ranges for healthy 
adults, the majority of the volunteers had estimated GPx activity results within the lower 
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end of the ranges. The mean GPx activity of the healthy volunteers in the study by Borm et 
al [1986] were also low (2.86 U/g Hb) despite the use of a different assay procedure.  
 
In addition, the GPx optimisation experiments showed a within-subject coefficient of 
variation (CV) of between 11.4% and 126.3% (with a mean of 39.0%). However, the 
Glutathione Peroxidase Assay Kit manufacturer reported a much lower intra-assay CV of 
5.7% when they assayed a larger sample size [CaymanChemical, 2004]. One reason for the 
high CVs obtained in the current study is the stringent criteria used to reject outliers. Only 
data observations greater than 2.IQR above or below the mean were considered outliers 
and therefore some replicate values that were much lower or higher than the other replicate 
could not be excluded from the data sets. The high CVs obtained in the current study may 
also indicate that the assay is not as reproducible as reported.  
 
In the CC16 optimisation experiments the CC16 levels ranged from 0.59 to 8.30 µg/l with 
a mean of 5.81 µg/l. Other studies have reported serum CC16 levels of between 6.6 and 
23.2 µg/l in healthy adult males and between 3.7 and 22.9 µg/l in healthy adult females 
[Shijubo et al., 2003]. Similar to the GPx results, some of the NIOH volunteers had CC16 
levels well below the reported ranges for healthy adults while the majority of the 
volunteers had CC16 levels within the lower end of the ranges. The results of the current 
study were, however, consistent with the CC16 levels obtained for the healthy controls 
(5.77 ± 1.64 µg/l) in the second phase of the project [Murray et al., 2006]. The lower CC16 
and GPx levels in the healthy South African population therefore warrants further 
investigation. 
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The CC16 optimisation experiments showed a within-subject coefficient of variation (CV) 
of between 7.5% and 47.5% (with a mean of 17.2%). The CVs may have been lower if less 
stringent criteria were used to determine outliers.  
 
 
4.2 Field work 
 
 
During the field work portion of this project, a total of 80 volunteer miners were recruited 
upon their return from leave (a period of little or no crystalline silica exposure) and blood 
samples were collected. Follow up blood samples were then collected from 53 of the 
volunteers after they had returned to work (and had been exposed to crystalline silica dust). 
Due to various reasons (for example the refusal to continue with the study or the inability 
to be contacted telephonically) there were 27 volunteers from whom no follow up samples 
could be collected.  
 
The follow up samples were collected 8 to 25 weeks (2 to 6 months) after the volunteers 
had returned to work. This variation in the duration of exposure to crystalline silica 
allowed the effect of exposure duration on the change in biomarker levels (between the ex-
leave and follow up samples) to be investigated (the results of which are discussed in 
section 4.2.4). As previously detailed in section 2.4.3, the original protocol for the follow 
up sample collection procedure was revised so that blood specimens were collected on 
either a Monday (pre-shift), a Wednesday (pre- and post-shift), or a Friday (post-shift). 
This adaptation of the study design due to the lack of participation by volunteers resulted 
in a reduction in the number of samples obtained (only 16 Monday, 24 Wednesday, and 16 
Friday follow up samples were collected) and therefore a decrease in the power of the 
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results. In addition, it limited the ability to examine inter-individual changes in the 
biomarker levels over time.   
 
4.2.1 Demographics of the study population  
 
The entire group of volunteers had a mean age of 40 years, consisted of a majority of black 
individuals and had prevalence of radiological silicosis of 11%. Additionally, the group 
consisted of an approximately equal number of individuals in high and low dust exposure 
jobs.  
The characteristics of the group of volunteers who donated follow up samples were then 
compared to those of the group of volunteers who did not donate follow up samples. It was 
found that there was no significant difference between the two groups in terms of age, 
apparent race group, smoking habits, job classification (an estimate of dust exposure level), 
silicosis prevalence, return from leave GPx activities or return from leave CC16 
concentrations. It was therefore concluded that there was no selection bias in the miners 
who donated follow up blood specimens. 
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4.2.2 Parameters affecting biomarker levels in ex-leave miners 
 
4.2.2.1 Erythrocyte GPx 
 
As indicated earlier, GPx is a marker of oxidative stress. The effect of age, race, cigarette 
smoking, and silicosis on the levels of erythrocyte GPx activity (in specimens collected 
from miners upon their return from leave) was therefore assessed because oxidative stress 
has been associated with aging [Habif et al., 2001], silicosis [Ghio et al., 1990] and 
cigarette smoking [Quinlan et al., 1994]. The effect of race on GPx activity was also 
investigated as any effect would influence the recruitment of study volunteers in future 
projects.  
 
The current study showed no significant correlation between age and erythrocyte GPx 
activity. These findings were in agreement with those reported in phase II of the project 
[Murray et al., 2006] as well as with those reported in other investigations [Andersen et al., 
1997, Habif et al., 2001]. On the other hand, a significant positive correlation between age 
and GPx activity [Ceballos-Picot et al., 1992, Bolzan et al., 1997] and a negative 
correlation between GPx activity and an age of 60 years or older [Ho et al., 2005, 
Guemouri et al., 1991] have been reported. The lack of significant correlation between 
GPx activity and age observed in our results may therefore be explained by the mean age 
of our group being below 60 years. 
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The current study also found that, although the GPx activity of the group of white 
individuals was slightly higher than the group of black individuals, there was no significant 
effect of race on GPx activity. Due to the lack of convincing literature regarding race 
differences in GPx activity, further investigation into possible effects of race group on GPx 
activity is required. 
 
In addition, no significant effect of cigarette smoking on erythrocyte GPx activity was 
found. These results confirm those reported in the second phase of the project [Murray et 
al., 2006] and in other investigations [Toth et al., 1986, Guemouri et al., 1991, Habif et al., 
2001, Bolzan et al., 1997].  However, a few studies have indeed shown a significant 
decrease in erythrocyte GPx activity in smokers versus non-smokers [Duthie et al., 1991, 
Kondo et al., 1994, Ho et al., 2005]. It should be noted that the participants in the current 
study who described themselves as smokers only smoked a relatively low number of 
cigarettes per day and this may have contributed to the lack of a significant finding. 
 
Finally, the level of GPx activity in the group of volunteers with silicosis was significantly 
lower than in the group with no signs of silicosis. Despite the small number of subjects in 
our silicotic group, larger studies involving silicotic patients and controls have also shown  
a decrease in erythrocyte GPx activity [Borm et al., 1986, Zhou et al., 1999]. 
 
4.2.2.2 Serum CC16  
 
When the effect of age on serum CC16 concentration was investigated in the current study, 
no significant correlation was observed. Similar findings were also reported in phase II of 
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the project [Murray et al., 2006] and in a study by Hermans et al [1998] which also 
assayed CC16 by means of ELISA. In studies using latex immunoassay as the assay 
method, a significant correlation between age and CC16 concentration was found and it 
was attributed to age-related structural and functional changes in the lung or a decline in 
renal function [Robin et al., 2002, Bernard et al., 1994b].   
 
In addition, no significant effect of race on serum CC16 concentration was found. Similar 
to GPx activity, no studies could be found that examined the effect of race on CC16 
concentration and therefore further research into this field is required.   
 
The current study also showed that, although the smokers (current and ex-smokers) had 
higher CC16 concentration than the non-smokers; there was no significant effect of 
cigarette smoking on serum CC16 concentration. These findings were in agreement with 
the findings of phase II of the project [Murray et al., 2006] and a study by Wang et al 
[2007] which involved silica exposed workers and controls.  
  
Lastly, the volunteers in the current study with radiological silicosis (of ILO grade 1/1 or 
greater) had higher CC16 concentrations than the volunteers with no silicosis. Although 
the non-parametric statistical test indicated that the increase was just significant, the 
parametric tests performed on the transformed data indicated that there was no significant 
effect of silicosis on CC16 concentration. The contradicting results were likely due to the 
small number of subjects with silicosis. An earlier study involving silica-exposed workers 
in China found no significant difference between the participants with and without silicosis 
[Wang et al., 2007].   A more comprehensive investigation into the effect of silicosis on 
serum CC16 concentration is therefore required.  
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4.2.3 Comparison between biomarker levels in the return from 
leave (ex-leave) and return to work (follow up) samples  
 
As previously mentioned, ex-leave samples were collected from miners after a period of no 
crystalline silica exposure and follow up samples were collected, throughout the week, 
following 8 to 25 weeks of crystalline silica exposure. The levels of erythrocyte GPx 
activity and serum CC16 concentration in the ex-leave samples were then compared to 
those in the follow up samples to determine the effect of 8 to 25 weeks (2 to 6 months) of 
crystalline silica exposure. In addition, the levels of erythrocyte GPx activity and serum 
CC16 concentration in the Monday, Wednesday and Friday follow up samples were 
compared to each other to determine the effect of short term crystalline silica exposure.  
 
4.2.3.1 Erythrocyte GPx 
 
A significant decrease was found when comparing the mean GPx activity of the ex-leave 
samples with that of the Monday, Wednesday (pre- and post-shift) and Friday follow up 
samples.  The statistical comparisons were paired so that ex-leave GPx activity levels were 
compared with the follow up GPx activity levels in the same individual.  A significant 
decrease in GPx activity was also found when the mean GPx activity of the ex-leave 
samples was compared to that of the follow up groups combined (26.30 U/g Hb versus 
22.48 U/g Hb,   p = 0.00). Since the ex-leave samples were collected after a period of leave 
(usually four weeks), the results suggest that GPx levels decrease after two to six months 
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of chronic exposure to silica dust and then increase or even recover to normal during a 
period of leave.  
 
When the mean GPx activity levels of the Monday (pre-shift), Wednesday (pre- or post-
shift) and Friday (post-shift) follow up samples were compared to each other, no 
significant differences were found.  It was therefore suggested that the GPx levels remain 
decreased throughout the week and do not recover over a weekend away from work.  
 
The decrease in mean GPx activity, upon exposure to crystalline silica dust, found in this 
phase of the project therefore confirms the findings of the second phase of the project 
[Murray et al., 2006]. A significant decrease in GPx activity as a result of exposure to 
silica containing dust has also been demonstrated in studies of silicosis patients [Borm et 
al., 1986, Zhou et al., 1999], coal miners [Nadif et al., 2001], and cement workers [Orman 
et al., 2005]. In addition, significant decreases in GPx activity have been observed in other 
diseases or exposures in which oxidative stress has been implicated: such as COPD 
[Kluchova et al., 2007], asthma [Powell et al., 1994], and cadmium exposure [Babu et al., 
2006].  
 
A possible explanation for the observed decrease lies in the fact that the study participants 
were chronically exposed to respirable crystalline silica. Acute exposure to crystalline 
silica can cause an increase in erythrocyte GPx levels as a result of increased antioxidant 
action to counteract the oxidative stress induced by the crystalline silica particles 
[Vallyathan et al., 1995]. On the other hand, chronic exposure to crystalline silica could 
cause the antioxidant system to be overwhelmed leading to a decrease in GPx activity. 
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4.2.3.2 Serum CC16 
 
The mean CC16 concentration of the ex-leave samples was very similar to those of the pre-
shift follow up samples collected on Monday and Wednesday but higher than those of the 
post-shift follow up samples collected on Wednesday and Friday. The decrease in CC16 
concentration between the ex-leave and Wednesday (post-shift) samples was statistically 
significant while the decrease between the ex-leave and Friday samples was only just not 
significant (when Bonferonni adjusted alpha was used as the level of significance). Since 
the ex-leave samples were collected in the morning, the majority of the pre-shift follow up 
samples were collected in the morning and the majority of the post-shift follow up samples 
were collected in the afternoon (refer to figure 3.2), the results indicate a significant 
decrease between the CC16 levels in the morning and afternoon samples. This was 
confirmed by the comparison of the different follow up samples which showed a 
significant decrease between the Wednesday (pre- and post-shift) CC16 levels. Although a 
significant difference between the CC16 levels of the Monday (pre-shift) and Wednesday 
(post-shift), the Friday and Monday and the Friday and Wednesday (pre-shift) samples was 
also expected, the comparisons were unpaired and therefore not as accurate as a paired 
comparison.   
 
One possible explanation for results observed in the current study is that CC16 levels fall 
quite rapidly during the period of a work shift but return to near normal levels during the 
16 hours between shifts. This implies that CC16 levels may be a marker of recent silica 
exposure.  Similar results were found in studies of workers exposed to welding fumes 
[Halatek et al., 2004] and nitric oxides [Halatek et al., 2005]. Both studies measured CC16 
levels on a Monday morning, Monday afternoon (after an eight hour shift) and a Friday 
  
 
 161 
afternoon.  While the study of welders found a significant decrease between the Monday 
morning and the Monday afternoon and Friday afternoon samples, the study of nitric oxide 
exposed workers found a similar but non-significant result. From these results the authors 
suggested that depletion in CC16 levels as a result of exposure to welding fumes and nitric 
oxides can already be seen after a single eight hour shift.  
 
On the other hand, the results of the current investigation may have been influenced by 
time-dependent diurnal variation in CC16 levels that have been observed in other studies. 
When Anderson et al [2007] and Helleday et al [2006] investigated diurnal variation of 
CC16 in serum samples they found a decrease in serum CC16 concentrations over the day 
with the highest CC16 concentration occurring in the morning sample and the lowest in the  
afternoon sample. In addition, Helleday et al. [2006] proposed the use of an equation 
(∆CC16 = 0.032t2 – 0.582t) to describe the relationship between time of day and CC16 
levels. Although the exact times at which specimens were collected were not recorded in 
this study; the Helleday equation could be used to estimate the expected change in CC16 
levels due to diurnal variation.  Assuming average shift duration of 8 hours, it was 
estimated that diurnal variation could cause CC16 levels to drop an average of 2.6 ng/ml 
between morning and afternoon samples. In the present study, the decreases in CC16 
concentration observed between the ex-leave and follow up samples and between the pre- 
and post-shift follow up samples (table 3.2.4.2.b) were well within this expected fall of 
2.61 ng/ml. Therefore, we cannot fully attribute the declines in CC16 levels observed in 
this study to the effects of crystalline silica exposure during the shift as these declines may 
also be due to diurnal variation. 
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In unpublished results of the Phase II study by Wilson et al. (Appendix A), the miners 
exposed to crystalline silica had a mean CC16 level of 5.6 ng/ml while the non-exposed 
controls had a mean CC16 level of 6.6 ng/ml. Since the majority of the Phase II specimens 
were collected at similar times, the decrease in CC16 levels (due to crystalline silica 
exposure) observed in that study were unlikely to be due entirely to diurnal variation. 
 
It is therefore proposed that the current study results are compatible with the results 
reported in phase II of the project [Murray et al., 2006] and exposure to crystalline silica 
dust more than likely contributed to the reduction in CC16 levels observed.   
 
A decrease in serum CC16 levels, as a result of crystalline silica exposure, has also been 
observed in studies involving silica-exposed mine workers and controls [Bernard et al., 
1994a, Wang et al., 2007]. The authors proposed that the decrease in CC16 levels in serum 
were as a result of a decreased secretion or production of CC16 due to the destruction of 
Clara cells by silica. They suggested that the number or integrity of Clara cells might be 
compromised by 1) direct damage of Clara cells (which are sensitive to attack from 
pneumotoxic chemicals) by silica particles; 2) damage caused by cytotoxic mediators 
released from activated macrophages after they have engulfed silica particles and 3) 
prevention of the renewal of Clara cells (since Clara cells have been implicated in the 
renewal of bronchiolar epithelium). They concluded that changes in the serum CC16 
concentration likely reflects early toxic effects of silica on Clara cells (before significant 
effects on the lungs can be detected by chest x-ray examination) and therefore that serum 
CC16 is a sensitive marker which might improve the ability to detect exposure to silica in 
the respiratory tract.  
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4.2.4 Effect of crystalline silica exposure on the change in 
biomarker levels  
 
An attempt was then made to establish whether the observed decrease in GPx activity and 
CC16 concentration was correlated to either the job classification (an estimate of dust 
exposure level) of the volunteers or the duration of crystalline silica exposure (the duration 
between the collection of the ex-leave and follow up samples). 
 
4.2.4.1 Erythrocyte GPx 
 
It was determined that the decrease in GPx activity observed was not significantly related 
to the job classification (dust exposure level) or the duration of crystalline silica exposure. 
These results confirm that GPx may be a marker of early effect from crystalline silica 
exposure since the GPx levels decrease upon exposure to crystalline silica, following a 
period of leave, and do not change significantly as the duration of exposure increases.  
 
4.2.4.2 Serum CC16 
 
Similar to GPx activity, no significant correlation was found between the changes in CC16 
concentration observed and the job classification (dust exposure level) of the volunteers or 
the crystalline silica exposure duration.  
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It is, however, important to treat these results with caution since the dust exposure level 
classifications were based on current job descriptions and were therefore not a reliable or 
accurate measure of the volunteers personal dust exposure. In addition, the duration of dust 
exposure observed in the current study was short and the number of observations in each 
duration group was small. Therefore, although the current investigation found no 
correlation between the change in GPx activity and CC16 concentration levels and the 
level or duration of dust exposure, it does not mean that a correlation does not exist. 
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4.3 Limitations of the study 
 
The study participants were all volunteers and therefore no attempt should be made to 
generalise these findings to all miners, in particular in respect of establishing what 
constitutes normal baseline biomarkers levels for unexposed miners. 
 
Three main limitations arose during the study: 
 
Firstly, the original project plan involved the collection of the return to work specimens 
from each volunteer on a Monday (pre-shift), a Wednesday (pre- and post-shift), and a 
Friday (post-shift). This collection procedure proved difficult to achieve as volunteers were 
not willing to give four specimens in one week. The specimen collection procedure was 
then revised so that miners were asked whether they would be prepared to give two 
specimens (a pre- and post-shift specimen) on a Wednesday. Those who said they were not 
prepared to do so were allocated to a single specimen collected either pre-shift on a 
Monday or post-shift on a Friday by randomization. This adaptation of the study design 
due to the lack of participation by volunteers resulted in a reduction in the number of 
follow up samples obtained and therefore a decrease in the power of the study to detect 
differences.   
 
Secondly, the dust exposure level classifications used were based on current job 
descriptions and were therefore an unreliable indication of the volunteer’s personal dust 
exposure. It would have been better to determine the personal dust exposure level of the 
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volunteer by performing 8-hour full-shift personal dosimetry and measuring the amount of 
respirable crystalline silica by X-ray diffraction (XRD) spectroscopy.   
 
Thirdly, since the levels of GPx (a general marker for oxidative stress) and CC16 (a 
general lung damage marker) are both affected by a number of toxicants they are not 
specific for crystalline silica exposure. Although in occupational exposure settings it is 
often possible to exclude other factors affecting the biomarker levels and therefore a 
relative specificity is possible [Aitio, 1999], the question remains whether the observed 
changes are only due to respirable crystalline silica exposure.  
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4.4 Future research & recommendations 
 
1. The effect of diurnal variation of CC16 levels needs to be further investigated in 
silica-exposed subjects. Helleday et al developed a second-degree polynomial 
mathematical model (with the formula ∆CC16 = -0.582t + 0.032t2) to explain the 
decrease in serum CC16 due to diurnal variation. In future studies, the baseline 
morning CC16 concentration should be determined so that the model can be used to 
compensate for the diurnal variation and therefore any remaining decrease could be 
interpreted as an effect of the silica exposure. This factor was not taken into account 
in the design of the current study since the relevant paper had not yet been published. 
It would probably also be wise to investigate the possibility of diurnal variations of 
the GPx levels in non-exposed workers.  
 
2. Although the GPx activity was found to decrease after two to six months of 
crystalline silica exposure, the point in time (after the return to work) at which the 
decrease in GPx activity actually occurs (a dose response curve) needs to be further 
investigated.  
 
3. Although a great deal of research indicates that both GPx and CC16 could be markers 
of silica exposure it would be worthwhile, as a precautionary step, to examine this 
issue further by measuring these biomarkers in miners with no silica exposure. If  this 
research finds no change in GPx or CC16 levels (i.e. confirm the specificity of these 
biomarkers for crystalline silica exposure) then the next question that needs to be 
answered is whether there exists a threshold of silica exposure at which the 
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biomarker levels fall, and whether this threshold (if it exists) correlates with 
dosimetric silica measurements.  
 
4. The baseline levels of GPx and CC16 for individuals with no history of crystalline 
silica exposure needs to be determined. A study could be conducted in which new 
recruits (with no previous silica exposure) are followed up periodically over a 
number of years to establish the changes occur in the levels GPx and CC16. 
 
5. It is possible that silica-induced damage to Clara cells may be permanent or that it 
might take longer than one month (the duration of the leave periods) for them to 
recover or for destroyed Clara cells to be replaced. It would therefore be interesting 
to study CC16 levels in ex-miners who have been away from the mines for longer 
than one month to determine whether there is any observable increase in CC16 levels 
with time, and, if so, how long this might take. 
 
6. The drawing of blood, although not as invasive as BAL, is still considered an 
invasive procedure. Although not possible for GPx, it would be wise to investigate 
the possibility of using non-invasive methods (for example urine, breath or saliva) to 
assay CC16.  This would facilitate routine sampling in human studies and may 
overcome ethical issues [Waterfield and Timbrell, 2000]. In fact, a correlation 
between serum CC16 and urine CC16 has been found [Andersson et al., 2007] and 
the use of urinary CC16 (U-CC16) as an alternative to serum CC16 as a biomarker of 
airway toxicity has been investigated [Timonen et al., 2004]. Therefore, further 
consideration and investigation into the use of urine CC16 as an alternative to serum 
CC16 in silica exposed subjects is recommended. 
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7. The inter-assay and intra-assay variations of the Glutathione Peroxidase Assay Kit 
and Human Clara Cell Protein ELISA Kit used in the current study should be 
investigated in healthy South African controls.  
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Chapter 5:  
CONCLUSION 
 
Despite dust control measures in place to limit the inhalation of crystalline silica, silicosis 
continues to pose a significant threat to the health of South African gold miners. It would 
therefore be invaluable if biomarkers of effect of crystalline silica exposure were identified 
and validated as they could be used to detect early adverse effects of silica exposure and 
evaluate the success of dust control methods. 
 
An earlier phase of this project on biomarkers identified two potential biomarkers, 
erythrocyte glutathione peroxidase (GPx) and serum Clara cell protein 16 (CC16), which 
were significantly affected by crystalline silica exposure. This third phase of the project 
seemed to confirm the results of the earlier phase in that a decrease in the levels of GPx 
activity and CC16 concentration was observed following exposure to crystalline silica.     
 
Regarding the levels of GPx, the results suggest that GPx levels decrease after two to six 
months of chronic exposure to crystalline silica dust and remain decreased (throughout the 
working week and over a weekend) and then increase or even recover to normal levels 
during a period of leave. It was therefore concluded that GPx activity levels rise and fall, in 
response to crystalline silica dust exposure, gradually and over periods of some time, 
possibly months.  
 
The CC16 results were, however, less promising. It was found that, after two to six months 
of exposure to crystalline silica, there was a significant decrease in serum CC16 
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concentration on a Wednesday afternoon following an 8-hour shift and during the duration 
of a shift. In addition, there is the possibility that the observed changes were due to a time-
dependent diurnal variation in the CC16 levels.   
 
In conclusion, the results of the current phase warrant further research into the use of 
erythrocyte GPx and serum CC16 as biomarkers of early effect from crystalline silica 
exposure. 
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APPENDICES 
 
 
Appendix A: Abstract for poster presented by Mrs K. Wilson at the 2008 
EPICOH conference. 
 
Predictors of Clara Cell Protein (CC16) level: an investigation of CC16 as a silica 
exposure biomarker. 
 
Kerry Wilson, 1,2, Jill Murray1,2, Brendan Girdler-Brown3, Paul Borm4, Ken Donaldson5, 
Val Vallyathan6, Vincent Castranova6 and Mary Gulumian1,2. 
 
1National Institute for Occupational Health, 2University of the Witwatersrand, 3University 
of Pretoria, 4Centre for life Science, 5ElEGI, 6NIOSH 
 
Introduction: Clara cell protein (CC16) is a protein that is mainly produced by Clara cells 
in the respiratory epithelium. CC16 can be measured in bronchoalveolar lavage specimens, 
serum, urine and sputum. Clara cells and CC16 may play a role in protecting the lung from 
oxidative stress. A change in CC16 reflects chronic damage to Clara cells and may 
therefore be a useful biomarker for crystalline silica induced lung damage. This paper 
presents an analysis of predictors of CC16 in gold miners exposed to silica and unexposed 
controls. 
 
Methods: 118 African male volunteers participated in this cross-sectional study. They were 
recruited from a gold mine (silica exposed, n= 64), a blood donor service (silica non-
exposed n= 37) and a hospital HIV clinic (silica non-exposed n= 18). Data were collected 
on age, work history, smoking habits and HIV status. CC16 was assayed in the serum 
using an ELISA kit. Multiple linear regression was performed with post-regression 
residuals analysis to identify the factors that might explain the observed variation in CC16.  
 
Results: Arithmetic mean (AM), geometric mean (GM) and geometric standard deviation 
(GSD) for the whole group CC16 level were 6.0ng/ml, 5.27ng/ml and 1.67ng/ml.  AM, 
GM, and GSD for the silica exposed group were 5.56, 4.87 and 1.69, and for the 
unexposed group were 6.49, 5.77 and 1.64. The CC16 results were log-normally 
distributed. Tests for unpaired data with equal variance indicated a crude relationship 
between silica exposure and CC16 levels, p = 0.074; and smoking and CC16 levels, p = 
0.0001. Multiple regression with the factors investigated in this study explained 20% of the 
variation (coefficient of determination r = 0.19) and the model identified exposure to silica 
as a significant risk for a lower level of CC16 (p = 0.024) smoking was no longer 
significant (p = 0.082).   
 
Conclusion: CC16 levels were lowered in silica exposed subjects and were not affected by 
HIV status. CC16 is a suitable candidate for further research.  Factors that further explain 
the variance in CC16 levels need to be identified before it can be confidently used as a 
biomarker for silica dust exposure. 
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Appendix B: Copy of KC4 report obtained from the assay of the GPx 
activity of samples 31 to 34.  
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 175 
Appendix C: Analysis page from the Cayman Chemical Company workbook entitled “GSHasesTriple” 
 
The values in the cells are taken from the KC4 results printout (Appendix B) from the analysis of the erythrocyte lysate samples of 
volunteer 31 to 34 
ASSAY 
 
1
 
           
             
LAYOUT 1 2 3 4 5 6 7 8 9 10 11 12 
A BLANK                       
B CTRL 1:1                     
C Smpl31 1:30                     
D Smp32 1:30                     
E Smpl33 1:30                     
F Smpl34 1:30                     
G 
                        
H 
                        
             
TIME 0:00 1 2 3 4 5 6 7 8 9 10 11 12 
A 0.4090 0.4100 0.414                   
B 0.3690 0.3690 0.378                   
C 0.5250 0.5300 0.54                   
D 0.5610 0.5640 0.561                   
E 0.5310 0.5360 0.538                   
F 0.5440 0.5640 0.558                   
G 
                        
H 
                        
TIME 1:00             
A 0.3980 0.4010 0.405                   
B 0.3280 0.3330 0.344                   
C 0.4840 0.4870 0.497                   
D 0.5270 0.5290 0.53                   
E 0.4980 0.5090 0.508                   
F 0.5190 0.5350 0.525                   
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G 
                        
H 
                        
TIME 2:00             
A 0.3880 0.3900 0.395                   
B 0.2860 0.2940 0.307                   
C 0.4390 0.4420 0.454                   
D 0.4940 0.4940 0.498                   
E 0.4670 0.4800 0.481                   
F 0.4890 0.5030 0.495                   
G 
                        
H 
                        
TIME 3:00             
A 0.3770 0.3800 0.384                   
B 0.2420 0.2530 0.225                   
C 0.3940 0.3980 0.411                   
D 0.4610 0.4590 0.465                   
E 0.4360 0.4500 0.453                   
F 0.4590 0.4710 0.465                   
G 
                        
H 
                        
TIME 4:00             
A 0.3670 0.3690 0.372                   
B 0.1970 0.2100 0.225                   
C 0.3500 0.3540 0.368                   
D 0.4270 0.4230 0.432                   
E 0.4050 0.4200 0.424                   
F 0.4280 0.4380 0.436                   
G 
                        
H 
                        
TIME 5:00             
A 0.3560 0.3580 0.361                   
B 0.1530 0.1670 0.182                   
C 0.3080 0.3110 0.326                   
D 0.3930 0.3880 0.356                   
E 0.3740 0.3870 0.396                   
F 0.3970 0.4060 0.406                   
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G 
                        
H 
                        
 
 
 
 
         
Time BLANK CTRL Smpl31 Smp32 Smpl33 Smpl34             
0 0.4110 0.3720 0.5317 0.5620 0.5350 0.5553             
1 0.4013 0.3350 0.4893 0.5287 0.4980 0.5263             
2 0.3910 0.2957 0.4450 0.4953 0.4760 0.4957             
3 0.3803 0.2400 0.4010 0.4617 0.4463 0.4650             
4 0.3693 0.2107 0.3573 0.4273 0.4163 0.4340             
5 0.3583 0.1673 0.3150 0.3790 0.3857 0.4030             
y-int= 0.4117 0.3738 0.5320 0.5651 0.5325 0.5563       
slope= -0.0106 -0.0415 -0.0435 -0.0358 -0.0292 -0.0306       
R2= 0.9994 0.9957 0.9999 0.9952 0.9973 0.9999       
Rxn Rate= 0.0105 0.0409 0.0328 0.0261 0.0193 0.0199       
             
Time                         
0 
                        
1 
                        
2 
                        
3 
                        
4 
                        
5 
                        
y-int= 
            
slope= 
            
R2= 
            
Rxn Rate= 
            
             
RESULTS GPx Dilution Activity GPx Dilution Activity       
 Smpl31 30 2506.17             
 Smp32 30 1991.69             
 Smpl33 30 1477.21             
 Smpl34 30 1523.06             
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Ctrl 1 104.25       
       
Activity in nmol/min/ml 
      
             
             
             
FILENAME 
GSHasesTriple - M31-Al to 
M34-Al           
             
VERSION 2004D314           
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Appendix D: Graph page from the Cayman Chemical Company workbook 
entitled “GSHasesTriple” 
 
The graphs were automatically constructed by the workbook using the values entered into the 
Analysis page (see Appendix C) for volunteer 31 to 34. 
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Appendix E: Certificate of analysis for CC16 
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Appendix F: Copy of KC4 report obtained from the assay of the CC16 
concentration of samples 1 to 26 
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Appendix G: Information sheet for NIOH volunteers 
 
 
     MINE HEALTH AND SAFETY COUNCIL  
                                  and the 
      NATIONAL INSTITUTE for 
              OCCUPATIONAL HEALTH 
 
 
Subject Information Sheet for volunteers 
 
Hello, my name is Kerry Makinson, I am a researcher at the National Institute of Occupational 
Health (NIOH), and my contact number is 011 712 6469. My co-worker is Professor Brendan 
Girdler-Brown. 
 
I would like to invite you to participate in our study. We are looking for a new blood test that 
might be used to see if silica dust levels at the gold mines are a danger to workers.  
However, before we conduct experiments on the miners’ blood we need to determine the best 
conditions for handling, storage and assaying of the samples. In order to do this we need to do 
experiments with blood from volunteers.  
 
If you decide to participate, I would like to explain to you what will happen. First you need to 
sign a consent form. Then we will need to draw 15ml of blood (3 teaspoons) from your arm. 
This will not take long. After we take your blood it will be kept frozen at the National Institute 
for Occupational Health and will only be used for these optimization experiments. It will not 
be used for any other purpose without your written permission. 
 
Your personal information and results will be kept confidential and will not be shown to any 
other person.   
 
If you decide not to take part in this study it will not affect you or your job in any way. The 
only risk to you from taking part in this study will be a little discomfort when the blood 
specimen is taken and for a short time afterwards.  
 
Thank you  
Kerry Makinson 
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Appendix H: Consent form for NIOH volunteers 
 
 
     MINE HEALTH AND SAFETY COUNCIL  
                                  and the 
      NATIONAL INSTITUTE for 
              OCCUPATIONAL HEALTH 
 
 
  106 Joubert Street Ext ● PO Box 4788 Johannesburg 2000 South Africa ● Tel: 27 11 712 6400 ● 
  Fax: 27 11 712 6545 
 
 
Validation of biomarkers for assessment of exposure to silica dust. 
 
The information sheet about this study has been read to me and I understand what will be 
required of me if I take part in the study. My questions concerning this study have been 
answered by…………………........................ (Name of study member). 
 
My participation in this study is voluntary; I understand that if I do not wish to take part it will 
have no effect on me or my job.  
 
I ____________________________________________________________ agree to take part 
in the study. I agree to give 15ml of blood. I understand that all individual and personal 
information will be kept confidential.  
 
Signed_______________________________________Date_____________ 
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Appendix I: Standard Operating Procedure (SOP) for the analysis of 
erythrocyte glutathione peroxidase activity using the Cayman Chemical 
Glutathione Peroxidase Assay Kit 
 
 
Objective: To describe the Standard Operating Procedure (SOP) for the collection, handling and 
storage of blood samples from volunteer miners and for assaying the amount of Glutathione Peroxidase 
(GPx) activity in the samples using the Cayman Chemical Glutathione Peroxidase Assay Kit 
 
Principle: Glutathione peroxidase (GPx) catalyzes the reduction of organic hydroperoxides (including 
hydrogen peroxide) by reduced glutathione and functions to protect the cell from oxidative damage 
[Ursini et al., 1985]. The Cayman Chemical Glutathione Peroxidase Assay Kit measures GPx activity 
indirectly by a coupled reaction with glutathione reductase (GR). Oxidized glutathione (GSSG), 
produced upon reduction of hydroperoxide by GPx, is recycled to its reduced state by GR and NADPH 
[Ursini et al., 1985]: 
 
R-O-O-H + 2GSH           GPx             R-O-H + GSSG + H2O 
 
GSSG + NADPH + H+       GR            2GSH + NADP+ 
 
The oxidation of NADPH to NADP+ is accompanied by a decrease in absorbance at 340 nm. Under 
conditions in which the GPx activity is rate limiting, the rate of decease in the A340 is directly 
proportional to the GPx activity in the sample [Paglia and Valentine, 1967]. The Cayman GPx Assay 
Kit can be used to measure all of the glutathione-dependent peroxidases in plasma, erythrocyte lysates, 
tissue homogenate, and cell lysates [Cayman Chemical Company, 2004]. 
 
Sensitivity: The range of the assay is limited only by the accuracy of the absorbance measurement. 
Most plate readers are linear to an absorbance of 1.2. Samples containing GPx activity between 50-344 
nmol/min/ml can be assayed without further dilution or concentration. This GPx activity is equivalent 
to an absorbance decrease of 0.02 to 0.135 per minute. [Cayman Chemical Company, 2004]. 
 
Precision: When a series of seventy-seven GPx measurements were performed on the same day by the 
manufacturer, the intra-assay coefficient of variation was 5.7%. When a series of seventy-seven GPx 
measurements were performed on five different days under the same experimental conditions (by the 
manufacturer), the inter-assay coefficient of variation was 7.2%. [Cayman Chemical Company, 2004].  
 
Interferences:  
1. Samples that have a high intrinsic absorbance at 340 nm may exceed the absorbance maximum of 
the plate reader. Therefore, samples with an initial absorbance >1.2 should be diluted with Sample 
buffer until the absorbance is lowered. 
2. Samples containing high levels of GSSG or NADPH consuming enzymes will cause the GPx levels 
to be overestimated. A blank containing no cumene hydroperoxide can be performed to assess non-
specific oxidation of NADPH.  
3. The following reagents have been shown to interfere with the assay: Chymostatin (a protease 
inhibitor) and 2-Mercaptoethanol. [Cayman Chemical Company, 2004]. 
 
Storage and Expiration of Kit: The Kit is stored at -20oC. Under these conditions the Kit is stable 
until the expiration date (indicated on the label of the box). 
 
Primary sample: Human erythrocyte lysate 
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Container of storage: 1.0 ml CryoTubes 
 
Equipment needed: 
 
1. A microplate reader with a 340 nm filter. 
2. Adjustable pipettes to deliver 10-1000 µl and disposable tips. 
3. A centrifuge capable of 1300 x g and 10 000 x g.  
4. Microcentrifuge tubes for diluting the samples. 
5. Multichannel pipette to deliver 20-100 µl. 
 
 
Reagents needed: 
 
1. The Cayman Chemical Glutathione Peroxidase Assay Kit.  
2. HPLC-grade water. 
 
Safety Precautions: See attached MSDS. 
 
Quality control: A Glutathione Peroxidase control (provided in the kit) is run in triplicate with the 
samples. 
 
Supplier Details: 
 
The Cayman Chemical Glutathione Peroxidase Assay Kit (Catalogue number 703102). 
Cayman Chemical Company 
Ann Arbor,  
Michigan, 
United States of America 
Customer Service Department: (734) 975-3999 (USA) 
Technical Service Staff: (734) 975-3888 (USA) or techserv@caymanchem.com 
 
Local Supplier:  
 
Calicom Trading 262 (PTY) LTD  
Tel: +27 11 472-7300 
Email: keith@katmedical.com 
 
 
A. SOP FOR THE COLLECTION OF BLOOD SAMPLES FROM VOLUNTEER MINERS 
 
 
1. Draw venous blood into two 6 ml BD Vacutainer tubes containing lithium heparinate as an 
anticoagulant. 
 
2. The blood should be drawn and handled at room temperature (25oC). 
 
 
B. SOP FOR THE SEPARATION OF THE COLLECTED BLOOD SAMPLES 
 
 
1. The bloods should be separated within 2 hours of being collected. 
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2. To separate the blood, centrifuge the tube of blood at 1300 x g for 10 minutes at room 
temperature. 
 
3. Remove the upper plasma layer and discard. 
 
4. Remove the buffy coat (leukocytes) above the packed erythrocytes. 
 
5. Pipette 0.3 ml of erythrocytes into a 1.5 ml Eppendorf tube, in triplicate. 
 
6. Add 1.2 ml of ice-cold deionised water to each aliquot to lyse the erythrocytes. 
 
7. Close the lids of the Eppendorf tubes and gently invert a few times to mix. 
 
8. Centrifuge the Eppendorf tubes at 10 000 x g for 15 minutes at 4oC. 
 
9. During centrifugation, the ruptured erythrocyte membranes pellet to the bottom of the 
Eppendorf tubes and the contents of the erythrocytes (including the enzyme GPx) are 
suspended in the supernatant (known as the erythrocyte lysate). 
 
10. Following centrifugation, remove 1 ml of the erythrocyte lysate from each Eppendorf tube and 
place it in separate 1.5 ml CryoTubes (that are clearly labelled).  
 
 
C. SOP FOR THE STORAGE OF THE ERYTHROCYTE LYSATE 
 
 
1. Ensure that the lids of the CryoTubes are securely fastened. 
 
2. Shock freeze the CryoTubes by using a pair of tongs to lower the CryoTubes into a Dewar tank 
of liquid nitrogen. 
 
3. Transport the frozen CryoTubes back to the National Institute for Occupational Health (NIOH) 
in a cooler box containing enough ice packs to ensure that the CryoTubes remain frozen. 
 
4.  As soon as the CryoTubes arrive at the NIOH transfer them to a clearly labelled container. 
 
5. Place the container in the -80oC Freezer. 
 
6. Record the sample in the Sample Log Book. 
 
 
D. SOP FOR OPERATING THE MICROPLATE READER AND ACCOMANYING 
SOFTWARE 
 
 
The microplate reader needs to be set up before beginning the assay as the absorbance of the assay 
microplate needs to be read as soon as the initiating reagent (Cumene Hydroperoxide) is added. 
 
1. To measure the absorbance in the wells of the microplate during the assay, an ELx800 
Automated Microplate reader (Bio-Tek) is used and the accompanying software is KC4TMv3.4 
(Bio-Tek). 
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2. Plug in the microplate reader and switch it on (the ON/OFF switch is located on the right hand 
side of the machine). 
 
3. The reader will go through an automatic self-test to ensure it is functioning properly. 
 
4. Wipe down the surface of the microplate reader with a damp paper towel. 
 
5. Connect the laptop loaded with the KC4 software to the microplate reader and to the printer. 
 
6. Switch on the laptop and open the KC4 program. 
 
7. Click on the ‘Protocol’ tab and select the ‘Wizard’ option 
 
8. In the ‘Plate settings’ box select the ‘Description’ box. 
 
9. In the ‘Plate description parameters’ box fill in the necessary prompts (for example the 
experiment name or the name of the experimenter). These are optional. 
 
10. Click ‘OK’ 
 
11. In the ‘Plate settings’ box select the ‘Reading Parameters’ box 
 
12. Select the ‘Kinetic’ reading type. 
 
13. Click on the small box labelled ‘Kinetic’. A box will appear. Fill in a Run time of 5 minutes 
(00:05:00) and an Interval of 1 minute (00:01:00). Click “OK’ 
 
14. Select the ‘Meas. Filter’. Click the down arrow on the side of the white box next to the Meas 
Filter option. Select a wavelength of 340 nm. 
 
15. Click the down arrow on the side of the white box next to the Plate type and select a ‘96 Well 
Plate’. 
 
16. Fill in the wells that are being used on the plate in the ‘First well’ and ‘Last well’ boxes (For 
example if the whole plate is being used the first well is A1 and the last well is H12). 
 
17. Click “OK’ 
 
18. In the ‘Plate settings’ box select the ‘Layout’ box 
 
19. A layout for a 96 Well Plate will appear in a box labelled ‘Plate layout’. Select the type of 
sample being assayed (for example a blank (background), control or sample) by clicking the 
down arrow on the side of the white box next to the ‘Type’ option. Once you have selected the 
type of sample, click on the well that sample will occupy in the microplate. The name of the 
sample will then appear in that well. (For example, select the Blank as the type of sample and 
click on the well labelled A1. The word Blank will then appear in well A1).  
 
20. Once the plate layout has been filled in click ‘OK’ 
 
21. Select the ‘Output’ tab. 
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22. In the ‘Output’ box select the ‘Report’ box 
 
23. In the ‘Available data’ box click on the name of the type of data that is wanted in the final 
report of the results (for example the template). Click on the small box labelled ‘Add’. The 
name of the data that was selected will then appear in the ‘Selected data’ box. Continue this 
process until all the data that is wanted in the report is listed in the ‘Selected data’ box.(If a 
data type is added that is no longer wanted click on the small box labelled ‘Remove’ and the 
data name will be removed from the ‘Selected data’ box). 
 
24. The only data type that must be selected is ‘M 340’ (The absorbance values obtained for the 
samples at 340 nm). In order to add this data type one first needs to select the ‘Table’ format. 
The name of the first and last wells of the plate that need to be assayed must also be filled in 
the white boxes next to the ‘From’ and ‘To’ kinetic readings. 
 
25. Once all the data needed has been selected click ‘OK’ 
 
26. Click ‘OK’ 
 
27. Save the protocol under a chosen name. 
 
28. Select the ‘Read’ Box in the tool bar. 
 
29. Fill in the necessary prompts and any comments.  
 
30. Do not click on the ‘Start Reading’ box. This is only done once the plate is ready to be read. 
 
31. Perform the assay as described below. 
 
 
E. SOP FOR ASSAYING THE AMOUNT OF GPx ACTIVITY IN THE ERYTHROCYTE 
LYSATE 
 
 
1.  The erythrocyte lysate samples (stored in CryoTubes in the -80oC freezer) should be assayed 
no later than 9 weeks after they were collected. 
 
2. The amount of GPx activity in the RBC lysate samples will be assayed using a Glutathione 
Peroxidase Assay Kit purchased from Cayman Chemical Company (USA). 
  
3. When not in use, store the kit at -200C in a freezer. 
 
4. To use the kit, remove from the fridge and allow the contents of the kit to come to room 
temperature (25oC). 
 
5. To prepare the 1 X assay buffer, pipette 2 ml of 10 X Assay buffer concentrate (provided in the 
kit) into a clearly labelled sterile 50 ml Falcon tube. Add 18 ml of HPLC-grade water to the 
assay buffer and mix gently. The diluted assay buffer is stable for 2 months if stored at 4oC. 
 
6. To prepare the 1 X sample buffer, pipette 2 ml of 10 X Sample buffer concentrate (provided in 
the kit) into a clearly labelled sterile 50 ml Falcon tube. Add 18 ml of HPLC-grade water to the 
sample buffer and mix gently. The diluted sample buffer is stable for 1 month if stored at 4oC. 
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7. To prepare the Co-substrate mixture (provided in the kit); add 2 ml of HPLC-grade water to 
the vial provided and vortex gently to mix. Three vials of Co-substrate mixture are provided in 
the kit and each reconstituted vial is enough for 40 wells. It is therefore only necessary to 
reconstitute the number of vials needed to supply the number of wells that will be used. The 
reconstituted Co-substrate mixture is stable for 2 days if stored at 40C. 
 
8.  Remove the erythrocyte lysate samples that will be assayed from the -80oC freezer and allow 
them to thaw at room temperature (25oC). 
 
9.  In 1.5 ml Eppendorf tubes, pipette the amount of 1x Sample buffer necessary to dilute the 
erythrocyte lysate sample 30 X. If the erythrocyte lysate sample is being assayed in singlet 
pipette 145 µl of 1 X Sample buffer into the Eppendorf tube. If the sample is being assayed in 
duplicate pipette 290 µl of 1 X Sample buffer into the Eppendorf tube etc. 
 
10. Ensure that 1 X Sample buffer has been added to all the Eppendorf tubes needed before any 
erythrocyte lysate sample is added. 
 
11. Gently tap the CryoTubes containing the thawed erythrocyte lysate sample to mix. 
 
12. Pipette 5 µl of the mixed RBC lysate sample into the 1x sample buffer in the Eppendorf tube 
and aspirate to mix.  
 
13. Repeat for all the samples using a clean pipette tip for each sample. 
 
14. To prepare the Glutathione Peroxidase control (provided in the kit), add 10 µl of GPx control 
to 490 µl of 1 X sample buffer in a 1.5 ml Eppendorf tube and aspirate to mix. Keep the GPx 
control on ice (it is stable for 4 hours). 
 
15. A microplate containing 96 wells is provided in the kit. In each plate there are 12 columns 
(Columns 1 to 12) each consisting of 8 wells (Rows A to H).  
 
16. Pipette 120 µl of 1 X assay buffer into 3 wells of the microplate (if using the whole kit use 
wells A1, A2 and A3). These wells are the background wells (non-enzymatic wells). 
 
17. Pipette 100 µl of 1 X assay buffer into 3 wells of the microplate (if using the whole kit use 
wells A4, A5 and A6). These wells are the positive control wells. 
 
18. Pipette 100 µl  of 1 X assay buffer into the number of wells needed for the number of samples 
that will be assayed (For example if a total of 30 samples are being assayed in singlet, add    
100 µl of 1 X assay buffer into 30 wells). These wells are the sample wells. 
 
19. Add 50 µl reconstituted Co-substrate mixture into each of the wells being used. 
 
20. Gently tap the Eppendorf tube containing the diluted GPx control (positive control) to mix. 
Pipette 20 µl of GPx control into each of the 3 positive control wells. 
 
21. For each sample, gently tap the Eppendorf tube containing the diluted erythrocyte lysate 
sample to mix. Pipette 20 µl of each diluted sample into one of the sample wells. 
 
22. Carefully place the microplate into the designated holder in the microplate reader. 
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23. Add 20 µl of Cumene Hydroperoxide (provided in the kit) to each well. The Cumene 
Hydroperoxide initiates the reaction. 
 
24. If more than three rows of the plate are being used, only add 20 µl Cumene Hydroperoxide to 
two rows of the microplate and then read the absorbance of those two rows. Repeat for the next 
two rows until all the rows with sample have been read. 
 
25. Carefully shake the microplate for a few seconds to mix the contents in the wells. 
 
26. Select the ‘Start Reading’ box that is displayed in the KC4 program. 
 
27. The absorbance at 340 nm is automatically measured five times at one minute intervals in each 
of the microplate wells being used.  
 
28. Once the microplate reader has finished measuring the absorbance of the plate, click on the 
‘Save’ box in the toolbar and save the report under a chosen name. If one requires the report to 
be printed, click on the ‘Print’ box in the toolbar. 
 
29. Remove the microplate from the microplate reader 
 
30. Wipe down the microplate reader with a damp paper towel. 
 
31. Switch off the microplate reader and unplug. 
 
 
F. SOP FOR CALCULATING THE GPx ACTIVITY FROM THE ABSORBANCE DATA 
OBTAINED BY THE ASSAY  
 
 
A. Electronically using a worksheet 
 
Cayman Chemical Company supplies a tool on their website that allows one to calculate the GPx 
activity from the absorbance values obtained. 
 
1. Open the website for Cayman Chemical Company: www.caymanchem.com 
 
2. Under the heading ‘Products’ (on the right hand side of the page), select ‘Analysis tools’. 
 
3. Under the heading ‘Non-EIA tools’, select ‘Glutathione Enzyme (GSHases)’. 
 
4. Under the heading ‘Download’, click on ‘GSHases Triple’ to start downloading. 
 
5. Save the file in a chosen location. 
 
6. Open the file. 
 
7. In the worksheet labelled ‘Analysis’ fill in the necessary information about the sample number 
and dilution (a 1:30 dilution was used) in the designated boxes.  
 
8. Also in the ‘Analysis’ worksheet, fill in the absorbance values obtained for the background, 
positive control and RBC lysate samples at times 0 to 5 minutes as indicated.  
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9. The GPx activity is automatically calculated for the background, positive control and 
erythrocyte lysate samples and displayed in a table labelled ‘Results’ at the bottom of the 
worksheet. 
 
10. The corresponding graphs of absorbance versus time for each sample are also automatically 
constructed and illustrated in the worksheet labelled ‘Graphs’. 
 
11. Save the workbook under a chosen name. 
 
B. Manually using formulas 
 
1. Determine the change in absorbance (∆A340) per minute by: 
a. Plotting the absorbance values as a function of time to obtain the slope (rate of the 
linear portion of the curve – or-  
 
b. Selecting two points on the linear portion of the curve and determining the change in 
absorbance during that time using the following equation: 
 
∆A340/ min = (A340 (Time 2) – A340 (Time 1)) / (Time 2 (min) – Time 1 (min)) 
 
(Method b is the most preferred, with Time 2 being 5 minutes and Time 1 being 0 minutes) 
 
2. Determine the rate of ∆A340/min for the background wells and subtract this rate from the rate of 
the sample wells. 
 
3. Use the following formula to calculate the GPx activity: 
 
GPx Activity = ((∆A340/ min)/ 0.00373 µM-1) x (0.19 ml/0.02 ml) x Sample Dilution = nmol/min/ml 
 
Where: 
0. 00373 µM-1 is the NADPH extinction coefficient 
0.19 ml is the final volume of the assay in each well 
0.02 ml is the volume of sample in the well 
The sample dilution is 30 X 
 
References: 
 
Cayman Chemical Company. (2004). Glutathione Peroxidase Assay Kit Instruction Insert, Cayman 
Chemical Company, Ann Arbor, USA. pg 1-22, 2004. 
 
Paglia, D.E. and Valentine, W.N. Studies on the quantitative and qualitative characterization of 
erythrocyte glutathione peroxidase. (1967). Journal of Laboratory and Clinical Medicine, 70, 158-
169. 
 
Ursini, F., Maiorino, M., and Gregolin, C. (1985). The selenoenzyme phospholipid hydroperoxide 
glutathione peroxidase. Biochimica et Biophysica Acta, 839, 62-70. 
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Appendix J: Standard Operating Procedure (SOP) for the analysis of serum 
Clara Cell Protein 16 (CC16) using the BioVendor Human Clara Cell 
Protein ELISA  
 
 
Objective: To describe the Standard Operating Procedure (SOP) for the collection, handling and 
storage of blood samples from volunteer miners and for assaying the amount of Clara Cell Protein 16 
(CC16) in the samples  
 
Intended Use of the BioVendor Human Clara Cell Protein ELISA: It is a biotin labelled antibody 
based sandwich enzyme liken immunoassay for the quantitative measurement of human Clara Cell 
Protein in serum, plasma, tissue culture medium and bronchoalveolar lavage fluid. It is intended for in 
vitro research use only. [BioVendor Laboratory Medicine, 2006]. 
 
Principle: Human Clara Cell Protein (CC16) belongs to a family of secretoglobins and is a secreted 
product of non-ciliated bronchiolar Clara Cells. It has been proposed as potential peripheral marker of 
respiratory epithelial injury. 
In the BioVendor’s Human Clara Cell Protein ELISA, calibrators or samples are incubated with rabbit 
polyclonal anti-human Clara Cell Protein antibody, which is coated in microtiter wells. After one-hour 
incubation and a washing, biotin-labelled polyclonal anti-human Clara Cell Protein antibody is added 
and incubated with captured Clara Cell Protein. After one hour incubation and washing, streptavidin-
horseradish peroxidase conjugate is added. After one hour incubation and the last washing step, the 
remaining conjugate is allowed to react with the substrate H2O2-tetramethylbenzidine. The reaction is 
stopped by addition of acidic solution and absorbance of the resulting yellow product is measured at 
450 nm. The absorbance is proportional to the concentration of Clara Cell Protein. A Standard curve is 
constructed by plotting absorbance values versus Clara Cell Protein concentrations of calibrators, and 
concentrations of the unknown samples are determined using the standard curve. [BioVendor 
Laboratory Medicine, 2006]. 
 
Storage and Expiration of Kit: The Kit is stored at 2-8oC. Under these conditions the Kit is stable 
until the expiration date (indicated on the label of the box). [BioVendor Laboratory Medicine, 2006]. 
 
Limitations of the Assay: Results exceeding Clara Cell Protein level of 100 ng/ml should be repeated 
with diluted samples. Dilution factors then need to be taken into consideration in calculating the Clara 
Cell Protein concentration. [BioVendor Laboratory Medicine, 2006]. 
 
Sensitivity: The limit of detection is defined as follows: 
Analytical Limit of Detection: It is calculated from the real human Clara Cell Protein values in the 
wells and it has a value of 20 pg/ml 
Assay sensitivity: It takes the dilution of the samples into consideration and is calculated using the 
formula: Assay sensitivity = Analytical Limit of Detection x sample dilution (20 pg/ml x 25) and has a 
value of 500 pg/ml. [BioVendor Laboratory Medicine, 2006]. 
 
Specificity: The antibodies in the Human Clara Cell protein ELISA kit are highly specific for human 
Clara Cell Protein with no detectable cross reactivities to the cytokines that may be present in human 
serum. 
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Precautions: 
 
1. For in vitro research use only. 
2. The Kit contains components of human origin. The materials were found to be non-reactive for 
HbsAg, HCV antibody and for HIV ½ antibody and antigen. However, the materials should be handled 
as potentially infectious. 
3. Avoid contact with the acidic Stop Solution and Substrate Solution which contains hydrogen 
peroxide. Wear gloves and eye protection when handling these reagents. In the case of contact with the 
Stop Solution and the Substrate Solution, wash the skin thoroughly with water and seek medical 
attention if necessary. 
4. Wear gloves and laboratory coats when handling immunodiagnostic materials. 
5. Do not pipette materials by mouth. 
6. Do not mix reagents with different lot numbers. 
7. Do not use reagents beyond the indicated expiration date. [BioVendor Laboratory Medicine, 2006]. 
 
Primary sample: Human serum (Stable for 2 years when stored at -70oC) 
 
Container of storage: 1.0 ml CryoTubes 
 
Equipment needed: 
 
1. A centrifuge capable of 1300 x g. 
2. A microplate reader with a 450 nm filter. 
3. Adjustable pipettes to deliver 10-1000 µl and disposable tips. 
4. Multichannel pipette to deliver 100 µl. 
5. Glassware (graduated cylinder and bottle for the Wash solution). 
6. Microcentrifuge tubes for diluting the samples. 
7. Micro titration plate washer. 
8. Software package facilitating data generation and analysis. 
 
Reagents needed: 
 
1. The BioVendor Human Clara cell Protein ELISA Kit 
2. Distilled water. 
 
Quality control: A Clara Cell Protein Master Calibrator is included in the kit. The Clara Cell Protein 
Master calibrator is a 16 kDa dimerism protein that is purified from human urine. It is reconstituted to 
a concentration of 100 ng/ml. Serial dilutions of the master calibrator are performed to generate 
standards with Clara Cell Protein concentrations of 40 ng/ml, 20 ng/ml, 10 ng/ml, 5 ng/ml and 2 ng/ml. 
These standards and the master calibrator and run in duplicate along with the samples. A Quality 
Control High and a quality Control Low are also included in the kit. They are also run in duplicate 
along with the standards and samples. The CC16 concentrations obtained for the standards and Quality 
controls are compared to the expected concentrations, as indicated in the certificate of analysis 
included in the kit. 
 
 
Supplier Details: 
 
The BioVendor Human Clara cell Protein ELISA Kit (Catalogue number RD191022200). 
BioVendor Laboratory Medicine, Inc. 
CTPark Modrice 
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Evropska 873 
664 42 Modrice 
Czech Republic 
e-mail: info@biovendor.com 
http://www.biovendor.com 
 
Phone: +420-549 124 185 
 
Local Supplier:  
 
Calicom Trading 262 (PTY) LTD  
Tel: +27 11 472-7300 
Email: keith@katmedical.com 
 
 
A. SOP FOR THE COLLECTION OF BLOOD SAMPLES FROM VOLUNTEER MINERS 
 
 
1. Draw venous blood into a 6 ml BD Vacutainer tube containing Clot Act. 
 
2. The blood should be drawn and handled at room temperature (25oC). 
 
 
B. SOP FOR THE SEPARATION OF THE COLLECTED BLOOD SAMPLES 
 
 
1. The blood samples should be separated within 2 hours of being collected 
 
2. To separate the blood, centrifuge the tube of blood at 1300 x g for 10 minutes at room 
temperature. 
 
3. Pipette 300 µl of the upper serum layer into a 1.5 ml CryoTubes, in triplicate. 
 
 
C. SOP FOR THE STORAGE OF THE SERUM 
 
 
1. Ensure that the lids of the CryoTubes are securely fastened. 
 
2. Shock freeze the CryoTubes by using a pair of tongs to lower the CryoTubes into a Dewar 
flask of liquid nitrogen. 
 
3. Transport the frozen CryoTubes back to the National Institute for Occupational Health (NIOH) 
in a cooler box containing enough ice packs to ensure that the CryoTubes remain frozen. 
 
4.  As soon as the CryoTubes arrive at the NIOH transfer them to a clearly labelled container. 
 
5. Place the container in the -80oC Freezer. 
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D. SOP FOR OPERATING THE MICROPLATE READER AND ACCOMANYING 
SOFTWARE 
 
 
The microplate reader needs to be set up during the last step of the assay (after addition of the 
substrate) as the absorbance of the assay microplate needs to be read no longer than 15 minutes after 
adding the stop reagent. 
 
1. To measure the absorbance in the wells of the microplate during the assay, an ELx800 
Automated Microplate reader (Bio-Tek) is used and the accompanying software is KC4TMv3.4 
(Bio-Tek). 
 
2. Plug in the microplate reader and switch it on (the ON/OFF switch is located on the right hand 
side of the machine). 
 
3. The reader will go through an automatic self-test to ensure it is functioning properly. 
 
4. Wipe down the surface of the microplate reader with a damp paper towel. 
 
5. Connect the laptop loaded with the KC4 software to the microplate reader and to the printer. 
 
6. Switch on the laptop and open the KC4 program. 
 
7. Click on the ‘Protocol’ tab and select the ‘Wizard’ option 
 
8. In the ‘Plate settings’ box select the ‘Description’ box. 
 
9. In the ‘Plate description parameters’ box fill in the necessary prompts (for example the 
experiment name or the name of the experimenter). These are optional. 
 
10. Click ‘OK’ 
 
11. In the ‘Plate settings’ box select the ‘Reading Parameters’ box 
 
12. Select the ‘End reading’ reading type. 
 
13. Select the ‘Meas. Filter’. Click the down arrow on the side of the white box next to the Meas 
Filter option. Select a wavelength of 450 nm. 
 
14. Click the down arrow on the side of the white box next to the Plate type and select a ‘96 Well 
Plate’. 
 
15. Fill in the wells that are being used on the plate in the ‘First well’ and ‘Last well’ boxes (For 
example if the whole plate is being used the first well is A1 and the last well is H12). 
 
16. Click “OK’ 
 
17. In the ‘Plate settings’ box select the ‘Layout’ box 
 
18. A layout for a 96 Well Plate will appear in a box labelled ‘Plate layout’. Select the type of 
sample being assayed (for example a blank (background), control or sample) by clicking the 
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down arrow on the side of the white box next to the ‘Type’ option. Once you have selected the 
type of sample, click on the well that sample will occupy in the microplate. The name of the 
sample will then appear in that well. (For example, select the Blank as the type of sample and 
click on the well labelled A1. The word Blank will then appear in well A1). The standards and 
their corresponding concentrations must also be put into the layout. 
 
19. Once the plate layout has been filled in click ‘OK’ 
 
20. Select the ‘Basic Analysis’ tab. 
 
21. In the ‘Basic Analysis’ box select the ‘Curve Description’ tab. 
 
22. Select ‘M450 Corrected’ as the ‘Data to Interpolate’. 
 
23. Select the ‘Current plate’ as the ‘Curve origin’. 
 
24. In the ‘Basic Analysis’ box select the ‘Curve Fit’ tab. 
 
25. Select ‘4 Parameters’ as the ‘Curve fit’. 
 
26. Click ‘OK’ 
 
27. Select the ‘Output’ tab. 
 
28. In the ‘Output’ box select the ‘Report’ box 
 
29. In the ‘Available data’ box click on the name of the type of data that is wanted in the final 
report of the results (for example the template). Click on the small box labelled ‘Add’. The 
name of the data that was selected will then appear in the ‘Selected data’ box. Continue this 
process until all the data that is wanted in the report is listed in the ‘Selected data’ box.(If a 
data type is added that is no longer wanted click on the small box labelled ‘Remove’ and the 
data name will be removed from the ‘Selected data’ box). 
 
30. The data types that must be selected are ‘M 450’, ‘M450 corrected’, ‘Standard curve’, 
‘Sample concentrations’. 
 
31. Once all the data needed has been selected click ‘OK’ 
 
32. Click ‘OK’ 
 
33. Save the protocol under a chosen name. 
 
34. Select the ‘Read’ Box in the tool bar. 
 
35. Fill in the necessary prompts and any comments.  
 
36. Do not click on the ‘Start Reading’ box. This is only done once the plate is ready to be read. 
 
37. Perform the assay as described below. 
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E. SOP FOR ASSAYING THE CONCENTRATION OF CC16 IN THE SERUM 
 
 
1.  The serum samples (stored in CryoTubes in the -80oC freezer) should be assayed no later than 
9 weeks after they were collected. 
 
2. The concentration of CC16 in the serum samples will be assayed using a Human Clara Cell 
Protein ELISA Kit purchased from BioVendor Laboratory Medicine, Inc. (Czech Republic). 
  
3. When not in use store the kit at between 2 and 80C in a fridge. 
 
4. To use the kit, remove the kit from the fridge and allow the contents of the kit to come to room 
temperature. 
 
5. To prepare the 1 X Wash solution, dilute 100 ml of Wash Solution Concentrate (10 X) 
(provided in the kit) with 900 ml of deionised water in a 1L Schott bottle. Invert the bottle 
gently to mix. The diluted Wash Solution is stable for 1 month if stored between 2 and 8oC. 
 
6. To prepare the Human Clara Cell Protein Master Calibrator, reconstitute the Clara Cell Protein 
Master Calibrator (provided in the kit) with 0.5 ml of Dilution buffer (provided in the kit). 
Invert gently to mix. The concentration of the human Clara Cell Protein in the stock solution is 
100 ng/ml. The reconstituted master calibrator should be stored at -20oC until its expiration 
date. 
 
7.  A series of standards/calibrators are then prepared from the 100 ng/ml Clara Cell Protein stock 
by means of serial dilutions. A total of five standards are prepared from the 100 ng/ml stock 
with final concentrations of 40 ng/ml, 20 ng/ml, 10 ng/ml, 5 ng/ml and 2 ng/ml. The prepared 
standards should be stored at -20oC until the expiration date of the kit. 
 
8.  To prepare the 40 ng/ml Clara Cell Protein standard, pipette 300 µl of Dilution buffer into a 
clearly labelled 1 ml Eppendorf tube and add 200 µl of the 100 ng/ml Clara Cell Protein stock. 
Gently mix.  
 
9.  To prepare the 20 ng/ml Clara Cell Protein standard, pipette 200 µl of Dilution buffer into a 
clearly labelled 1 ml Eppendorf tube and add 200 µl of the 40 ng/ml Clara Cell Protein 
standard. Gently mix. 
 
10. To prepare the 10 ng/ml Clara Cell Protein standard, pipette 200 µl of Dilution buffer into a 
clearly labelled 1ml Eppendorf tube and add 200ul of the 20ng/ml Clara Cell Protein standard. 
Gently mix. 
 
11. To prepare the 5 ng/ml Clara Cell Protein standard, pipette 200 µl of Dilution buffer into a 
clearly labelled 1 ml Eppendorf tube and add 200 µl of the 10 ng/ml Clara Cell Protein 
standard. Gently mix. 
 
12. To prepare the 2 ng/ml Clara Cell Protein standard, pipette 300 µl of Dilution buffer into a 
clearly labelled 1 ml Eppendorf tube and add 200 µl of the 5 ng/ml Clara Cell Protein standard. 
Gently mix.  
 
13. Determine the number of 1.5 ml Eppendorf tubes needed to accommodate the number of 
standards and controls that will be run in the assay. It is recommended that the six Clara Cell 
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Protein standards, the Clara Cell Protein High control and the Clara Cell Protein Low control 
be assayed in duplicate (a total of 16 tubes). 
 
14. In each clearly labelled 1.5 ml Eppendorf tube, pipette the amount of Dilution buffer necessary 
to dilute the standards and controls 25 X. If the standards and controls are being assayed in 
duplicate pipette 240 µl of Dilution buffer into the Eppendorf tube. 
 
15. To dilute the Clara Cell Protein standards, pipette 10 µl of gently mixed 100 ng/ml Clara Cell 
Protein stock into the clearly labelled 1.5 ml Eppendorf tube containing 240 µl Dilution buffer 
and aspirate to mix. Repeat the above procedure to dilute the 40 ng/ml, 20 ng/ml, 10 ng/ml,     
5 ng/ml and 2 ng/ml Clara Cell Protein standards using a clean pipette tip for each standard. 
Do not store the diluted standards.  
 
16. To dilute the Clara Cell Protein High Control, pipette 10 µl of the Clara Cell Protein High 
Control (provided in the kit) into the clearly labelled 1.5 ml Eppendorf tube containing 240 µl 
Dilution buffer and gently mix. Do not store the diluted control.  
 
17. To dilute the Clara Cell Protein Low Control, pipette 10 µl of the Clara Cell Protein Low 
Control (provided in the kit) into the clearly labelled 1.5 ml Eppendorf tube containing 240 µl 
Dilution buffer and gently mix. Do not store the diluted control. 
 
18.  Remove the serum samples that will be assayed from the -80oC freezer and allow them to 
thaw at room temperature. 
 
19.  Determine the number of 1.5 ml Eppendorf tubes needed to accommodate the number of 
samples that will be run in the assay.  
 
20. In each clearly labelled 1.5 ml Eppendorf tube, pipette the amount of Dilution buffer necessary 
to dilute the serum sample 25 X. If the serum sample is being assayed in singlet pipette 120 µl 
of Dilution buffer into the Eppendorf tube. If the sample is being assayed in duplicate pipette 
240 µl of Dilution buffer into the Eppendorf tube etc. 
 
21. Ensure that Dilution buffer has been added to all the Eppendorf tubes needed before any serum 
sample is added. 
 
22. Gently tap the CryoTubes containing the thawed serum sample to mix. 
 
23. Pipette 5 µl of the mixed serum sample into the Dilution buffer in the Eppendorf tube and 
gently mix (if the sample is being assayed in duplicate add 10 µl of serum sample instead of    
5 µl).  
 
24. Repeat for all the samples using a clean pipette tip for each sample. Do not store the diluted 
samples. 
 
25. A microplate containing 96 wells is provided in the kit. In each plate there are 12 columns 
(Columns 1 to 12) each consisting of 8 wells (Rows A to H).  
 
26. Pipette 100 µl Dilution buffer into two wells of the microplate (if using the whole kit use wells 
A1 and A2). These wells are the background wells (non-enzymatic wells). 
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27. Pipette 100 µl of 25 X diluted 100 ng/ml Clara cell Protein Standard into two wells of the 
microplate (if using the whole kit use wells B1 and B2).  
 
28. Pipette 100 µl of 25 X diluted 40 ng/ml Clara cell Protein Standard into two wells of the 
microplate (if using the whole kit use wells C1 and C2). 
  
29. Pipette 100 µl of 25 X diluted 20 ng/ml Clara cell Protein Standard into two wells of the 
microplate (if using the whole kit use wells D1 and D2). 
  
30. Pipette 100 µl of 25 X diluted 10 ng/ml Clara cell Protein Standard into two wells of the 
microplate (if using the whole kit use wells E1 and E2).  
 
31. Pipette 100 µl of 25 X diluted 5 ng/ml Clara cell Protein Standard into two wells of the 
microplate (if using the whole kit use wells F1 and F2).  
 
32. Pipette 100 µl of 25 X diluted 2 ng/ml Clara cell Protein Standard into two wells of the 
microplate (if using the whole kit use wells G1 and G2). 
 
33.  Pipette 100 µl of 25 X diluted Clara cell Protein High Control into two wells of the microplate 
(if using the whole kit use wells H1 and H2). 
 
34. Pipette 100 µl of 25X diluted Clara cell Protein Low Control into two wells of the microplate 
(if using the whole kit use wells A3 and A4). 
 
35. Pipette 100 µl of each of the 25 X diluted serum samples into a separate well of the microplate.  
 
36. Cover the plate with foil and incubate the plate at room temperature (25oC) for 75 minutes. 
 
37. Remove the foil and carefully wash the plate five times with the 1 X diluted Wash Solution. 
(After washing gently tap the plate on a piece of paper towel to ensure it is dry).  
 
38. Pipette 100 µl Biotin Labelled Antibody (provided in the kit) into every well being used.  
 
39. Cover the plate with foil and incubate the plate at room temperature (25oC) for 75 minutes. 
 
40. Remove the foil and carefully wash the plate five times with the 1 X diluted Wash Solution. 
(After washing gently tap the plate on a piece of paper towel to ensure it is dry).  
 
41. Pipette 100 µl Streptavidin- HRP Conjugate (provided in the kit) into every well being used.  
 
42. Cover the plate with foil and incubate the plate at room temperature (25oC) for 75 minutes. 
 
43. Remove the foil and carefully wash the plate 5 times with the 1 X diluted Wash Solution. 
(After washing gently tap the plate on a piece of paper towel to ensure it is dry).  
 
44. Pipette 100 µl Substrate Solution (provided in the kit) into every well being used (this step 
should be performed out of direct sunlight).  
 
45. Cover the plate with foil and incubate the plate at room temperature (25oC) for 10 minutes (if 
the room temperature is below 20oC the incubation time should be increased up to 20 minutes). 
 
  
 
 202 
46. Pipette 100 µl Stop Solution (provided in the kit) into every well being used to stop the colour 
development.  
 
47. Carefully place the microplate into the designated holder in the microplate reader. 
 
48. Carefully shake the microplate for a few seconds to mix the contents in the wells. 
 
49. Select the ‘Start Reading’ box that is displayed in the KC4 program. 
 
50. The absorbance at 450 nm is automatically measured in the specified microplate wells.  
 
51. Once the microplate reader has finished measuring the absorbance of the plate, click on the 
‘Save’ box in the toolbar and save the report under a chosen name. If one requires the report to 
be printed, click on the ‘Print’ box in the toolbar. 
 
52. Remove the microplate from the microplate reader. 
 
53. Wipe down the microplate reader with a damp paper towel. 
 
54. Switch off the microplate reader and unplug. 
 
 
 
 
References: 
 
BioVendor Laboratory Medicine. (2006). The Human Clara Cell Protein ELISA Kit Instructions Insert; 
BioVendor Laboratory Medicine, Inc; Czech Republic, pg 1-24. 
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Appendix K: Subject information sheet for volunteers  
 
     MINE HEALTH AND SAFETY COUNCIL  
                                  and the 
      NATIONAL INSTITUTE for 
              OCCUPATIONAL HEALTH 
 
 
Subject Information Sheet for Volunteers 
 
Hello, my name is Kerry Makinson, I am a researcher from the National Institute of 
Occupational Health (NIOH) in Johannesburg, and my contact numbers are 011 712 6469 and 
082 494 1392. My co-worker is Professor Brendan Girdler-Brown. 
 
I would like to invite you to participate in our study. It is an independent study commissioned 
and funded by the Mine Health and Safety Council (SIMRAC) and carried out at the National 
Institute for Occupational Health (NIOH).We are looking for a new blood test that might be 
used to see if silica dust levels at your workplace are a danger to workers. We believe that if 
workers breathe in too much silica dust then their bodies will react by making certain 
chemicals that we can detect in blood samples taken from those workers.  
 
If you decide to participate, I would like to explain to you what will happen. First your 
answers to a short questionnaire are needed (this will take about 5 minutes). Then we need to 
look at your last X-ray. If you agree the nurse will show us your x-ray. We will also need to 
draw a small amount of blood (about 3 teaspoons) from your arm on 5 different occasions over 
a 3-4 week period. This will also only take about five minutes each time. These tests will not 
tell us if you are sick. In addition we will only be able to tell if the silica dust levels are too 
high in the future if we test a large number (say, 10 people) of workers and look at all their 
results together. It is unlikely that the blood tests will be able to tell if an individual miner has 
been exposed to too much silica dust. After we take your blood it will be kept frozen at the 
National Institute for Occupational Health and will only be used for this study. It will not be 
used for any other purpose without your written permission. We will not be testing for HIV.  
 
Your personal information and results will be kept confidential and will not be shown to any 
other person.  We will be coming back to the mine to talk about our results this year and you 
will be invited to come and ask any questions that you may have. At that time we will also 
give you your own individual results in writing (if you want them) along with an explanation 
of what they mean. 
 
If you decide not to take part in this study it will not affect you or your job in any way. By 
taking part you will be helping miners and future employees of mines, so that fewer people get 
sick. The only risk to you from taking part in this study will be a little discomfort when the 
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blood specimen is taken and for a short time afterwards. There will be a medical doctor 
present to take your blood specimens.  
 
Thank you  
Kerry Makinson 
 
The contact details for the Wits Human Research Ethics committee are: Ms Anisa Keshav 
(011 717 1234) 
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Appendix L: Consent form for volunteers 
 
     MINE HEALTH AND SAFETY COUNCIL  
                                  and the 
      NATIONAL INSTITUTE for 
       OCCUPATIONAL HEALTH 
 
 
106 Joubert Street Ext ● PO Box 4788 Johannesburg 2000 South Africa ● Tel: 27 11 712 6400 ●  
Fax: 27 11 712 6545 
 
 
Validation of biomarkers for assessment of exposure to silica dust 
 
The information sheet about this study has been read to me and I understand what will be required of 
me if I take part in the study. My questions concerning this study have been answered 
by…………………........................ (Name of study member). 
My participation in this study is voluntary; I understand that if I do not wish to take part it will have no 
effect on me or my job. At any time I may leave this study without any bad effect on my job or my 
health care. 
 
I ____________________________________________________________ agree to take part in the 
study. I am happy to allow my most recent X-rays to be given to Ms Kerry Makinson. I am happy to 
allow my personal silica dust exposure history to be told to Ms Kerry Makinson by the Human 
Resources department. I agree to give 15ml of blood on each of 5 times spread over 3-4 weeks. I 
understand that all individual and personal information will be kept confidential and I know that I can 
leave at anytime. 
 
Signed _______________________________________ Date __________________ 
 
 
  
 
 206 
Appendix M: Questionnaire administered to volunteers 
 
STUDY NUMBER STICKER: 
 
 
 
 
 
 TO BE COMPLETED BY INTERVIEWER CODING 
   
RECRUITMENT CENTRE:   
   
DATE: dd Mm yyyy  
   SHIFT: 
 
 
   SHAFT:   
   
JOB:  
 
 
   
JOB HISTORY:  
 
 
 
 
 
 CURRENT SMOKER?: YES NO  
 
 
 PREVIOUS SMOKER?: YES NO  
 
 
 CONTACT NUMBER: 
 
 
 
   
 X-RAY DATE: dd Mm yyyy  
   SILICOSIS SCORE: /  
   CURRENT TB Rx:   
 
 
Group: 
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DATE OF BIRTH: dd Mm yyyy  
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Appendix N: Consent Form for Photographs 
 
     MINE HEALTH AND SAFETY COUNCIL  
                                  and the 
      NATIONAL INSTITUTE for 
      OCCUPATIONAL HEALTH 
 
106 Joubert Street Ext ● PO Box 4788 Johannesburg 2000 South Africa ● Tel: 27 11 712 6400 ●  
Fax: 27 11 712 6545 
 
 
Validation of biomarkers for assessment of exposure to silica dust 
 
Please indicate (by means of a tick) which of the below reports you are willing to have your 
photograph and/or name published in: 
 
                                           Report                                                                                       Photograph Name 
A report for the South African Mine Health and Safety Council.   
The newsletter for the National Institute for Occupational Health (NIOH).   
A Scientific Journal (International or National) that will be read by 
medical and scientific personnel. 
  
Visual presentations at conferences (International or National).   
On the Internet on Occupational Health or Toxicology related sites.   
In Kerry Makinson’s MSc research dissertation.   
Annual reports for The University of the Witwatersrand, the University of 
Pretoria and the NIOH. 
  
 
I _____________________________________________ agree that my photograph can be 
taken and that my photograph and/or name can only be used for the purposes indicated above. 
I understand that if I do not agree to have my photograph and/or name published in any of the 
above papers that it will have no effect on me or my job.  
 
 
Signed _______________________________________ Date __________________ 
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Appendix O: Ethics clearance certificate 
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Appendix P: Individual GPx and CC16 ex-leave and follow up results 
 
 
Table 1: Mean erythrocyte GPx activities (in U/g Hb) of the ex-leave and the follow up samples of 
the individual volunteers. 
 
Volunteer Ex-leave  Monday  Wednesday  (pre-shift)  
Wednesday  
(post-shift)  Friday  
1 34.86 27.99       
4 32.25       20.22 
5 24.57   22.22 22.06   
6 19.54 17.90 16.34     
7 19.70   20.95     
8 26.03 20.47     25.48 
10 36.42   27.00 28.92   
11 26.93   24.29 25.20 19.91 
12 35.62   25.36 33.58   
14 32.00 25.99       
15 28.19   23.58 23.92   
17 24.18 19.12       
19 25.05 19.28       
20 30.28 19.55       
21 35.38       25.30 
22 17.89       15.88 
23 32.22   14.14 21.09   
24 17.85   13.95 12.11   
25 36.31     33.11   
26 25.80 17.35       
30 29.69   21.41 18.46   
31 49.92   41.35 41.34   
32 30.64 26.36       
33 31.48   20.42 20.71   
36 26.24 29.32       
37 16.79 16.95       
40 22.30   25.99 20.94   
41 17.66       18.25 
42 24.55       23.33 
43 21.87 18.51 18.18 18.86 19.12 
44 23.99   21.41 25.71   
45 23.10         
46 22.80   29.53 27.28   
47 24.24   23.01 19.87   
48 20.28 23.55       
50 22.94       22.88 
51 19.61   14.87 13.62   
52 20.41   14.58 14.30   
53 22.04   25.00 20.46   
59 22.57 17.30       
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60 28.88   39.14 36.88   
61 25.46   19.68 20.39   
62 32.14 22.99       
63 27.59       22.07 
65 27.14       17.73 
66 31.17   26.83 24.37   
68 19.84 15.28       
74 28.14       18.19 
75 34.44       26.49 
76 27.37       19.78 
77 23.04 21.62       
79 26.23 22.64       
80 30.21       34.79 
 
 
 
Table 2: Mean serum CC16 concentrations (in ng/ml) of the ex-leave and the follow up samples 
of the individual volunteers.  
 
Volunteer Ex-leave  Monday Wednesday  (pre-shift) 
Wednesday  
(post-shift) Friday 
1 5.18 8.86       
4 5.84       6.77 
5 5.87   5.93 4.51   
6 6.12 8.01 9.71     
7 6.64   7.09     
8 7.93 9.97     5.95 
10 9.15   8.06 5.94   
11 3.63   6.66 3.58 4.68 
12 15.70   16.74 13.08   
14 7.30 7.99       
15 2.46   3.18 2.30   
17 7.47 6.17       
19 8.42 8.63       
20 4.25 3.01       
21 6.61       4.57 
22 10.74       10.85 
23 2.24   1.87 2.78   
24 2.69   2.56 1.86   
25 4.59     3.15   
26 5.85 6.85       
30 6.68   5.84 4.86   
31 9.43   6.06 5.90   
32 5.63 5.99       
33 4.30   4.76 3.04   
36 4.41 2.71       
37 7.34 3.87       
40 5.29   2.21 3.37   
41 8.70       3.74 
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42 12.07       7.42 
43 12.37 8.71 8.65 4.53 5.14 
44 12.65   16.64 9.50   
45 12.34         
46 7.24   5.30 3.41   
47 9.49   7.06 5.11   
48 4.94 3.51       
50 7.88       7.21 
51 6.18   8.39 6.73   
52 2.72   3.34 2.67   
53 9.46   8.39 8.92   
59 10.38 8.41       
60 11.71   9.87 11.69   
61 4.59   2.69 1.99   
62 4.08 6.26       
63 8.02       7.52 
65 2.94       2.62 
66 5.19   4.22 4.45   
68 9.98 11.56       
74 6.54       6.68 
75 6.15       6.49 
76 5.85       4.43 
77 6.10 9.52       
79 4.55 5.35       
80 2.90       1.90 
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